Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED]  
Document Date:  31-Aug-2018A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator -
controlled Study to Evaluate the Safety, Tolerability, and 
Immunogenicity of V114 Followed by Administration of 
PNEUMOVAX™23 Six Months Later in Immunocompetent Adults 
Between 18 and 49 Years of Age at Increased Risk for Pneumococcal 
Disease (PNEU –DAY).
PRODUCT: V114 1
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. 
(MSD).
Protocol Title: A Phase 3, Multicenter, Randomized, Double -blind, Active Comparator -
controlled Study  to Evaluate the Safet y, Tolerability , and Immunogenicit y of V114 Followed 
by Administration of PNEUMOVAX™23 Six Months L ater in Immunocompetent Adults 
Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU –
DAY).
Protocol Number: 017-02
Compound Number: V114
Sponsor Name:
Merck Sharp & Dohme Corp., a subsidiary  of Merck & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One Merck Drive
P.O. Box 100
Whitehouse Station, New Jersey , 08889 -0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND
EudraCT14977
2017 -004915 -38
Approval Date: 31-August -2018 
  050DGF 
  05KG3M
PRODUCT: V114 2
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Sponsor Signatory
Typed Name:
Title:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide b y all provisions of this protocol.
Typed Name:
Title:Date 
  050DGF 
  05KG3M
PRODUCT: V114 3
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
PROTOCOL AMENDMENT S UMMARY OF CHANGES
Amendment: 02
Overall Rationale for the Amendments:
The primary  purpose of this amendment is to include a spirometry  assessment at Visit 1 (Screening) forthose otherwise eligible 
individuals who have a clinical history  of asthma or chronic obstructive pulmonary
 disease (COPD )and who do not have spirometry  
results from within the previous 5 y ears. This change will ensure that those individuals with a clinical diagnosis of asthma or COPD 
who do not hav e spirometry  results available within the previous 5 y ears meet the documentation requirements for inclusion in the 
study . Other clarifications and editorial revisions were also made as shown in the Summary  of Changes Table below.
Summary of Changes Table :
Section # and Name Description of Change  Brief Rationale  
1.2 Schema
1.3.1 Schedule of Activities for the 
Main Study
1.3.2 Schedule of Activities for Native 
Americans Enrolled through the Johns 
Hopkins Center for American Indian 
Health (CAIH) Partici pating in the 
Substudy
5.1 Inclusion CriteriaChanged to include a spirometry assessment 
at Visit 1 (Screening) for individuals who 
are otherwise eligible for study enrollment
based on a clinical history  of asthma or
COPD butwho do not have spirometry  
results from within the previous 5 y ears. 
Inclusion criteria 1c and 1d were updated 
with specific details ,and the Schema and 
Schedule of Assessments reflect these 
changes.Spirometry  assessment was included at 
Visit 1 (Screening) to:
improve recognition and diagnosis of 
chronic lung disease ( eg, asthma and/or 
COPD) through the use of a standard 
respiratory  lung function test, as these 
tests can support a clinical diagnosis of 
asthma/COPD in the primary  care 
setting , and 
increase the number of eligible 
individuals with chronic lung disease . 
  050DGF 
  05KG3M
PRODUCT: V114 4
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Section # and Name Description of Change  Brief Rationale  
1.3.2 Schedule of Activities for Native 
Americans Enrolled through the Johns 
Hopkins Center for American Indian 
Health (CAIH) Participating in the 
Substudy
8.1.9 Vaccination Report CardChanged to allow collection of the paper 
VRC for participants enrolled in the CAIH
substudy at either Visit 2Cor Visit 3, and at 
either Visit 4Cor Visit 5 (at the discretion of 
the sitepersonnel ). 
Clarified that the completed paper VRC will 
be reviewed in full with the participant by 
the site personnel at the time of collection.Collection of the paper VRC at Visits 2C 
and 4C allows for a more timely  collection 
and assessment of safet y data as these 
visits are approximately  15 day s after each 
study  vaccination .
5.1 Inclusion Criteria Thetime period between the following 
required diagnostic tests and screening , 
which are required to determine participant 
eligibility ,was increased to within 5 years of 
Visit 1 (Screening): FibroScan ®;
FibroTest ®;spirometry ;diagnostic 
documentation for chronic heart disease, 
including echocardiography .
Inclusion c riteria 1b, 1c, 1d, and 1e were 
updated accordingl y.Length of time between required 
diagnostic tests and screening was 
increased to provide more flexi bility  for 
inclusion of participants in the study .
5.2 Exclusion Criteria Proliferative diabetic retinopathy  was 
removed from exclusion criterion #2.Proliferative diabetic retinopathy  was 
originall y intended to be a marker for 
unstable diabetes . However , this procedure 
is not used consistently across the sites 
and, therefore, isnolonger considered to 
be a good marker of unstable diabetes . 
  050DGF 
  05KG3M
PRODUCT: V114 5
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Section # and Name Description of Change  Brief Rationale  
5.2 Exclusion Criteria Four exclusion criteria were added: 
#30:  Diabetes mellitus with HgA1c ≥10% 
at Visit 1 (Screening) .
#31:  C hronic liver disease with Child -Pugh 
Class B or C cirrhosis at Visit 1(Screening).
#32:  Chronic lung disease with COPD 
GOLD Stage 4 or severe persistent asthma 
at Visit 1 (Screening).
#33:  Chronic heart disease with NYHA 
heart failure Class 4 at Visit 1 (Screening).These additional exclusion criteria were 
added to clarify  that individuals with these 
conditions cannot be enrolled under a 
different risk category  (such as smokers).
8.1.8Study  Intervention 
AdministrationThe foll owing text was added:
Study  vaccines should be prepared and 
administered b y appropriately  qualified 
members of the stud y personnel (eg, 
physician, nurse, phy sician’s assistant, nurse 
practitioner, pharmacist, or medical 
assistant) as allowed b y local /state, country , 
and institutional guidance.
Adequate treatment provision, including 
epinephrine and equipment for maintaining 
an airway ,should be available for 
immediate use should an anaphy lactic or 
anaph ylactoid reaction occur [Centers for 
Disease Control and Prevention 2015] .Text was added to provide guidance on 
expected vaccine administration 
instructions. 
Throughout Editorial revisions Changes are minor and have not been 
summarized individually . 
  050DGF 
  05KG3M
PRODUCT: V114 6
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Table of Contents
PROTOCOL AMENDMENT S UMMARY OF CHANGES ............................................... 3
1 PROTOCOL SUMMARY ............................................................................................ 13
1.1 Synopsis ................................................................................................................. 13
1.2 Schema .................................................................................................................. 18
1.3 Schedule of Activities (SoA) ................................................................................ 19
1.3.1 Schedule of Activities for the Main Study ................................................... 19
1.3.2 Schedule of Activities for Native America ns Enrolled through the Johns 
Hopkins Center for American Indian Health (CAIH) Participating in the 
Substudy ....................................................................................................... 26
2 INTRODUCTION .......................................................................................................... 33
2.1 Study Rationale .................................................................................................... 33
2.2 Background .......................................................................................................... 34
2.2.1 V114 and Pneumococcal Disease ................................................................ 34
2.2.2 Preclinical and Clinical Studies ................................................................... 35
2.2.3 Information on Other Study -related Therap y.............................................. 35
2.2.3.1 Prevnar 13™ ...................................................................................... 35
2.2.3.2 PNEUMOVAX™23 .......................................................................... 36
2.3 Benefit/Risk Assessment ...................................................................................... 36
3 HYPOTHESIS, OBJECTIV ES, AND ENDPOINTS ................................................. 37
4 STUDY DESIGN ............................................................................................................ 39
4.1 Overall Design ...................................................................................................... 39
4.1.1 Main Study ................................................................................................... 39
4.1.2 Substudy ....................................................................................................... 40
4.2 Scientific Rationale for Study Design ................................................................ .41
4.2.1 Rationale for Endpoints ............................................................................... 42
4.2.1.1 Immunogenicit y Endpoints ................................................................ 42
4.2.1.2 Safety  Endpoints ................................................................................ 42
4.2.1.3 Future Biomedical Research .............................................................. 43
4.2.2 Rationale for the Use of Comparator/Placebo ............................................. 43
4.3 Justification for Dose ........................................................................................... 43
4.4 Beginning and End of Study Definition ............................................................. 44
4.4.1 Clinical Criteria for Early Study Termination ............................................. 44
5 STUDY POPULATION ................................................................................................ 44
5.1 Inclusion Criteria ................................................................................................ .44
5.2 Exclusion Criteria ................................................................................................ 47
5.3 Lifestyle Considerations ...................................................................................... 49 
  050DGF 
  05KG3M
PRODUCT: V114 7
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
5.4 Screen Failures ..................................................................................................... 49
5.5 Participant Replacement Strategy ...................................................................... 50
6 STUDY INTERVENTION ............................................................................................ 50
6.1 Study Intervention(s) Administered ................................................................... 50
6.2 Preparation/Handling/Storage/Accountability ................................................. 52
6.2.1 Dose Preparation .......................................................................................... 52
6.2.2 Handling, Storage, and Accountability ........................................................ 52
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. 52
6.3.1 Intervention Assignment.............................................................................. 52
6.3.2 Stratification ................................................................................................ .53
6.3.3 Blinding ........................................................................................................ 54
6.4 Study Intervention Compliance .......................................................................... 55
6.5 Concomitant Therapy .......................................................................................... 55
6.5.1 Rescue Medications and Supportive Care ................................................... 55
6.6 Dose Modification (Escalation/Titration/Other) ............................................... 56
6.7 Interve ntion After the End of the Study ............................................................ 56
6.8 Clinical Supplies Disclosure ................................................................................ 56
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
WITHDRAWAL ............................................................................................................ 56
7.1 Discontinuation of Study Intervention ............................................................... 56
7.2 Participant Withdrawal From the Study ........................................................... 57
7.3 Lost to Follow -up................................................................................................ .57
8 STUDY ASSESSMENTS AN D PROCEDURES ........................................................ 58
8.1 Administrative and General Procedures ........................................................... 59
8.1.1 Informed Consent ......................................................................................... 59
8.1.1.1 General Informed Consent ................................................................ .60
8.1.1.2 Consent and C ollection of Specimens for Future Biomedical 
Research ............................................................................................. 60
8.1.2 Inclusion/Exclusion Criteria ........................................................................ 60
8.1.3 Participant Identification Card ..................................................................... 60
8.1.4 Medical History ........................................................................................... 61
8.1.5 Prior and Concomitant Medications Review ............................................... 61
8.1.5.1 Prior Medications ............................................................................... 61
8.1.5.2 Concomitant Medications .................................................................. 61
8.1.6 Assignment of Screening Number ............................................................... 61
8.1.7 Assignment of Treatment/Randomization Number ..................................... 62
8.1.8 Study  Intervention Administration .............................................................. 62
8.1.8.1 Timing of Dose Administration ......................................................... 63 
  050DGF 
  05KG3M
PRODUCT: V114 8
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
8.1.9 Vaccination Report Card .............................................................................. 63
8.1.10 6-month Safe ty Follow -up Questionnaire .................................................... 64
8.1.11 Discontinuation and Withdrawal ................................................................ .64
8.1.11.1 Withdrawal From Future Biomedical Research ................................ 64
8.1.12 Participant Blinding/Unblinding .................................................................. 64
8.1.13 Calibration of Equipment ............................................................................. 65
8.2 Immunogenicity Assessments ............................................................................. 65
8.2.1 Multiplex Opsonophagocytic Assay (MOPA) ............................................. 66
8.2.2 Electrochemiluminescence (ECL) ............................................................... 66
8.3 Safety Assessments ............................................................................................... 66
8.3.1 Physical Examinations ................................................................................. 67
8.3.2 Pregnancy  Test ............................................................................................. 67
8.3.3 Body Temperature Measurement ................................................................ .67
8.3.4 Safety  Assessments and Use of the Paper VRC/eVRC ............................... 67
8.3.5 Clinical L aboratory  Assessments ................................................................ .68
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Reportable Safety Events .................................................................................... 68
8.4.1 Time Period and Frequency  for Collecting AE, SAE, and Other 
Reportable Safet y Event Inf ormation .......................................................... 69
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safet y Events ......70
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety  Event Information ...71
8.4.4 Regulatory  Repo rting Requirements for SAE ............................................. 71
8.4.5 Pregnancy  and Exposure During Breastfeeding .......................................... 71
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ 71
8.4.7 Events of Clinical I nterest (ECI s)................................................................ 72
8.5 Treatment of Overdose ........................................................................................ 72
8.6 Pharmacokinetics................................................................................................ .72
8.7 Pharmacodynamics .............................................................................................. 72
8.8 Future Biomedical Research Sample Collection ............................................... 72
8.9 Planned Genetic Analysis Sample Collection .................................................... 72
8.10 Biomarkers ........................................................................................................... 72
8.11 Medical Resource Utilization and Health Economics ....................................... 73
8.12 Visit Requirements ............................................................................................... 73
8.12.1 Screening ...................................................................................................... 73
8.12.2 Treatment Period/Vaccination Visit ............................................................ 73
8.12.3 Discontinued Participants Continuing to be Monitored in the Study .......... 73
9 STATISTICAL ANALYSIS PLAN ............................................................................. 73 
  050DGF 
  05KG3M
PRODUCT: V114 9
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
9.1 Statistical Analysis Plan Summary..................................................................... 73
9.2 Responsibility for Analyses/In -house Blinding ................................................. 75
9.3 Hypotheses/Estimation ........................................................................................ 75
9.4 Analysis Endpoints ............................................................................................... 75
9.4.1 Immunogenicit y Endpoints .......................................................................... 75
9.4.2 Safety  Endpoints .......................................................................................... 76
9.5 Analysis Populations ............................................................................................ 77
9.5.1 Immunogenicit y Analysis Populations ........................................................ 77
9.5.2 Safety Anal ysis Populations ........................................................................ 77
9.6 Statistical Methods ............................................................................................... 78
9.6.1 Statistical Methods for Immunogenicit y Anal yses...................................... 78
9.6.2 Statistical Methods for Safety Anal yses...................................................... 79
9.6.3 Demographic and Baseline Characteristics ................................................. 81
9.7 Interim Analyses .................................................................................................. 81
9.8 Multiplicity ........................................................................................................... 82
9.9 Sample Size and Power Calculati ons................................................................ .82
9.9.1 Sample Size and Power for I mmunogenicity  Analy ses............................... 82
9.9.2 Sample Size and Power for Safet y Anal yses............................................... 83
9.10 Subgroup Analyses ............................................................................................... 83
9.11 Compliance (Medication Adherence) ................................................................ .84
9.12 Extent of Exposure ............................................................................................... 84
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS ..................................................................................................... 85
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........ 85
10.1.1 Code of Conduct for Clinical Trials ............................................................. 85
10.1.2 Financial Disclosure ..................................................................................... 87
10.1.3 Data Protection ............................................................................................. 87
10.1.3.1 Confidentiality  of Data ...................................................................... 87
10.1.3.2 Confidentiality  of Participant Records ............................................... 87
10.1.3.3 Confidentiality  of IRB/IEC I nformation ............................................ 88
10.1.4 Committees Structure ................................................................................... 88
10.1.4.1 External Data Monitoring Committee ............................................... 88
10.1.4.2 Executive Oversight Committee ........................................................ 88
10.1.4.3 Scientific Advisory  Committee .......................................................... 88
10.1.5 Publication Policy ........................................................................................ 89
10.1.6 Compliance with Study  Registration and Results Posting Requirements ...89
10.1.7 Compliance with Law, Audit, and Debarment ............................................ 89
10.1.8 Data Qualit y Assurance ............................................................................... 90 
  050DGF 
  05KG3M
PRODUCT: V114 10
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
10.1.9 Source Documents ....................................................................................... 91
10.1.10 Study  and Site Closure ................................................................................. 91
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. 92
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 93
10.3.1 Definition of AE .......................................................................................... 93
10.3.2 Definition of SAE ........................................................................................ 94
10.3.3 Additional Events Reported ......................................................................... 95
10.3.4 Recording AE and SAE ............................................................................... 95
10.3.5 Reporting of AE, SAE, and Other Reportable Safety  Events to the 
Sponsor ...................................................................................................... 100
10.4 Appendix 4 : Medical Device Incidents: Definition and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ......................................... 102
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing ...................... 103
10.5.1 Definitions .................................................................................................. 103
10.5.2 Contraception Requirements ...................................................................... 104
10.5.3 Pregnancy  Testing ...................................................................................... 105
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research (Does not apply to CAIH participants) ....................... 105
10.7 Appendix 7: Country -specific Requirements .................................................. 110
10.8 Appendix 8: Abbreviations ............................................................................... 111
11 REFERENCES............................................................................................................. 113 
  050DGF 
  05KG3M
PRODUCT: V114 11
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
LIST OF TABLES
Table 1 Study  Interventions .................................................................................... 51
Table 2 Approximate Blood Volumes Drawn b y Stud y Visit and by Sample 
Types for Participants Enrolled at non -CAIH Sites ................................... 59
Table 3 Approximate Blood Volumes Drawn b y Stud y Visit and by Sample 
Types for Participants Enrolled at CAIH Sites .......................................... 59
Table 4 Reporting T ime Periods and Time Frames for Adverse Events and 
Other Reportable Safet y Events ................................................................ .70
Table 5 Analy sis Strategy  for Immunogenicit y Variables ...................................... 79
Table 6 Analy sis Strategy for Safety  Parameters Following Each Vaccination .....81
Table 7 Within -group 95% CIs for Varying Hypothetical OPA GMTs and 
Vary ing Standard Deviations ..................................................................... 83
Table 8 Protocol -required Safet y Laboratory  Assessments .................................... 92
Table 9 Contraceptive Methods ............................................................................ 104 
  050DGF 
  05KG3M
PRODUCT: V114 12
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
LIST OF FIGURES
Figure 1 V114 -017 Study  Design ............................................................................. 18 
  050DGF 
  05KG3M
PRODUCT: V114 13
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Phase 3, Multicenter, Randomized, Double -blind, Active Comparator -
controlled Study  to Evaluate the Safet y, Tolerability , and Immunogenicit y of V114 Followed 
by Administration of PNEUMOVAX™23 Six Months L ater in Immunocompetent Adults 
Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU –
DAY).
Short Title: Safet y andImmunogenicit y of V114 in Adults at Risk for Pneum ococcal 
Disease
Acronym: PNEUmococcal Conjugate Vaccine Trials: V114 -017 (PNEU –DAY)
Hypotheses, Objectives ,and Endpoints :
Objectives and endpoints described below will be evaluated in pneumococcal vaccine -naïve 
participants 18 to 49 y ears of age (inclusive) who are at increased risk for pneumococcal 
disease due to (1) an underly ing medical condition ,(2) behavioral habits such as smoking , or 
(3) living in a community/environment with increased risk of disease transmission.
Primary  Objectives Primary  Endpoints
-Objective: To evaluate the safet y and 
tolerability  of V114 and Prevnar 13™ with 
respect to the proportion of participants with 
adverse events (AEs) within each vaccination 
group separatel y.Following vaccination with V114 or 
Prevnar 13™:
-Solicited injection -site AEs from Day  1 
through Day  5 postvaccination 
-Solicited sy stemic AEs from Day  1 through 
Day 14 postvaccination
-Vaccine -related serious adverse events 
(SAEs) from Day  1 to Month 6
-Objective: To evaluate the serot ype-specifi c 
opsonophagocy tic activity (OPA) Geometric 
Mean Titers (GMTs) at 30 days 
postvaccination (Day  30) with V114 and 
Prevnar 13™ within each vaccination group 
separately .-Seroty pe-specific OPA responses for the 15 
seroty pes in V114 at Day 30 
  050DGF 
  05KG3M
PRODUCT: V114 14
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Secondary  Objectives Secondary  Endpoints
-Objective: To evaluate the safet y and 
tolerability  of PNEUMOVAX™23 
administered 6 months following V114 and 
following Prevnar 13™ with respect to the 
proportion of participants with AEs within 
each vaccination group separa tely.Following vaccination with 
PNEUMOVAX™23:
-Solicited injection -site AEs from Day  1 
through Day  5 postvaccination
-Solicited sy stemic AEs from Day  1 through 
Day 14 postvaccination
-Vaccine -related SAEs from Month 6 to 
Month 7
-Objective: To evalua te the serot ype-specific 
Immunoglobulin G (IgG) Geometric Mean 
Concentrations (GMCs) at 30 day s 
postvaccination (Day  30) with V114 and 
Prevnar 13™ within each vaccination group 
separately .-Seroty pe-specific IgG responses for the 15 
seroty pes in V114 at D ay 30
-Objective: To evaluate the serot ype-specific 
Geometric Mean Fold Rises (GMFRs) and 
proportions of participants with a ≥4-fold rise 
from prevaccination (Day 1) to 30 day s 
postvaccination (Day 30) for both OPA and 
IgG responses for participants admi nistered 
V114 and for participants administered 
Prevnar 13™ within each vaccination group 
separately . -Seroty pe-specific OPA and IgG responses 
for the 15 serot ypes in V114 at Day  1 and 
Day 30
-Objective: To evaluate the serot ype-specific 
(1) OPA GMTs and IgG GMCs at 30 day s 
postvaccination with PNEUMOVAX™23 
(Month 7), (2) GMFRs and proportions of 
participants with a ≥4-fold rise from 
prevaccination (Day  1) to 30 day s 
postvaccination with PNEUMOVAX™23 
(Month 7) for both OPA and IgG responses, 
(3) GMFRs and proportions of participants 
with a ≥4-fold rise from prevaccination with 
PNEUMOVAX™23 (Month 6) to 30 days 
postvaccination with PNEUMOVAX™23 
(Month 7) for both OPA and IgG responses 
for participants administered V114 and 
separately for participants adm inistered 
Prevnar 13™ 6 months before receipt of 
PNEUMOVAX™23.-Seroty pe-specific OPA and IgG responses 
for the 15 serot ypes in V114 at Day  1, Month 
6, and Month 7 
  050DGF 
  05KG3M
PRODUCT: V114 15
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Overall Desig n:
Study  Phase Phase 3
Primary  Purpose Prevention
Indication Pneumococcal disease
Population Pneumococcal vaccine -naïve participants 18 to 49 y ears of 
age (inclusive) who are at increased risk for pneumococcal 
disease due to (1) an underlying medical condition, (2) 
behavioral habits such as smoking, or (3) living in a 
community /environment with increased risk of disease 
transmission .
Study  Type Interventional
Intervention Model Parallel
This is a multi -sitestudy .
Type of Control Active control without placebo
Study  Blinding Double -blind
Masking Participant
Investigator
Estimated Duration o f Study The Sponsor estimates that the study will require 
approximately 20 months from the time the first participant 
signs the informed consent until the last participant’s last 
study -related telephone call or visit.
For purposes of analy sis and reporting, the overall study  
ends when the Sponsor receives the last serology  assay  
result.
Number of Participant s:
Approximately  1500 individuals will be randomly  assigned in a 3:1 ratio to receive either 
V114 (1 125 participants) or Prevnar 13™ (375 participants) at Visit 2 (Day 1). 
Approximately  600 participants will be Native American living on or near a reservation in 
the southwestern United States who are enrolled in the study  through clinical sites of Johns 
Hopkins CAI H.
A subset of Native American participants will be asked to participate in a substudy  in which 
naso-and orophary ngeal swabs and urine samples will be collected to support the 
development of a novel diagnostic assay  for the detection of pneumococcal disease.  
  050DGF 
  05KG3M
PRODUCT: V114 16
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Enrollment into the substudy  will be ha lted when 300 participants have been enrolled or 
when general enrollment into the main study  at the CAI H sites is completed, whichever event 
comes first.
Intervention Groups and Du ration :
Intervention 
Group s Intervention 
Group 
Name VaccineDose 
StrengthDose 
FrequencyRoute 
of 
Admin.Vaccination 
Regimen Use
V114V114 Refer to 
IBSingle 
doseIM Single Dose 
at Visit 2
(Day 1)Experimental
PNEUMOVAX™23Refer to 
product 
labelingSingle 
doseIMSingle Dose 
at Visit 4 
(Month 6)Experimental
Prevnar 
13™Prevnar 13™Refer to 
product 
labelingSingle 
doseIM Single Dose 
at Visit 2
(Day 1)Experimental
PNEUMOVAX™23Refer to 
product 
labelingSingle 
doseIMSingle Dose 
at Visit 4 
(Month 6)Experimental
IB=Investigator’s Brochure; IM = intramuscular
Total 
Number2 intervention groups
Duration of 
ParticipationEach participant will participate in the study  for approximately  7months from 
the time the participant signs the Informed Consent F orm (ICF) through the final 
contact.  
  050DGF 
  05KG3M
PRODUCT: V114 17
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Study Governance Committees:
Steering Committee No
Executive Oversight Committee Yes
Data Monitoring Committee Yes
Clinical Adjudication Committee No
Study  governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :Yes
A list of abbreviations used in this document can be found in Appendix 8. 
  050DGF 
  05KG3M
PRODUCT: V114 18
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
1.2 Schema
The key components of the study  design aredepicted in Figure 1.
Figure 1V114 -017 Study  Design
 
  050DGF 
  05KG3M
PRODUCT: V114 19
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
1.3 Schedule of Activities (SoA)
1.3.1 Schedule of Activities for the Main Study
Study PeriodScreening Intervention Follow -up
CommentsVisit Number: 1 2Telephone 
Contacta3 4Telephone 
Contacta5
Scheduled Time: Screening Day 1 Day 15 Day 30Month 
6 Month 6.5 Month 7
Visit Window:30 days 
or less 
after 
Visit 1Day 15 to 
Day 19 
after 
Visit 2bDay 30 
to Day 
44 after 
Visit 2bDay 166 
to Day 
194 
after 
Visit 2bDay 15 to 
Day 19 after 
Visit 4cDay 30 to 
Day 44 after 
Visit 4cTheresults from all screening 
procedures at Visit 1 must be available 
before enrollment into the study at 
Visit 2 (Day 1).
Administrative and General Procedures
Informed Consent X Consent must be obtained before any 
study procedures.
Informed Consent for Future 
Biomedical Research (Note: C onsent 
and samples will not be collected 
from Native American participants 
enrolled via Johns Hopkins Center 
for American Indian Health [CAIH ])X Informed consent for future biomedical 
research samples must be obtained 
before the blood sample (DNA sample) 
is collected.
Assignment of Screening Number X
Participant Identification Card X
Inclusion/Exclusion Criteria X X
Medical History X X The participant’s medical history for the 
5 years prior to these visits will be 
reviewed. History of tobacco use will 
also be collected for all participants. 
  050DGF 
  05KG3M
PRODUCT: V114 20
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Study PeriodScreening Intervention Follow -up
CommentsVisit Number: 1 2Telephone 
Contacta3 4Telephone 
Contacta5
Scheduled Time: Screening Day 1 Day 15 Day 30Month 
6 Month 6.5 Month 7
Visit Window:30 days 
or less 
after 
Visit 1Day 15 to 
Day 19 
after 
Visit 2bDay 30 
to Day 
44 after 
Visit 2bDay 166 
to Day 
194 
after 
Visit 2bDay 15 to 
Day 19 after 
Visit 4cDay 30 to 
Day 44 after 
Visit 4cTheresults from all screening 
procedures at Visit 1 must be available 
before enrollment into the study at 
Visit 2 (Day 1).
Disease -specific Laboratory and 
Diagnostic Assess ments:
Diabetes mellitus : hemoglobin A1c
Chronic liver disease : aspartate 
aminotransferase , alanine 
aminotransferase , total bilirubin, 
prothrombin time/international 
normalized ratio , albumin, platelets
Chronic lung disease : spirometry X Spirometry can be performed at 
screening if prospective participants 
have a clinical history of COPD or 
asthma consistent with inclusion criteria 
but no supporting documentation by 
spirometry as required by Inclusion 
Criteria 1c and 1d . 
Alcohol Use Disorders Identification 
Test (AUDIT -C)X AUDIT -C results will be used for 
stratification .
Assignment of Randomization Number X
Prior/Concomitant Medication and 
Non-Study Vaccination ReviewX X X X X X
V114 or Prevnar 13™ Administration 
(Blinded)X At Visit 2 (Day 1), participants will 
receive either a single dose of V114 (or 
a single dose of Prevnar 13™. 
PNEUMOVAX™23 Administration 
(Open -label)X At Visit 4 (Month 6), participants will 
receive a single dose of 
PNEUMOVAX™23 .
Provide Electronic Vaccination Report 
Card (eVRC) to Participants Not 
Enrolled through the CAIHX X Participants will be provided an eVRC 
at Visit 2 (Day 1) and Visit 4 (Month 6) 
to record adverse events (AEs) and 
body temperature measurements. 
Instructions for using the eVRC will be 
reviewed with the participant. 
  050DGF 
  05KG3M
PRODUCT: V114 21
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Study PeriodScreening Intervention Follow -up
CommentsVisit Number: 1 2Telephone 
Contacta3 4Telephone 
Contacta5
Scheduled Time: Screening Day 1 Day 15 Day 30Month 
6 Month 6.5 Month 7
Visit Window:30 days 
or less 
after 
Visit 1Day 15 to 
Day 19 
after 
Visit 2bDay 30 
to Day 
44 after 
Visit 2bDay 166 
to Day 
194 
after 
Visit 2bDay 15 to 
Day 19 after 
Visit 4cDay 30 to 
Day 44 after 
Visit 4cTheresults from all screening 
procedures at Visit 1 must be available 
before enrollment into the study at 
Visit 2 (Day 1).
Provide Paper Vaccination Report Card 
(VRC) to Native American participants 
enrolled via Johns Hopkins CAIHX X Participants will be provided a paper 
VRC at Visit 2 (Day 1) and Visit 4 
(Month 6) to record AEs and body 
temperature measurements. Instructions 
for using the paper VRC will be 
reviewed with the participant.
Review Paper VRC/eVRC Data with 
ParticipantXaX XaX Site personnel will discuss information 
entered into the paper VRC/eVRC with 
participants during the telephone 
contacts conducted on Day 15 and 
Month 6.5. A full review of the 
completed paper VRC/eVRC will occur 
at Visit 3 (Day 30) and Visit 5 
(Month 7).
Collect P aper VRC/eVRC from 
participantX X
6-month Safety Follow -up 
QuestionnaireX Site personnel will review the 
information in the 6 -month Safety 
Follow -up Questionnaire provided by 
the Sponsor with the participant. Data 
to be reported from this discussion will 
include SAEs and/or any updates to 
previously reported safety information. 
  050DGF 
  05KG3M
PRODUCT: V114 22
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Study PeriodScreening Intervention Follow -up
CommentsVisit Number: 1 2Telephone 
Contacta3 4Telephone 
Contacta5
Scheduled Time: Screening Day 1 Day 15 Day 30Month 
6 Month 6.5 Month 7
Visit Window:30 days 
or less 
after 
Visit 1Day 15 to 
Day 19 
after 
Visit 2bDay 30 
to Day 
44 after 
Visit 2bDay 166 
to Day 
194 
after 
Visit 2bDay 15 to 
Day 19 after 
Visit 4cDay 30 to 
Day 44 after 
Visit 4cTheresults from all screening 
procedures at Visit 1 must be available 
before enrollment into the study at 
Visit 2 (Day 1).
Safety Procedures
Directed Physical Examination X X To be performed by the investigator or 
medically qualified designee for 
determination of disease -specific 
physical assessments at Visit 1 
(Screening) and before 
PNEUMOVAX™23 vaccination at 
Visit 4 (Month 6).
Complete Physical Examination X To be performed by the investigator or 
medically qualified designee before 
study vaccine is administered.
Pregnancy Test – if applicable X X A pregnancy test consistent with local 
requirements (sensitive to at least 25 IU 
beta human chorionic gonadotropin 
[β-hCG]) must be performed before 
administration of the study vaccine in 
females who are of reproductive 
potential. Urine or serum tests can be 
used, and results must be negative 
before vaccination can occur.
Pregnancy tests can be repeated as 
needed based on local requirements . 
  050DGF 
  05KG3M
PRODUCT: V114 23
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Study PeriodScreening Intervention Follow -up
CommentsVisit Number: 1 2Telephone 
Contacta3 4Telephone 
Contacta5
Scheduled Time: Screening Day 1 Day 15 Day 30Month 
6 Month 6.5 Month 7
Visit Window:30 days 
or less 
after 
Visit 1Day 15 to 
Day 19 
after 
Visit 2bDay 30 
to Day 
44 after 
Visit 2bDay 166 
to Day 
194 
after 
Visit 2bDay 15 to 
Day 19 after 
Visit 4cDay 30 to 
Day 44 after 
Visit 4cTheresults from all screening 
procedures at Visit 1 must be available 
before enrollment into the study at 
Visit 2 (Day 1).
Body Temperature Measurement 
Before VaccinationX X Each participant's body temperature 
must be taken before vaccination. 
Participants who present with fever 
(oral or tympanic temperature ≥100.4°F 
[≥38.0°C]; axillary or temporal 
temperature ≥99.4°F [≥37.4°C]; or 
rectal temperature ≥101.4°F [≥38. 6°C]) 
will h ave the vaccination delayed until 
fever is resolved for 72 hours.
30-Minute Postvaccination Observation 
PeriodX X To be performed by blinded study site 
personnel only.
AE Monitoring X X X X X X X AEs (serious and nonserious) are to be 
reported from Days 1 through 14 
following each vaccination. Serious 
adverse events (SAEs) and deaths are to 
be reported throughout the duration of 
an individual’s study participation.
AEs that occur after the consent form is 
signed but before 
allocation/randomization are also to be 
reported (Section 8.4.1). 
  050DGF 
  05KG3M
PRODUCT: V114 24
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Study PeriodScreening Intervention Follow -up
CommentsVisit Number: 1 2Telephone 
Contacta3 4Telephone 
Contacta5
Scheduled Time: Screening Day 1 Day 15 Day 30Month 
6 Month 6.5 Month 7
Visit Window:30 days 
or less 
after 
Visit 1Day 15 to 
Day 19 
after 
Visit 2bDay 30 
to Day 
44 after 
Visit 2bDay 166 
to Day 
194 
after 
Visit 2bDay 15 to 
Day 19 after 
Visit 4cDay 30 to 
Day 44 after 
Visit 4cTheresults from all screening 
procedures at Visit 1 must be available 
before enrollment into the study at 
Visit 2 (Day 1).
Immunogenicity Procedures
Serum for Immunogenicity Assays 
(including retention serum)X X X X Blood samples must be collected before 
study vaccination when applicable.
After completion of 
opsonophagocytic (OPA) and 
electrochemiluminescence (ECL)
testing , serum samples will be 
stored to conduct any additional 
study -related testing as required by 
regulatory agencies or the Sponsor. 
Leftover sera from the study may 
be used for the development and/or 
validation of p neumococcal assays 
after completion of all study -related 
immunogenicity testing; this 
applies only to sera received from 
randomized study participants who 
provided consent for future 
biomedical research.
For participants enrolled via the 
CAIH, any sera rem aining after 
OPA and ECL testing will be 
returned to the CAIH for 
destruction. 
  050DGF 
  05KG3M
PRODUCT: V114 25
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Study PeriodScreening Intervention Follow -up
CommentsVisit Number: 1 2Telephone 
Contacta3 4Telephone 
Contacta5
Scheduled Time: Screening Day 1 Day 15 Day 30Month 
6 Month 6.5 Month 7
Visit Window:30 days 
or less 
after 
Visit 1Day 15 to 
Day 19 
after 
Visit 2bDay 30 
to Day 
44 after 
Visit 2bDay 166 
to Day 
194 
after 
Visit 2bDay 15 to 
Day 19 after 
Visit 4cDay 30 to 
Day 44 after 
Visit 4cTheresults from all screening 
procedures at Visit 1 must be available 
before enrollment into the study at 
Visit 2 (Day 1).
Future Biomedical Research
Blood (DNA) for Future Biomedical 
ResearchX Collected from randomized participants 
who provided consent for future 
biomedical research (Section 8. 8).
Native American participants enrolled 
via the CAIH will not participate in 
future biomedical research .
aFor participants enrolled via the CAIH, this visit may be conducted in person at the discretion of the investigator. 
bWhen scheduling the Telephone Contact (Day 15), Visit 3 (Day 30) ,and Visit 4 ( Month 6 ), “Day 1” is the date of Visit 2.
cWhen scheduling the Telephone Contact (Month 6.5)andVisit 5 (Month 7 ), “Day 1” is the date of Visit 4 . 
  050DGF 
  05KG3M
PRODUCT: V114 26
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
1.3.2 Schedule of Activities for Native Americans Enrolled through the Johns Hopkins Center for American Indian Health 
(CAIH) Participating in the Substudy
Study Period Screening InterventionFollow -
up
Visit Number: 1 2 2Aa2Ba2Ca3 4 4Aa4Ba4Ca5
Scheduled Time: ScreeningDay 
1Day 
3Day 
8Day 
15Day 
30Month 
6Day 
183Day
188Day
195Month 
7 Comments
Visit Window:30 days 
or less 
after 
Visit 1Day 2
to 
Day 4 
after 
Visit 2bDay 7
to 
Day 9 
after 
Visit 2bDay 15 
to 
Day 17 
after 
Visit 2bDay 30 
to 
Day 44 
after 
Visit 2bDay 166 
to 
Day 194 
after 
Visit 2bDay 2 
to 
Day 4 
after 
Visit 4cDay 7 
to 
Day 9 
after 
Visit 4cDay 15
to 
Day 17 
after 
Visit 4cDay 30
to 
Day 44 
after 
Visit 4cThe results from all 
screening procedures at 
Visit 1 must be available 
before enrollment into the 
study at Visit 2 (Day 1).
Adm inistrative Procedures and General Procedures
Informed Consent (to 
include consent for 
nasopharyngeal [NP]and 
oropharyngeal [OP]swabs 
and urine collection 
substudy)X Consent must be obtained 
before any study procedures.
Assignment of Screening 
NumberX
Participant I dentification 
CardX
Inclusion/Exclusion 
CriteriaX X
Medical History X X The participant’s medical 
history for the 5 years prior 
to these visits will be 
reviewed. History of tobacco 
use will also be collected for 
all participants. 
  050DGF 
  05KG3M
PRODUCT: V114 27
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Study Period Screening InterventionFollow -
up
Visit Number: 1 2 2Aa2Ba2Ca3 4 4Aa4Ba4Ca5
Scheduled Time: ScreeningDay 
1Day 
3Day 
8Day 
15Day 
30Month 
6Day 
183Day
188Day
195Month 
7 Comments
Visit Window:30 days 
or less 
after 
Visit 1Day 2
to 
Day 4 
after 
Visit 2bDay 7
to 
Day 9 
after 
Visit 2bDay 15 
to 
Day 17 
after 
Visit 2bDay 30 
to 
Day 44 
after 
Visit 2bDay 166 
to 
Day 194 
after 
Visit 2bDay 2 
to 
Day 4 
after 
Visit 4cDay 7 
to 
Day 9 
after 
Visit 4cDay 15
to 
Day 17 
after 
Visit 4cDay 30
to 
Day 44 
after 
Visit 4cThe results from all 
screening procedures at 
Visit 1 must be available 
before enrollment into the 
study at Visit 2 (Day 1).
Disease -specific 
Laboratory and 
Diagnostic Assessments:
Diabetes mellitus:
hemoglobin A1c
Chronic liver disease:
aspartate aminotra nsferase, 
alanine aminotransferase, 
total bilirubin, prothrombin 
time/international 
normalized ratio, albumin, 
platelets  
Chronic lun g disease : 
spirometryX Spirometry can be 
performed at screening if 
prospective participants have 
a clinical history of COPD 
or asthma consistent with 
inclusion criteria but no 
supporting documentation 
by spirometry as required by 
Inclusion Criteria 1c and 1d.
Alcohol Use Disorders 
Identification Test 
(AUDIT -C) X AUD IT-C results will be 
used for stratification.
Assignment of 
Randomization NumberX
Prior/Concomitant 
Medication and Non -Study 
Vaccination ReviewX X X X X X
V114 or Prevnar 13™ 
Administration (Blinded)X At Visit 2 (Day 1), 
participants will receive 
either a single dose of V114 
or a single dose of 
Prevnar 13™. 
PNEUMOVAX™23 
Administration (Open -
label)X At Visit 4 (Month 6), all 
participants will receive a 
single dose of 
PNEUMOVAX™23. 
  050DGF 
  05KG3M
PRODUCT: V114 28
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Study Period Screening InterventionFollow -
up
Visit Number: 1 2 2Aa2Ba2Ca3 4 4Aa4Ba4Ca5
Scheduled Time: ScreeningDay 
1Day 
3Day 
8Day 
15Day 
30Month 
6Day 
183Day
188Day
195Month 
7 Comments
Visit Window:30 days 
or less 
after 
Visit 1Day 2
to 
Day 4 
after 
Visit 2bDay 7
to 
Day 9 
after 
Visit 2bDay 15 
to 
Day 17 
after 
Visit 2bDay 30 
to 
Day 44 
after 
Visit 2bDay 166 
to 
Day 194 
after 
Visit 2bDay 2 
to 
Day 4 
after 
Visit 4cDay 7 
to 
Day 9 
after 
Visit 4cDay 15
to 
Day 17 
after 
Visit 4cDay 30
to 
Day 44 
after 
Visit 4cThe results from all 
screening procedures at 
Visit 1 must be available 
before enrollment into the 
study at Visit 2 (Day 1).
Provide P aper Vaccination 
Report Card (VRC) to 
ParticipantsX X Participants will be provided 
a paper VRC at Visit 2 
(Day 1) and Visit 4 
(Month 6) to record adverse 
events (AEs) and body 
temperature measurements. 
Instructions for using the 
paper VRC will be reviewed 
with the participant.
Review P aper VRC Data 
with ParticipantX X X X Site personnel will fully 
review all information 
entered onto the paper VRC 
with CAI H Substudy 
participants during Visit 2C 
and Visit 4C. A full review 
of the completed paper VRC 
will occur at Visit 3 (Day 
30) and Visit 5 (Month 7) if 
not reviewed and collected 
at the previous visit . 
  050DGF 
  05KG3M
PRODUCT: V114 29
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Study Period Screening InterventionFollow -
up
Visit Number: 1 2 2Aa2Ba2Ca3 4 4Aa4Ba4Ca5
Scheduled Time: ScreeningDay 
1Day 
3Day 
8Day 
15Day 
30Month 
6Day 
183Day
188Day
195Month 
7 Comments
Visit Window:30 days 
or less 
after 
Visit 1Day 2
to 
Day 4 
after 
Visit 2bDay 7
to 
Day 9 
after 
Visit 2bDay 15 
to 
Day 17 
after 
Visit 2bDay 30 
to 
Day 44 
after 
Visit 2bDay 166 
to 
Day 194 
after 
Visit 2bDay 2 
to 
Day 4 
after 
Visit 4cDay 7 
to 
Day 9 
after 
Visit 4cDay 15
to 
Day 17 
after 
Visit 4cDay 30
to 
Day 44 
after 
Visit 4cThe results from all 
screening procedures at 
Visit 1 must be available 
before enrollment into the 
study at Visit 2 (Day 1).
Collect P aper VRC from 
ParticipantX X X X The paper VRC after the 
first vaccination can be 
collected at either Visit 
2Cor Visit 3, and the 
paper VRC after the 
second vaccination can 
be collected at either 
Visit 4Cor Visit 5 at the 
discretion of the study 
personnel . A full review 
of eachcompleted paper 
VRC with the participant 
will occur at the time of 
collection by the site.
6-month Safety Follow -
up QuestionnaireX Site personnel will 
review the information in 
the 6- month Safety 
Follow -up Questionnaire 
provided by the Sponsor 
with the participant. Data 
to be reported from this 
discussion will include 
SAEs and/or any updates 
to previously reported 
safety information 
  050DGF 
  05KG3M
PRODUCT: V114 30
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Study Period Screening InterventionFollow -
up
Visit Number: 1 2 2Aa2Ba2Ca3 4 4Aa4Ba4Ca5
Scheduled Time: ScreeningDay 
1Day 
3Day 
8Day 
15Day 
30Month 
6Day 
183Day
188Day
195Month 
7 Comments
Visit Window:30 days 
or less 
after 
Visit 1Day 2
to 
Day 4 
after 
Visit 2bDay 7
to 
Day 9 
after 
Visit 2bDay 15 
to 
Day 17 
after 
Visit 2bDay 30 
to 
Day 44 
after 
Visit 2bDay 166 
to 
Day 194 
after 
Visit 2bDay 2 
to 
Day 4 
after 
Visit 4cDay 7 
to 
Day 9 
after 
Visit 4cDay 15
to 
Day 17 
after 
Visit 4cDay 30
to 
Day 44 
after 
Visit 4cThe results from all 
screening procedures at 
Visit 1 must be available 
before enrollment into the 
study at Visit 2 (Day 1).
Safety Procedures
Directed Physical 
ExaminationX X To be performed by the 
investigator or medically 
qualified designee at Visit 1 
(Screening) for 
determination of disease -
specific physical 
assessments, and before 
PNEUMOVAX™23 
vaccination at Visit 4 
(Month 6).
Complete Physical 
ExaminationX To be performed by the 
investigator or medically 
qualified designee before 
study vaccine is 
administered.
Pregnancy Test – if 
applicableX X A pregnancy test consistent 
with local requirements 
(sensitive to at least 25 I U 
beta human chorionic 
gonadotropin [β-hCG]) must 
be performed before 
administration of the study 
vaccine in females who are 
of reproductive potential. 
Urine or serum tests can be 
used, and results must be 
negative before vaccination 
can occur.
Pregnancy tests can be 
repeated as needed based on 
local requirements. 
  050DGF 
  05KG3M
PRODUCT: V114 31
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Study Period Screening InterventionFollow -
up
Visit Number: 1 2 2Aa2Ba2Ca3 4 4Aa4Ba4Ca5
Scheduled Time: ScreeningDay 
1Day 
3Day 
8Day 
15Day 
30Month 
6Day 
183Day
188Day
195Month 
7 Comments
Visit Window:30 days 
or less 
after 
Visit 1Day 2
to 
Day 4 
after 
Visit 2bDay 7
to 
Day 9 
after 
Visit 2bDay 15 
to 
Day 17 
after 
Visit 2bDay 30 
to 
Day 44 
after 
Visit 2bDay 166 
to 
Day 194 
after 
Visit 2bDay 2 
to 
Day 4 
after 
Visit 4cDay 7 
to 
Day 9 
after 
Visit 4cDay 15
to 
Day 17 
after 
Visit 4cDay 30
to 
Day 44 
after 
Visit 4cThe results from all 
screening procedures at 
Visit 1 must be available 
before enrollment into the 
study at Visit 2 (Day 1).
Body Temperature 
Measurement Before 
VaccinationX X Each participant's body 
temperature must be taken 
before vaccination. 
Participants who present 
with fever (oral or tympanic 
temperature ≥100.4°F 
[≥38.0°C]; axillary or 
temporal temperature 
≥99.4°F [≥37.4°C]; or rectal 
temperature ≥101.4°F 
[≥38.6°C]) will have the 
vaccination delayed until 
fever is resolve d for 
72hours.
30-Minute Postvaccination 
Observation PeriodX X To be performed by blinded 
study site personnel only.
AE Monitoring X X X X X X X X X X X AEs (serious and 
nonserious) are to be 
reported from Days 1 
through 14 following each 
vaccination. Serious adverse 
events (SAEs) and deaths 
are to be reported throughout 
the duration of an 
individual’s study 
participation. AEs that occur 
after the consent form is 
signed but before 
allocation/randomization are 
also to be reported 
(Section 8.4.1). 
  050DGF 
  05KG3M
PRODUCT: V114 32
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Study Period Screening InterventionFollow -
up
Visit Number: 1 2 2Aa2Ba2Ca3 4 4Aa4Ba4Ca5
Scheduled Time: ScreeningDay 
1Day 
3Day 
8Day 
15Day 
30Month 
6Day 
183Day
188Day
195Month 
7 Comments
Visit Window:30 days 
or less 
after 
Visit 1Day 2
to 
Day 4 
after 
Visit 2bDay 7
to 
Day 9 
after 
Visit 2bDay 15 
to 
Day 17 
after 
Visit 2bDay 30 
to 
Day 44 
after 
Visit 2bDay 166 
to 
Day 194 
after 
Visit 2bDay 2 
to 
Day 4 
after 
Visit 4cDay 7 
to 
Day 9 
after 
Visit 4cDay 15
to 
Day 17 
after 
Visit 4cDay 30
to 
Day 44 
after 
Visit 4cThe results from all 
screening procedures at 
Visit 1 must be available 
before enrollment into the 
study at Visit 2 (Day 1).
Immunogenicity Procedures
Serum for Immunogenicity 
AssaysX X X X Blood samples must be 
collected before study 
vaccination when applicable.
Anysera remaining after 
OPA and ECL testing will 
be returned to the CAI H for 
destruction.
Substudy Assay Development Procedures
NP and OP swab collection 
for NP/OP colonization 
testing; urine sample 
collection for urine antigen 
detection assayX X X X X X X X X X Any samples from NP/OP 
swab and urine collection 
remaining after protocol -
specified testing has been 
completed will be returned 
to the CAIH for destruction 
or for further testing by 
CAIH if agreed upon 
between Native American 
community and CAI H.
aSubstudy -specific visit.
bWhen scheduling these visits , “Day 1” is the date of Visit 2.
cWhen scheduling these visits, “Day 1” is the date of Visit 4 . 
  050DGF 
  05KG3M
PRODUCT: V114 33
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
2 INTRODUCTION
Merck Sharp & Dohme Corp. (MSD) is developing an investigational 15 -valent 
pneumococcal conjugate vaccine (PCV) (referred to as V114) for prevention of 
pneumococcal disease caused by  the serot ypes contained in the vaccine. V114 contains the 
13 seroty pes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 23F ) present in the licensed 
vaccine Prevnar 13™ (pneumococcal 13 -valent conjugate vaccine [diphtheria CRM 197
protein], Wy eth Pharmaceuticals, a subsidiary  of Pfizer, I nc., Philadelphia, PA), plus 
2 additional seroty pes (22F, 33F).
2.1 Study Rationale
Chronic h eart, liver and lung disease ,and diabetes increase the risk for invasive and 
noninvasive pneumococcal disease [Wey cker, D., et al 2016] [Curcio, D., et al 2015] 
[Morton, J. B., et al 2017] [Torres, A., et al 2015] .Immunocompetent persons with 1or more 
of these conditions are classified as immunocompetent ‘at risk’ b y the Advisory  Committee 
on Immunization Practices (ACI P), in contrast to the ‘high risk’ group of 
immunocompromised individua ls [Centers for Disease Control and Prevention (CDC) 2010] .
In the United States ( US), the ACI P guidelines have included recommendations for 
pneumococcal vaccination for adults with diabetes and chronic cardiac, lung, and liver 
disease since the first pneumococcal pol ysaccharide vaccine was marketed in 1978 [Center 
for Disease Control 1978] ; asthma and smoking were added as specific risk factors in 2010 
[Centers for Disease Control and Prevention (CDC) 2010] . Currently , PNEUMOVAX ™23 
(pneumococcal vacci ne, poly valent [23-valent ], MSD )is the only  pneumococcal vaccine 
recommended b y the ACIP for at -risk immunocompetent adults 19 to64years of age. 
However, in other countries, pneumococcal vaccine recommendations for this population 
also include Prevnar 13™, or sequential vaccination with Prevnar 13 ™and 
PNEUMOVAX ™23, as some evidence suggests that functional antibod y responses induced 
by PCVs are superior to those induced by pneumococcal poly saccharide vaccines [Centers 
for Disease Control and Prevention (CDC) 2010] [Center for Disease Control and Prevention 
2012] [Falkenhorst, G., et al 2017] [Australian Government Department of Health 2017] 
[French High Council for Public Health 2017] [Castiglia, P. 2014] [Jackson, L . A., et al 
2013] .
The burden of pneumococcal disease is disproportionally  high in some Native American 
communities on tribal land compared to the general US population [Weatherholtz, R., et al 
2010] .While the youngest and oldest individuals are at highest risk, elevated rates of 
invasive pneumococcal disease (IPD) are found throughout all age groups. Among Navajo 
adults, chronic heart failure, alcohol use ,and unemploy ment are associated with an increased 
risk of I PD [Watt, J. P., et al 2007] . Many  Native American populations experience a high 
burden of chronic medical conditions and poor socioeconomic risk facto rs. In 1997, the 
ACIP recommended routine use of PNEUMOVAX ™23 for individuals ages 2 through 64 
yearsof age belonging to Alaska Natives or certain American Indian tribes, in addition to the 
age-based recommendation for individuals ≥ 65 years [Centers for Disease Control and 
Prevention 1997] . This recommendation was removed in 2010 due to the routine use of  
  050DGF 
  05KG3M
PRODUCT: V114 34
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
PCVs in infants . However , an option was retained for targeted vaccination of adults living in 
areas with el evated risk for I PD compared to the general US population [Centers for Disease 
Control and Prevention (CDC) 2010] .
Despite ACI P vaccination recommendations and the herd protection provided to adults due to 
routi ne infant PCV immunization, rates of I PD caused by  serot ypes included in currentl y 
marketed pneumococcal vaccines ,as well as those not included in any  vaccine, remain 
higher in at -risk adults than in health y individuals [Pilishvili, T., et al 2014] . The associated 
morbidity andmortality  and healthcare costs are substantial [Wey cker, D., et al 2016] [Shea, 
K. M., et al 2014] and emphasize the need for new preve ntive strategies, including PCVs 
with extended seroty pe coverage.
This clinical study  is designed to evaluate the safety , tolerability , and immunogenicity  of a 
single dose of V114 andPrevnar 13 ™in immunocompetent, at -risk individuals ,followed b y 
sequential administration of PNEUMOVAX ™23 6 months later .This study  design will 
assess the safety  of V114 for 6 months, while also providing d ata on the safety  and 
immunogenicit y of the sequential administration of PNEUMOVAX23 ™in this popula tion.
The data from this study  will contribute to the overall safet y database and immunogenicit y 
profile of V114 to support initial licensure in adults 18 through 49 years of age.
2.2 Background
2.2.1 V114 and Pneumococcal Disease
Refer to the Investigator’s Brochure (IB) for V114 for more detailed background, including 
information on pneumococcal disease burden.
Streptococcus pneumoniae is a significant cause of disease worldwide, with clinical 
manifestations including pneumonia, meningitis, otitis media, sinusitis, and sepsis. Adults 
with comorbid conditions, in particular immunocompromised individuals, have a higher 
incidence of IPD morbidity  and mortalit y in all age groups compared to adults without the 
comorbid conditions [Lexau, C. A., et al 2005] .
Currently  licensed pneumococcal conjugate vaccines (eg, Prevnar™, Sy nflorix™, and 
Prevnar 13™) were first implemented in infant immunization programs in many  countries 
worldwide. Prevnar™ was first licensed in 2000 and later replaced by Prevnar 13™ in 2009 
for the European Union and 2010 for the United States . Although Prevnar 13™ is indicated 
for children and adults, Synflorix™ is only  indicated for children up to 5 y ears of age. 
Widespread use of PCVs has reduced the burden of pneumococcal disease caused b y the 
seroty pes contained in the vaccines in children who were targeted b y the vaccination 
programs and unvaccinated individuals from other age groups (herd protection) [Centers for 
Disease Control and Prevention 2008] [Ruckinger, S., et al 2009] [Farrell, D. J, et al 2007] 
[Pilishvili, Tamara, et al 2010] [L exau, C. A., et al 2005] [Metlay , J. P., et al 2006] [Whitney , 
Cynthia G., et al 2003] [Moore, M. R., et al 2015] [L epoutre, A., et al 2015] [Weiss, S., et al 
2015] [Martinelli, D., et al 2014] [Guevara, M., et al 2016] [Waight, P. A., et al 2015] 
[Jokinen, J., et al 2015] [ Palmu, A. A., et al 2015] [Wagenvoort, G. H., et al 2016] .  
  050DGF 
  05KG3M
PRODUCT: V114 35
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Prevnar 13™ was also shown to be efficacious against vaccine -type nonbacteremic 
pneumococcal pneumonia and IPD in adults ≥65 years of age [Bonten, M. J. , et al 2015]. 
These stud y results were the basis of the recommendation from the ACI P for the sequential 
administration of Prevnar 13™ followed at least 12 months later by PNEUMOVAX™23 in 
adults ≥65 y ears of age [Tomczy k, S., et al 2014] [Kobay ashi, M., et al 2015] .
Although cases of IPD have decreased following implementation of PCVs, an increase in 
IPD caused b y serotypes not covered b y currently  available vaccines has been observed. 
V114 contains 2 additional serot ypes (22F, 33F) compared with Prevnar 13™. The sele ction 
of 22F and 33F was primarily based on epidemiological importance of these 2 additional 
seroty pes. Recent data from the US suggest that 22F is the most common serotype not 
included in Prevnar 13™ in adults ≥18 y ears of age, causing 13% of I PD cases. S eroty pe 33F 
is associated with an additional 5% of I PD cases [Moore, M. R., et al 2015] . Data from the 
United Kingdom also showed that ,in 2013/2014, 22F and 33F are frequent seroty pes in 
adults ≥65 y ears of age , accounting for approximately  10% and 4% of I PD cases in that age 
group, respectively  [Waight, P. A., et al 2015] .Data from 2014 reported in the 2016 annual 
epidemiological report on I PD by  the European Centre for Disease Prevention and Control 
showed that both serot ypes 22F and 33F are among the most common seroty pes causing IPD 
[European Centre for Disease Prevention and Control 2016] .
The serot ypes included in V114 will provide broad coverage of the leading seroty pes 
associated with pneumococcal disease worldwide. V114 is designed to meet continuing 
medical and public health needs for PCVs globally, as well as to address the emergence of 
pneumococcal disease caused by serot ypes not contained in currently licensed PCVs. V114 is 
designed to offer broader seroty pe coverage than Prevnar 13™ against pneumococcal disease 
in both pediatric and adult populations.
2.2.2 Preclinical and Clinical Studies
Refer to the IB for informat ion on completed preclinical and clinical studies conducted with 
V114.
2.2.3 Information on Other Study -related Therapy
2.2.3.1 Prevnar 13™
Refer to approved labeling for detailed background information on Prevnar 13™.
Prevnar 13™ contains all of the pneumococcal seroty pes included in Prevnar™ (4, 6B, 9V, 
14, 18C, 19F, 23F) plus 6 additional serotypes (1, 3, 5, 6A, 7F, and 19A).
The adult indication was approved based on immune responses elicited b y Prevnar 13™ in 
comparison with PNEUMOVAX™23. A placebo -controlled clinical efficacy  trial 
(Community Acquired Pneumonia I mmunization Trial in Adults [CAPiTA]) evaluated the 
efficacy  of Prevnar 13™ against pneumococcal pneumonia and IPD in immunocompetent
adults ≥65 y ears of age. Results from CAPiTA showed that Prevnar 13™ was 45.6% 
(95% confidence interval [CI ]:21.8% to 62.5%) efficacious against vaccine -type  
  050DGF 
  05KG3M
PRODUCT: V114 36
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
nonbacteremic pneumococcal pneumonia and 75.0% (95% CI: 41.4% to 90.8%) efficacious 
against vaccine -type IPD in adults ≥65 y ears of age [Bonten, M. J., et al 2015] .
A post hoc anal ysis of the CAPiTA trial in individuals with defined comorbidities, including 
diabetes mellitus, chronic heart disease, respiratory or liver disease, asplenia ,and smoking ,
showed higher vaccine efficacy  in individuals with diabetes mellitus and a non -significant 
trend towards lower efficacy  in people with respiratory  diseases [Huijts, S. M., et al 2017] .
Prevnar™ and Prevnar 13™ are also known as Prev enar™ and Prevenar 13™ in many  
countries outside of the US; these vaccines arereferred to as Prevnar™ and Prevnar 13™ 
throughout this document.
2.2.3.2 PNEUMOVAX™23
Refer to approved labeling for detailed background information on PNEUMOVAX™23.
PNEUMOVAX™23 is comprised of the poly saccharides from 23 of the most important 
seroty pes causing disease in adults (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 
17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F). The formulation is not adjuvanted and no 
carrier protein is used.
In the US, PNEUMOVAX™23 is recommended by  the ACIP for routine use in 
immunocompetent adults ≥65 y ears of age as sequential administration at least 1 y ear after 
Prevnar 13™ [Kobay ashi, M., et al 2015] . It is also recommended for use in adults aged 19 
through 64 years of age with underly ing medical conditions that increase the risk for serious 
pneumococcal infection. These conditions include, but are not limited to, chronic heart 
disease, chronic lung d isease (including chronic obstructive pulmonary  disease, emph ysema, 
and asthma), diabetes mellitus, alcoholism, chronic liver disease (including cirrhosis), and 
cigarette smoking [Centers for Disease Control and Prevention 2010] .
PNEUMOVAX™23 is also recommended in immunocompromised adults ≥19 y ears of age; 
in this population, a dose of PNEUMOVAX™23 is recommended ≥8weeks following a 
dose of Prevnar 13™ [Kobay ashi, M. , et al 2015] . Many  countries follow similar age -based 
and/or risk -based recommendations for the use of PNEUMOVAX™23 [Castiglia P. 2014] .
2.3 Benefit/Risk Asse ssment
It cannot be guaranteed that participants in clinical studies will directly  benefit from 
treatment during participation, as clinical studies are designed to provide information about 
the safet y and effectiveness of an investigational vaccine .
Approximately 25% of participants will receive Prevnar 13™, the standard of care, as the 
active comparator in this study . V114 is expected to provide comparable immune responses 
to Prevnar 13™ for the shared seroty pes while providing additional coverage for the 
2serot ypes (22F , 33F) unique to V114. I t is unknown if the investigational V114 will have 
the same benefit as Prevnar 13™.  
  050DGF 
  05KG3M
PRODUCT: V114 37
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Additional details regarding specific benefits and risks for participants participating in this 
clinical study  may  be found in the accompa nying IB and Informed Consent Form ( ICF).
3 HYPOTHESIS, O BJECTIVES ,AND ENDPOINTS
Objectives and endpoints described below will be evaluated in pneumococcal vaccine -naïve 
participants 18 to 49 y ears of age (inclusive) who are at increased risk for pneumococcal 
disease due to (1) an underly ing medical condition ,(2) behavioral habits such as smoking , or 
(3) living in a community/environment with increased risk of disease transmission.
Objectives Endpoints
Primary
•Objective : To evaluate the safet y and 
tolerability  of V114 and Prevnar 13™
with respect to the proportion of 
participants with adverse events (AEs)
within each vaccination group separatel y.Following vaccination with V114 or 
Prevnar 13™:
•Solicited injection -site AEs from Day  1 
throu gh Day  5 postvaccination 
•Solicited sy stemic AEs from Day  1 
through Day  14 postvaccination
•Vaccine -related serious adverse events 
(SAEs )from Day  1 to Month 6
•Objective: To evaluate the serot ype-
specific opsonophagocy tic activity  (OPA) 
Geometric Mean Tite rs (GMTs) at 
30days postvaccination (Day  30) with 
V114 and Prevnar 13™ within each 
vaccination group separately .•Seroty pe-specific OPA responses for the 
15 seroty pes in V114 at Day  30
Secondary
•Objective: To evaluate the safet y and 
tolerability  of PNEUMOVAX™23 
administered 6 months following V114 
and following Prevnar 13™ with respect 
to the proportion of participants with AEs
within each vaccination group separatel y.Following vaccination with 
PNEUMOVAX™23:
•Solicited injection -site AEs from Day  1 
through Day  5 postvaccination
•Solicited sy stemic AEs from Day  1 
through Day  14 postvaccination
•Vaccine -related SAEs from Month 6 to 
Month 7 
  050DGF 
  05KG3M
PRODUCT: V114 38
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Objectives Endpoints
•Objective: To evaluate the serot ype-
specific Immunoglobulin G (IgG) 
Geometric Mean Concentration s (GMCs )
at 30 day s postvaccination (Day  30) with 
V114 and Prevnar 13™ within each 
vaccination group separately .•Seroty pe-specific IgG responses for the 
15 seroty pes in V114 at Day  30
•Objective: To evaluate the serot ype-
specific Geometric Mean Fold Rises
(GMFRs )and proportions of participants 
with a ≥4-fold rise from prevaccination 
(Day  1) to 30 day s postvaccination 
(Day 30) for both OPA and IgG 
responses for participants administered 
V114 and for participants administered 
Prevnar 13™ within each vaccination 
group separatel y.•Seroty pe-specific OPA and IgG 
responses for the 15 serotypes in V114 
at Day  1 and Day  30
•Objective: To evaluate the serot ype-
specific (1) OPA GMTs and IgG GMCs 
at 30 day s postvaccination w ith 
PNEUMOVAX™23 (Month 7), 
(2)GMFRs and proportion s of 
participants with a ≥4-fold rise from 
prevaccination (Day  1) to 30 day s 
postvaccination with 
PNEUMOVAX™23 (Month 7) for both 
OPA and IgG responses, (3) GMFRs and 
propor tions of participants with a ≥4-fold 
rise from prevaccination with 
PNEUMOVAX™23 (Mo nth6) to 
30days postvaccination with 
PNEUMOVAX™23 (Month 7) for both 
OPA and IgG responses for participants 
administered V114 and separately  for 
participants administered Prevnar 13™ 6 
months before receipt of 
PNEUMOVAX™23 .•Seroty pe-specific OPA and IgG 
responses for the 15 serotypes in V114 at 
Day 1, Month 6, and Month 7 
  050DGF 
  05KG3M
PRODUCT: V114 39
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Objectives Endpoints
Tertiary /Exploratory
•Objective: To evaluate the serot ype-
specific OPA GMTs and IgG GMCs at 
30days postvaccination (Day  30) with 
V114 compared with Prevnar 13™.•Seroty pe-specific OPA and IgG 
responses for the 15 serotypes in V114 
at Day  30
•Objective: To evaluate the serot ype-
specific OPA GMTs and IgG GMCs at 
30days postvaccination with 
PNEUMOVAX™23 (Month 7) for 
participants administered V114 compared
with participants administered P revnar 
13™ 6 months before receipt of 
PNEUMOVAX™23.•Seroty pe-specific OPA and IgG 
responses for the 15 serotypes in V114 
at Month 7
4 S TUDY DESIGN
4.1 Overall Design
4.1.1 Main Study
Approximately  1500 individuals will be randomly  assigned in a 3:1 ratio to receive either 
V114 (1125 participants) or Prevnar 13™ (375 participants) on Visit 2 (Day 1). All 
participants will also receive a single dose of PNEUMOVAX™23 at Visit 4 (Month 6).
Of the 1500 participants, approximately  600 will be Native American participants en rolled 
through clinical sites of the Johns Hopkins Center for American Indian Health (CAIH ).
Participants must belong to at least 1of the following risk categories:
1.Native American enrolled through a CAIH site
2.diabetes mellitus
3.chronic liver disease
4.chron ic lung disease
5.chronic heart disease
6.current smoker 
  050DGF 
  05KG3M
PRODUCT: V114 40
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Participants with underlying chronic lung, liver, or heart disease, diabetes ,orsmoking areto 
meet disease -specific enrollment criteria as outlined in Section 5.1 and areto be on stable 
treatment for their medical condition for at least 3 months, without any  anticipated treatment 
changes. 
Participants will be followed for local and s ystemic AEs through Day  14 following each 
vaccination. Information for SAEs and deaths, regardless of whether the events are 
considered to be vaccine -related b y the investigator, will be collected from the time consent 
is signed through completion of participation in the study. An external Data Monitoring 
Committee (DMC) will conduct a periodic review of safet y and tolerabi lity data for the adult 
V114 Phase 3 program. A description of the structure, function, and guidelines for decision -
making b y the DMC, along with the timing and content of the safet y reviews ,will be 
outlined in the DMC charter. Information regarding the c omposition of the DMC is provided 
in Appendix 1.
Blood samples for immunogenicity  assay s will be drawn immediately before V114 or 
Prevnar 13™ vaccination at Visit 2 (Day  1), at 30 day s postvaccination at Visit 3 (Day  30), 
immediately  before PNEUMOVAX™23 va ccination at Visit 4 (Month 6), and 30 day s 
postvaccination at Visit 5 (Month 7).
For participants NOT enrolled via the CAIH, after completion of OPA and 
electrochemiluminescence (ECL )testing, serum samples will be stored to conduct an y 
additional study -related testing as required by regulatory  agencies or the Sponsor. Leftover 
sera from the study  may  be used for the development and/or validation of pneumococcal 
assay s after completion of all study -related immunogenicity  testing; this applies only  to sera 
received from randomized study  participants who provided consent for future biomedical 
research .
For participants enrolled via the CAIH, an y sera remaining after OPA and ECL testing wil l 
be returne d to the CAIH for destruction. Based on community  preference, Native American 
participants enrolled via the CAIH will not participate in future biomedical research.
Specific procedures to be performed during the study , as well as their prescrib ed times and 
associated visit windows, are outlined in the Schedule of Activities ( SoA)in Section 1.3. 
Details of each procedure are provided in Section 8.
4.1.2 Substudy
The Sponsor is developing a multivalent pneumococcal serotype -specific urine antigen 
detection assay  (UAD) using serot ype-specific monoclonal capture and detection antibodies 
in a sandwich- binding format on the Luminex platform as a tool for diagnosing invasive and 
non-invasive pneumococcal disease due to serot ypes contained in V114. This substudy  will 
be conducted in the Native American cohort enrolled via CAIH due to higher nasophary ngeal 
(NP) carriage rates in this population than the general population and due to feasibility of 
frequent sample collection via home visits. Each Native American participant enroll ed 
through CAIH sites will be asked to participate in a substudy  and enrollment will be halted 
either when 300 participants have been enrolled in the substudy or when enrollment at CAI H 
sites is completed for the main study ,whichever event comes first. 
  050DGF 
  05KG3M
PRODUCT: V114 41
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
In addition to the procedures prescribed for the main study , substudy  procedures will include 
the collection of NP and orophary ngeal (OP)swabs and urine sample sat defined time points 
before and after each vaccine administration. The combined procedures from the main study  
and the substudy  are outlined in the Substudy  SoA in Section 1.3. 2.Samples will be collected 
within 10 day s before each vaccine administration (V114 or Prevnar 13™ ,and 
PNEUMOVAX™23) for baseline measurements and at the postvaccination visits indicated 
in the Substudy  SoA.
This substudy  will evaluate whether vaccination with V114 or with Prevnar 13™ and/or 
NP/OP colonization with S. pneumoniae will lead to a positive UAD for any  of the 
15pneumococcal serot ypes included in V114. The rationale is based on experiences with 
other pneumococcal UADs .It has been shown that pneumococcal vaccination can turn the 
commerciall y available BinaxNOW™ S.pneumoniae , which detects the C -polysaccharide 
common to different pneumococcal serot ypes, as well as i nvestigative seroty pe-specific 
UADs positive [Priner, M., et al 2008] [Grijalva, C. G., et al 2015] . Furthermore, NP 
colonization with S.pneumoniae can lead to a posit iveBinaxNOW™ S. pneumoniae in 
adults and children and to a positive serotype-specific UAD in children [Esposito, S., et al
2004] [Turner, P., et al 2011] [Knoll, M. D., et al 2016] . The impact of NP/OP colonization 
on seroty pe-specific UAD sin adults is unknown. Inthis substudy , an NP/OP swabs will be 
evaluated for the presence of pneumococcal serotypes via poly merase chain reaction testing 
[Gillis, H. D., et al 2017] .
An initial assessment on the day  of vaccination will establish a baseline for each participant. 
It is unknown for how long pneumococcal antigens could be excreted in urine after 
vaccination. Therefore, multiple postvaccinatio n samples will be taken to be able to provide 
estimates for the duration of the impact of vaccination on UAD performance. A UAD which 
turns positive for 1 or more serot ypes in the day s following vaccination in the absence of 
NP/OP colonization with the sam e serot ype(s) or clinical pneumococcal disease is likely due 
to the pneumococcal vaccine administered.
There are no h ypotheses associated with the NP/OP colonization and urine antigen testing 
conducted within this substudy . The results will be summarized i n a report separate from the 
Clinical Study  Report (CSR).
4.2 Scientific Rationale for Study Design
After infancy , the risk for pneumococcal disease increases with age and many  guidelines 
include age- based criteria for pneumococcal immunization recommendations . However, 
chronic medical conditions can also predispose y ounger adults to pneumococcal disease 
[Wey cker, D., et al 2016] .With a rise of obesity  and metabolic sy ndrome -related illnesses, 
many  individuals are suffering from more than 1of these chronic diseases. Risk stacking and 
advanced disease stages are associated with disproportionally  higher occurrence of 
pneumococcal infections and associated mortality  in these ind ividuals [Curcio, D., et al
2015] [Morton, J. B., et al 2017] [Torres, A., et al 2015] . It is therefore important to evaluate 
the safet y and immunogenicity of V114 in this population. 
  050DGF 
  05KG3M
PRODUCT: V114 42
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
This study  will investigate the safety , tolerability ,and immu nogenicit y of V114 in 
pneumococcal vaccine -naïve participants 18 to 49 y ears of age (inclusive) who are at 
increased risk for pneumococcal disease due to (1) an underl ying medical condition ,(2) 
behavioral h abits such as smoking , or (3) living in a community /environment with increased 
risk of disease transmission ( Native American living on or around a reservation in the 
southwestern United States who is enrolled through clinical sites of the CAIH). The stud y 
population is representative of individuals with high morbidity due to pneumococcal disease, 
who may benefit from pneumococcal vaccination. Alcohol use increases the risk for 
pneumococcal disease but its impact on the immune response to pneumococcal vaccin es is 
not well described [Bhatty , M., et al 2011] [McMahon, B. J., et al 1993] .Enrollment in this 
study  will be stratified b y the level of alcohol consumption of the participant based on results 
ofthe Alcohol Use Disorders Identification Test (AUDIT -C)screening . 
Individuals with end -stage heart, liver or lung disease and those with uncontrolled diabetes 
will be excluded from this study  in order to allow them to prioritize their medical care over 
participation in this study  and to avoid interference of medical treatment with the safet y and 
immunogenicit y of the vaccine.
4.2.1 Rationale for Endpoints
4.2.1.1 Immunogenicity Endpoints
Sera from participants will be used to measure vaccine -induced, serot ype-specific OPA and 
IgG responses for all 15 seroty pes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23 F, 
and 33F) included in V114 using the Multiplexed Opsonophagocy tic Assay  (MOPA) assay  
and pneumococcal electrochemiluminescence (PnECL ) assay . 
Several studies h ave shown a positive correlation between serot ype-specific IgG antibody  
concentrations and OPA titers in children and adults [Centers for Disease Control and 
Prevention 2010] [Anttila, M., et al 19 99] [Romero -Steiner, S., et al 1997] .OPA assesses 
levels of functional antibodies capable of opsonizing pneumococcal capsular polysaccharides
for presentation to phagocy tic cells for engulfment and subsequent killing, and therefore ,is 
considered an impor tant immunologic surrogate for protection against I PD in adults. Note 
that no seroty pe-specific IgG concentration or OPA titer have been defined as the threshold 
value that correlates with protection in adults.
Details on the immunogenicity  endpoints evaluated in this stu dy can be found in 
Section 9.4.1.
4.2.1.2 Safety Endpoints
The safet y endpoints evaluated in this study  were selected based on the product’s safet y 
profile demonstrated in previous studies, published data from marketed PCVs, and feedback 
recei ved from regulatory  agencies during product development. 
Vaccination report cards (VRCs) will be used to record AEs during the postvaccination 
periods, as defined in Section 8.1.9. Participants enrolled via the CAIH will use paper VRCs 
and all other subjects will use electronic VRCs (eVRCs) . This choice is based on community  
preference within the CAIH sites. 
  050DGF 
  05KG3M
PRODUCT: V114 43
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
The VRCs were structured as recommended in the final Food and Drug Administration 
Patient Repor ted Outcome Guidance [U.S. Food and Drug Administration 2009] .
Details on the safet y endpoints evaluated in this study  can be found in Section 8.3.4 and 
Section 9.4.2.
Details on AEs, including definitions and reporting requirements, can be found in Appendix 
3.
4.2.1.3 Future Biomedical Research
The Sponsor will conduct future biomedical r esearch on specimens for which consent was 
provided during this study . This research may  include genetic anal yses (DNA), gene 
expression profiling ( ribonucleic acid [ RNA ]), proteomics, metabolomics (serum, plasma), 
and/or the measurement of other analy tes, depending on whi ch specimens are consented for 
future biomedical r esearch.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study ) and will only  be conducted on specimens from 
appropriatel y consented participants. The objective of collecting/retaining specimens for 
future biomedical r esearch is to explore and identify  biomarkers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the correct drug/vaccine at the co rrect time. The 
details of this future biomedical r esearch substudy  are presented in Appendix 6
.
Native American participants enrolled via the CAIH will not participate in future biomedical 
research.
4.2.2 Rationale for the Use of Comparator/Placebo
This study utilizes Prevnar 13™ as the active comparator ,as this is the only  PCV licensed in 
many  developed countries for use in adults.  
Prevnar 13™ is approved for adults 18 y ears of age and older for the prevention of 
pneumococcal pneumonia and invasive disease caused by  13 S.pneumoniae serot ypes (1, 3, 
4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F).
Refer to approved labeling for detailed background information on Prevnar 13™.
4.3 Justification for Dose
The dosing regimen of V114 is similar to that used in prev ious adult V114 clinical studies in 
which 1 dose has resulted in a robust immune response (refer to the V114 IBfor more 
detailed information on dose selection) .
The doses of Prevnar 13™ and PNEUMOVAX™23 selected for use in this study  are the 
approved doses. 
  050DGF 
  05KG3M
PRODUCT: V114 44
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
4.4 Beginning and End of Study Definition
The overall study  begins when the first participant signs the ICF. The overall study  ends 
when the last participant completes the last study -related telephone -call or visit, withdraws 
from the study , or is lost to follow -up (ie, the participant is unable to be contacted b y the 
investigator).
For purposes of analy sis and reporting, the overall study  ends when the Sponsor receives the 
last serology  assay  result.
4.4.1 Clinical Criteria f orEarly Study Termination
There a re no prespecified criteria for terminating the study  early.
5 STUDY POPULATION
Male/Female participants between the ages of 18and 49years (inclusive) who are at 
increased risk for pneumococcal disease due to (1) an underl ying medical condition ,
(2)behavioral habits such as smoking , or (3)living in a community /environment with 
increased risk of disease transmission will be enrolled in this study .
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protoc ol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
Participants are eligible to be included in the study onl y if all o f the following criteria apply:
1.Native American from clinical sites of the CAIH in good health without any of the risk 
conditions for pneumococcal disease listed below (any underl ying chronic illness must be 
documented to be in stable condition);
OR
Native American from clinical sites of the CAIH ORa participant from sites other than 
the CAIH with ≥1 of the following risk conditions for pneumococcal disease:
a.Diabetes mellitus Ty pe 1 or Ty pe 2, receiving treatment with at least 1 approved 
anti-diabetic medication; with hemoglobin A1c ( HgA1c )<10% at Screening 
(Visit 1).
b.Chronic liver disease with compensated cirrhosis (Child -Pugh Class A) due to 
non-alcoholic fatty  liver disease, chronic hepatitis B, chronic hepatitis C,or 
alcoholic liver disease, diagnosed b y clinician’s assessment, with at least 1 of the 
following liver staging assessments ( Note : In cases where more than 1staging 
assessment is available, only  1result may  be used to determine fibrosis status. 
Biopsy  should be preferred over every  other test and FibroScan® over the blood 
test based assessment .Participants with hepatitis C must have either completed a 
  050DGF 
  05KG3M
PRODUCT: V114 45
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
course of treatment with direct antiviral therap y and had a 12 -week treatment -free 
follow -up or be expected to remain untreated during the duration of this study): 
i.Prior liver biopsy  demonstrating cirrhosis 
ii. FibroScan® performed with an interpretable sco re >12.5 kPa within 5 years
of Visit 1 (Screening). 
iii. A FibroTest® (F ibroSure®) with Fibrosis Score >0.75 performed within 5 
yearsof Visit 1 and an aspartate aminotransferase (AST): platelet ratio index 
(APRI ) of >2 at Visit 1 (Screening) APRI formula:  AST ÷lab upper limit of 
normal (ULN) for AST x 100 ÷ (platelet count ÷100) (APRI calculation to be 
provided by the central laboratory) .
iv. Prior imaging study  with evidence of cirrhosis and an APRI  of >2 at Visit 1 
(Screening)
v. Prior imaging study  with evid ence of cirrhosis with splenomegaly  and 
platelet count <120 ,000/µL at Visit 1 (Screening)
c.Confirmed diagnosis of chronic obstructive pulmonary  disease (COPD) with 
spirometric data in the preceding 5years showing post -bronchodilator forced 
expiratory  volum e in 1 second (FEV 1) over forced vital capacit y (FVC) ratio 
(FEV 1/FVC) <0.7, and FEV 1≥30% predicted, corresponding to spirometric 
Global I nitiative for Chronic Obstructive Lung Disease Stage 1 to 3 b y severity 
assessment. For otherwise eligible individu als with a clinical history  of COPD 
who do not have spirometry  data from the preceding 5 y ears, spirometry  can be 
performed a tVisit 1 during the screening process by  adequatel y trained personnel 
according to accepted guidelines .
d.Confirmed diagnosis of mil d or moderate persistent asthma with documented 
reversible airflow obstruction on spirometry consistent with guidelines for the 
diagnosis of asthma performed within 5 y ears prior to Visit 1 ,and receipt of
guideline -directed therapy  for mild to moderate as thma. Forotherwise eligible 
individuals with a clinical history  of asthma who are receiving guideline directed 
therap y for mild to moderate asthma but do not have spirometry data from the 
previous 5 y ears, spirometry  can be performed atVisit 1 during the screening 
process b y adequatel y trained personnel according to accepted guidelines for 
assessing reversibility . Inhaled bronchodilator and/or inhaled steroid therapy  
should be withheld prior to spirometry  for a “wash -out” as per recommended 
guidelines .
e.Confirmed diagnosis of chronic heart disease due to 1of the following conditions 
documented within the last 5years (Note : Participants must have New York Heart 
Association (NYHA) heart failure Class 1 to 3 at Visit 1 (Screening) and receive 
guideline dir ected oral heart failure treatment): 
  050DGF 
  05KG3M
PRODUCT: V114 46
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
i.Heart failure with reduced ejection fraction (EF): transthoracic 
echocardiograph y (TTE) or transesophageal echocardiograph y (TEE) with 
left ventricular EF <40%
ii. Heart failure with preserved EF as diagnosed b y a cardiolog ist based on 
clinical signs and s ymptoms, a TTE/TEE with left ventricular EF ≥50%, and 
either 1) plasma brain natriuretic peptide ( BNP )>100 pg/mL or NT -proBNP 
>300 pg/mL or 2) at least 1 prior hospitalization or emergency  room visit for 
heart failure
iii. Non-cyanotic congenital heart disease 
f.Current smoker who has smoked at least 100 cigarettes during lifetime, is 
currentl y smoking every  day or most day s of the week, and is not currently 
receiving smoking cessation therap y at Visit 1 (Screening) or plannin g to receive 
therap y during the stud y.
2. Receiving stable medical management for the conditions listed in I nclusion 
Criterion 1a-f, if applicable, for at least 3 months with no anticipated major change 
expected for the duration of the study.
Demographics
3.Participant is male or female 18 to 49 years of age (inclusive) .
Female Participants
4.A female participant is eligible to participate if she is not pregnant (Appendix 5), not 
breastfeeding, and at least 1 of th e following conditions applies:
a.Not a woman of childbearing potential (WOCBP) as defined in Appendix 5.
OR
b.A WOCBP who agrees to use 1 of the contraceptive methods as defined in Appendix 
5during the treatment period and for at least 6 weeks after the last dose of study  
intervention .
Informed Consent
5.The participant provides written in formed consent for the stud y. The participant may a lso 
provide consent for future biomedical r esearch . However, the participant may  participate 
in the main study  without participating in future biomedical research.
Native American participants enrolled via the CAIH will not participate in future 
biomedical research. 
  050DGF 
  05KG3M
PRODUCT: V114 47
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
5.2 Exclusion Criteria
Participants are excluded from the study if an y of the following criteria apply:
Medical Conditions
1.History  of active hepatitis with elevation in pretreatment aspartate transaminase (AST ) or 
alanine transaminase (ALT) values > 5times the ULN within 3 months of Visit 1 
(Screening) .
2.History  of diabetic ketoacidosis or >1 episode of severe , symptomatic hypoglycemia
within 3 months of Visit 1 (Screening). 
3.Myocardial infarction, acute coronary  syndrome, transient ischemic attack ,orischemic or 
hemorrhagic stroke within 3 months of Visit 1 (Screening). 
4.History  of severe pulmonary  hypertension with World Heal th Organization functional 
class ≥3 or history  of Eisenmenger s yndrome .
5.History  of IPD (positive blood culture, positive cerebrospinal fluid culture, or positive 
culture at another sterile site) or known history  of other culture -positive pneumococcal 
disea sewithin 3 y ears of Visit 2 (Day  1).
6.Known hy persensitivity  to any  component of pneumococcal pol ysaccharide vaccine, 
PCV , or any  diphtheria toxoid -containing vaccine.
7.Known or suspected impairment of immunological function including, but not limited to 
a history  of congenital or acquired immunodeficiency, documented HIV infection, 
functional or anatomic asplenia, history  of autoimmune disease (including but not limited 
to the autoimmune conditions outlined in the I nvestigator Trial File Binder for this 
study).
8.History  of malignancy  ≤5 years prior to signing informed consent (including 
hepatocellular carcinoma), except for adequatel y treated basal cell or squamous cell skin 
cancer or in situ cervical cancer.
9.History  ofStage 4 or 5 Chronic Kidney  Disease (Gl omerular Filtration Rate below 
30mL/min/1.73 m2) or nephrotic s yndrome .
10.History  of alcohol withdrawal or alcohol withdrawal seizure in the past 12 months. 
11.History  of coagulation disorder contraindicating intramuscular vaccinations.
12.*Recent febrile illness (defined as oral or t ympanic temperature ≥100.4°F [≥38.0°C]; 
axillary  or temporal temperature ≥99.4°F [≥37.4°C]; or rectal temperature ≥101.4°F 
[≥38.6°C]) or received antibiotic therapy for an y acute illness occurring within 72 hours
before receipt of study  vaccine. 
  050DGF 
  05KG3M
PRODUCT: V114 48
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
13.History  of hospitalization within 3 months of Visit 1 (Screening). 
14.Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned 
major surgery  during the duration of this study .
15.Expected surviva l for less than 1 y earaccording to the investigator’s judgment .
16.A WOCBP who has a positive urine or serum pregnancy  test before the first vaccination 
at Visit 2 (Day  1). 
Prior/Concomitant Therapy
17. Prior administration of any  pneumococcal vaccine or expec ted to receive any  
pneumococcal vaccine during the stud y outside of the protocol.
18.Received s ystemic corticosteroids (prednisone equivalent of ≥20 mg/day ) for 
≥14consecutive day s and has not completed intervention at least 30 days before stud y 
entry .  
19.Received s ystemic corticosteroids exceeding ph ysiologic replacement doses 
(approximately  5 mg/day prednisone equivalent) within 14 day sbefore vaccination.  
(Note : Topical, ophthalmic, intra -articular or soft -tissue [eg, bursa, tendon steroid 
injections], an d inhaled/nebulized steroids are permitted).
20.Receiving immunosuppressive therapy, including chemotherapeutic agents used to treat 
cancer or other conditions, and interventions associated with organ or bone marrow 
transplantation, or autoimmune disease.
21.Receiving immunomodulatory therap y with biological agents such as monoclonal 
antibodies directed against interleukin or cy tokine pathway s which could potentially  
interfere with immunogenicity  assessment.
22.*Received an y licensed, non -live vaccine within the 14 day s before receipt of an y study 
vaccine or is scheduled to receive an y licensed, non -live vaccine within 30 day s 
following receipt of an y study  vaccine. Exception: I nactivated influenza vaccine may  be 
administered but must be given at least 7 days befo re receipt of an y stud y vaccine or at 
least 15 day s after receipt of an y study vaccine.
23.*Received an y live vaccine within 30 days before receipt of an y study vaccine or is 
scheduled to receive an y live vaccine within 30 days following receipt of any  study  
vaccine. 
24.Received a blood transfusion or blood products, including immunoglobulins within the 
6months before receipt of study  vaccine or is scheduled to receive a blood transfusion or 
blood product within 30 day s of receipt of study  vaccine. Autologous blood transfusions 
are not considered an exclusion criterion.
25.Receiving chronic home oxygen therap y. 
  050DGF 
  05KG3M
PRODUCT: V114 49
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Prior/Concurrent Clinical Study Experience
26.Is currently  participating in or has participated in an interventional clinical study  with an 
investigational compound or device within 2 months of participating in this current stud y.
Other Exclusions 
27.Is, at the time of signing informed consent, a user of recreational or illicit drugs or has 
had a recent history  (within the last y ear) of drug abuse or dependence as assessed by the 
study  investigator .
28.Has history  or current evidence of any  condition, therap y, lab abnormalit y or other 
circumstance that might expose the participant to risk by participating in the study, 
confound the results of the study , or interfere with the participant’s participation for the 
full duration of the study .
29.Is or has an immediate f amily  member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study.
30.Diabetes mellitus with HgA1c ≥10% at Visit 1 (Screening).
31.Chronic liver disease with Child -Pugh Class B or C cirrhosis at Visit 1(Screening) .
32.Chronic lung disease with COPD GOLD Stage 4 or severe persistent asthma at Visit 1 
(Screening) .
33.Chronic heart disease with NYHA heart failure Class 4 at Visit 1 (Screening).
For items with an asterisk (*), if the participa nt meets these exclusion criteria, the 
Day 1 Visit may be rescheduled for a time w hen these criteria are not met.
5.3 Lifestyle Considerations
No lifesty le restrictions are required.
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study , but 
are not subsequently randomized in the study . A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Tria ls (CONSORT) publishing requirements and to 
respond to queries from regulatory  authorities . Minimal information includes demograph y, 
screen failure details, eligibility criteria, and any AEs or SAEs meeting reporting 
requirements as outlined in the data en try guidelines. 
  050DGF 
  05KG3M
PRODUCT: V114 50
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
5.5 Participant Replacement Strategy
A participant who withdraws from the stud ywill not be replaced .
6 STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention (s), marketed product(s), 
placebo, or medical device(s) in tended to be administered to a study  participant according to 
the study  protocol.
Clinical supplies [V114, Prevnar 13™, PNEUMOVAX™23 ] will be packaged to support 
enrollment . Clinical supplies will be affixed with a clinical label in accordance with 
regulatory  requirements.
6.1 Study Intervention(s) Administered
The study intervention (s) to be used in this study areoutlined inTable 1. 
  050DGF 
  05KG3M
PRODUCT: V114 51
PROTOCOL/AMENDMENT N O.:017-02
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Table 1 Study  Intervention s
Arm 
NameArm 
TypeIntervention 
NameType Dose Formulation Unit Dose 
Strength(s)Dosage 
Level(s)Route of 
AdminVaccination 
RegimenUse IMP/
NIMPSourcing
V114 Experime
ntalV114 Biological
/VaccineSterile suspension 
(prefilled syringe)Refer to IB 0.5 mL IM Single Dose 
at Visit 2 
(Day 1)Experimental IMP Central
PNEUMOVAX
™23Biological
/VaccineSterile solution 
(prefilled syringe)Refer to 
product 
labeling0.5 mL IM Single Dose 
at Visit 4 
(Month 6)Experimental IMP Central
Prevnar
13™Active 
Comparat
orPrevnar 13™ Biological
/VaccineSterile suspension 
(prefilled syringe)Refer to 
product 
labeling0.5 mL IM Single Dose 
at Visit 2 
(Day 1)Experimental IMP Central
PNEUMOVAX
™23Biological
/VaccineSterile solution 
(prefilled syringe)Refer to 
product 
labeling0.5 mL IM Single Dose 
at Visit 4 
(Month 6)Experimental IMP Central
Admin=administration; IB =Investigator’s Brochure; IM=intramuscular; IMP =investigational medicinal product ; NIMP =non-investigational medicinal 
product
Thedefinition of IMP and NIMP is based on guidance issued by the European Commission. Regional and/or country differences of the definition of IMP/NIMP 
may exist. In these circumstances, local legislation is followed.
All supplies indicated in Table 1will be provided per the “Sourcing ”row depending upon local country  operational requirements. 
Every  attempt should be made to source these supplies from a single lot/batch number .
Refer to Section 8.1.8 for details regarding administration of the study  intervention. 
  050DGF 
  05KG3M
PRODUCT: V114 52
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
6.2 Preparation/Handling/Storage/Accountability
6.2.1 Dose Preparation
There are no specific calculations or evaluations required to be performed in order to 
administer the proper dose to each participant. T he rationale for selection of doses to be used 
in this study  is provided in Section 4.3. 
6.2.2 Handling, Storage ,and Accountability
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received, and an y discrepancies are 
reporte d and resolved before use of the stud y intervention .
Only  participants enrolled in the study  may  receive study  intervention , and only  authorized 
site staff may  supply  or administer study  intervention . All study  intervention s must be stored 
in a secure, env ironmentally  controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y intervention accountability , reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all stud y sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability  and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study  site is responsible for recording the lot number, manufacturer, and expiry  date for 
any locall y purchased product (if applicable) as per local guidelines unless otherwise 
instructed by  the Sponsor.
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of stud y 
intervention s in accordance with the protocol and any applicable laws and regulations.
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Treatment allocation/randomization will occur centrally using an interactive response 
technology  (IRT) s ystem. There are 2study  intervention arms. Participants will be assigned 
randomly  in a 3:1ratio to V114 or Prevnar 13™ , respectivel y
. 
  050DGF 
  05KG3M
PRODUCT: V114 53
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
6.3.2 Stratification
Randomization will be stratified based on :
1.whether a participant is enrolled at CAIH (approximately  600 Native American 
participan ts, 40% of the total enrollment) or not .
2.the ty pe/number of risk factors for pneumococcal disease a participant has at the time of 
randomization.
Risk factors for pneumococcal disease include an y chronic condition listed under Inclusion 
Criteria 1a –1f(Section 5.1) . In addition, based on the association of alcohol consumption 
andpneumococcal disease, an AUDIT -C score ≥5 will count as a n additional risk factor for 
stratification . Note that Native American participants enrolled at CAIH sites can be enrolled 
in the study  without having an y of the chronic conditions listed under Inclusion Criteria 1a –
1f. For these participants, the AUDIT -C score canbe the only  risk factor for stratification. 
All participants who are not enrolle d at CAIH sites must have ≥1 of the chronic conditions 
listed under Inclusion Criteria 1a –1f. Therefore, for participants who are not enrolled at 
CAIH sites ,the AUDIT -C score cannot be the only risk factor for stratification . However, an 
AUDIT -C score ≥5 contributes to the strata for assessment of risk stacking (by placing 
participants into the strata of 2or ≥3risk factors as shown below ).
Categories of risk factors for stratified randomization will be defined as follows :
For participants enrolled at CAIH, randomization will be stratified into 1 of the following 
9levels/strata : 
Individuals with onl y chronic liver disease
Individuals with onl y diabetes mellitus
Individuals with onl y chronic lung disease
Individuals with onl y chronic heart disease
Individuals who are a current smoker onl y
Individuals who onl y have an AUD IT-C score ≥5 
2 of the risk factors: chronic liver disease, diabetes mellitus, chronic lung disease, chronic 
heart disease, current smoker, AUDIT -C score ≥5 
3 or more of the risk factors: chronic liver disease, diabetes mellitus, chronic lung 
disease, chronic heart disease, current smoker, AUDIT -C score ≥5
Individuals with no risk factors who are Native American but do not fall into 1of the 8 
strata above 
  050DGF 
  05KG3M
PRODUCT: V114 54
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
For participants NOT enro lled at CAIH, randomization will be stratified into 1 of the 
following 7 levels/strata :
Individuals with onl y chronic liver disease
Individuals with onl y diabetes mellitus
Individuals with onl y chronic lung disease
Individuals with onl y chronic heart dise ase
Individuals who are a current smoker onl y
2 of the risk factors: chronic liver disease, diabetes mellitus, chronic lung disease, chronic 
heart disease, current smoker, AUDIT -C score ≥5†
3 or more of the risk factors: chronic liver disease, diabetes me llitus, chronic lung 
disease, chronic heart disease, current smoker, AUDIT -C score ≥5†
†While an AUDIT -C score ≥5 cannot be the onl y risk factor for stratification, an AUDIT -C 
score ≥5 can contribute to the strata for assessment of risk stacking.
6.3.3 Blindin g
Adouble -blinding technique will be used. V114 andPrevnar 13™ will be prepared and/or 
dispensed by  an unblinded pharmacist or unblinded qualified study  site personnel. The 
participant and the investigator who is involved in the clinical evaluation of the participants 
will remain blinded to the group assignments.
Because the V114 and Prevnar 13™ have a different appearance, a member of the study  site 
staff will be unblinded for the purposes of receiving, maintaining, preparing and/or 
dispensing, and administering the study  vaccine s. PNEUMOVAX™23 will also be prepared 
and/or dispensed and administered by unblinded study  site staff for consist ency even though 
it will be provided open label in this study .In order to avoid bias, the unblinded study 
personnel will have no further contact with study participants for an y study -related 
procedures/assessments after administration of study  vaccines, w hich includes all safet y 
follow -up procedures. Additionally , blinded site personnel will no t be present in the exam 
room when study  vaccines are administered. Contact between participants and unblinded 
study  personnel after vaccination administration is st rictly  prohibited. Blinded site personnel 
will be responsible for all safety and immunogenicity follow -up procedures after vaccine 
administration.
An unblinded Clinical Research Associate will monitor vaccine accountability  at the study  
site. All other Spo nsor personnel or delegate(s) and Merck Research Laboratories employ ees 
directly  involved with the conduct of this study  will remain blinded to the participant -level 
intervention assignment.
See Section 8.1.12for a description of the method of unblinding a participant during the 
study  should such action be warranted. 
  050DGF 
  05KG3M
PRODUCT: V114 55
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
6.4 Study Intervention Compliance
Interruptions from the protocol specified plan for V114 or Prevnar 13™ vaccination at 
Visit 2 (Day  1) and PNEUMOVAX ™23 vaccination at Visit 4 ( Month 6 ) vaccination require 
consultation between the investigator and the Sponsor and written documentation of the 
collaborative decision on participant management.
6.5 Concomitant Therapy
Medications or vaccinatio ns specificall y prohibited in the exclusion criteria are not allowed
during the ongoing stud y. If there is a clinical indication for an y medication or vaccination 
specificall y prohibited, di scontinuation from study intervention may be required. The 
investigator should disc uss any  questions regarding this with the Sponsor Clinical Director. 
The final decision on any supportive therap y or vaccination rests with the investigator and/or 
the participant’ s primary  physician. However, the decision to continue the participant on 
study intervention requires the mutual agreement of the investigator, the Sponsor, and the 
participant.
Listed below (items 1 to 4) are specific restrictions for concomitant therapy or vaccination
during the course of the study :
1.Any administration of a non-study  pneumococcal vaccine is prohibited during the stud y.
2.Live and non -live vaccines may only  be administered prior to or following the receipt of 
study  vaccine according to the time frames specified in Exclusion Criteria (Section 5.2). 
Exception : Inactivated influenza vaccine may  be administered but must be given at least 
7 day s before receipt of any  study  vaccine or at least 15 day s after receipt of any  study  
vaccine.
3.Participants should not receive s ystemic corticosteroids ( prednisone equivalent of 
≥20mg/day  for ≥14 consecutive day s) starting from 30 day s prior to through 30 day s 
following vaccination. Note : Topical, ophthalmic, intra -articular or soft -tissue (eg, bursa, 
tendon steroid injections), and inhaled/nebulized steroids are permitted.
4.Participants should not receive s ystemic corticosteroids exceeding ph ysiologic 
replacement doses (prednisone equivalent dose >5 mg/day ) within 14 day sbefore any  
vaccination. Note :Topical, ophthalmic, intra -articular or soft -tissue (eg, bursa, tendon 
steroi d injections), and inhaled/nebulized steroids are permitted.
Any deviation from the above requires consultation between the investigator and the Sponsor 
and written documentation of the collaborative decision on participant management.
6.5.1 Rescue Medications and Supportive Care
No rescue or supportive medications are specified to be used in this study. 
  050DGF 
  05KG3M
PRODUCT: V114 56
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
6.6 Dose Modification (Escalation/Titration/Other)
No dose modification is allowed in this study .
6.7 Intervention After the End of the Study
There is no stud y-specified intervention following the end of the stud y.
6.8 Clinical Supplies Disclosure
This study  is blinded but supplies are provided open label; therefore, an unblinded 
pharmacist or unblinded qualified study  site personnel will be used to maintain the blinding 
of study  staff who are directly  involved in the clinical evaluation of participants in the study . 
Study  intervention identity  (name, strength, or potency ) is included in the label text; random 
code/disclosure envelopes or lists are n ot provided.
The emergency  unblinding call center will use the intervention /randomization schedule for 
the study  to unblind participants and to unmask study  intervention identity . The emergency  
unblinding call center should only  be used in cases of emergen cy (see Section 8.1. 12). In the 
event that the emergency unblinding call center is not available for a given site in this study , 
the central electronic intervention allocation/randomization sy stem (IRT) should be used to 
unblind participants and to unmask study  intervention identity . The Sponsor will not provide 
random code/disclosure envelopes or lists with the clinical supplies.
S
ee Section 8.1.12for a description of the method of unblinding a participant during the 
study , should such action be warranted .
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
WITHDRAWAL
7.1 Discontinuation of Study Intervention
Discontinuation of study  intervention does not represent withdrawal from the study .
As certain data on clinical events bey ond study  intervention discontinuation may  be 
important to the study , they  must be collected through the participant’s last scheduled follow -
up, even if the participant has discontinued study intervention. Therefore, all participants 
who discontinue study  intervention prior to c ompletion of the protocol -specified vaccination 
regimen will still continue to participate in the study  as specified in Section 1.3 and Section 
8.12.3 unless the participant withdraws consent (Section 7.2) .
Participants may  discontinue study  intervention a t any  time for any  reason or be d iscontinued 
from the study  intervention at the discretion of the investigator should an y untoward effect 
occur. In addition, a participant may  be discontinued from study  intervention by  the 
investigator or the Sponsor if st udy intervention is inappropriate, the stud y plan is violated, or 
for administrative and/or other safet y reasons. Specific details regarding procedures to be 
performed at study  intervention discontinuation are provided in Section 8.1. 11. 
  050DGF 
  05KG3M
PRODUCT: V114 57
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
A participant must be discontinued from study  intervention but continue to be monitored in 
the study  for an y of the following reasons:
•The participant requests to discontinue study  intervention.
•The participant has a medical condition or personal circumstance which, in the opinion of 
the investigator and/or Sponsor, placed the participant at unnecessary risk from continued 
administration of study intervention.
•The participant has a confirmed positive urine or serum pregnancy  test before vaccination 
with PNEUMOVAX™23 at Visit 4 (Month 6).
For participants who are discontinued from study  intervention but continue to be monitored 
in the study , see Section 1.3 and Section 8.12.3 for those procedures to be completed at each 
specified visit.
Discontinuation from study  intervention is “permanent.” Once a participant is discontinued, 
he/she shall not be allowed to restart stud y intervention .
7.2 Participant Withdrawal From the Study
A participant must be withdrawn from the study  if the participant withdraws consent from the 
study .
If a pa rticipant withdraws from the study , they  will no longer receive study  treatment or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study ,as well as specific det ails regardi ng withdrawal from future biomedical r esearch, are 
outlined in Section 8.1.
11.The procedures to be performed should a participant repeatedl y 
fail to return for scheduled visits and/or if the study site is unable to contact the participant 
are outlined in Section 7.3.
7.3 Lost to Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact the participant, the following procedures are to be performed:
•The site must attempt to contact the participan t and reschedule the missed visit. I f the 
participant is contacted, the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
•The investigator or designee must make every  effort to regain contact with the p articipant 
at each missed visit (eg, telephone calls and/or a certified letter to the participant’s last 
known mailing address or locally  equivalent methods). These contact attempts should be 
documented in the participant’s medical record.
•Note: A particip ant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and anal ysis guidelines. 
  050DGF 
  05KG3M
PRODUCT: V114 58
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
8 STUDY ASSESSMENTS AN D PROCED URES
•Study  procedures and their timing are summarized in the SoA.
•Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
•The investigator is responsible for ensuring that procedures are conducted by  
appropriatel y qualified or trained staff. Delegation of study site personnel responsibilities 
will be documented in the Investigator Study File Binder (or equivalent).
•All study -related medical decisions must be made by  an investigator who is a qualified 
physician .
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
•Additional evaluations/testing may  be deemed necessary  by the investigator and or the 
Sponsor for reasons related to participant safet y. In some cases, such evaluation/testing 
may be potentially  sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. I n these 
cases, such evaluations/testing will be performed in accordance with those regulat ions.
The approximate blood volumes drawn b y stud y visit and sample ty pe are shown in Table 2
for the main study  and Table 3for the substud y. The maximum amount of blood collected 
from each participant at each study  visit for immunogenicity  assessments willnot exceed 
40mL. For those participants that consent to future biomedical research , an additional blood 
sample of approximately  8.5 mL  will be taken.
Native American participants enrolled via the CAIH will not participate in future biomedical 
research.
Repeat or unscheduled samples may  be taken for safet y reas ons or for technical issues with 
the samples. 
  050DGF 
  05KG3M
PRODUCT: V114 59
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Table 2 Approximate Blood Volumes Drawn b y Stud y Visit and by Sample Types for 
Participants Enrolled at non -CAIH S ites
Study VisitVisit 1
ScreeningVisit 2
Day 1Visit 3
Day 30Visit 4
Month 6Visit 5
Month 7
Disease -specific laboratory assessments; only 
for subjects with:
Diabetes mellitus: Hemoglobin A1c
Chronic liver disease: AST, ALT, total bilirubin, 
PT/INR, albumin, platelets  0 to 12
mLN/A N/A N/A N/A
Serum for immunogenicity assays (including 
retention serum)N/A 40 mL 40 mL 40 mL 40 mL
Blood (DNA) for future biomedical research N/A 8.5 mL N/A N/A N/A
Expected total (mL) 0 to 12
mL48.5 mL 40 mL 40 mL 40 mL
ALT = alanine aminotransferase; AST = aspartate aminotransferase; DNA = deoxyribonucleic acid; 
INR =international normalized ratio; N/A = not applicable; PT = prothrombin time
Table 3 Approximate Blood Volumes Drawn b y Stud y Visit and by  Sample Ty pes for 
Participants Enrolled at CAI H Sites
Study VisitVisit 1
ScreeningVisit 2
Day 1Visit 3
Day 30Visit 4
Month 6Visit 5
Month 7
Disease -specific laboratory assessments; only 
for subjects with:
Diabetes mellitus: Hemoglobin A1c
Chronic liver disease: AST, ALT, total bilirubin, 
PT/INR, albumin, platelets  0to 12
mLN/A N/A N/A N/A
Serum for immunogenicity assays (including 
retention serum)N/A 40 mL 40 mL 40 mL 40 mL
Expected total (mL) 0to12 mL 40 mL 40 mL 40 mL 40 mL
ALT = alanine aminotransferase; AST = aspartate aminotransferase; INR =international normalized ratio; N/A 
= not applicable; PT = prothrombin time
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically  qualified designee (con sistent with local requirements) must 
obtain documented consent from each potential participant prior to participating in a clinical 
study or future biomedical r esearch .If there are changes to the participant’s status during the 
study  (eg, health or age o f majority  requirements), the investigator or medically  qualified 
designee must ensure the appropriate consent is in place. 
  050DGF 
  05KG3M
PRODUCT: V114 60
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
8.1.1.1 General Informed Consent
Consent must be documented by  the participant’s dated signature on a consent form along 
with the dated sign ature of the person conducting the consent discussion.
A cop y of the signed and dated consent form should be given to the participant before 
participation in the study .
The initial I CF, any  subsequent revised written ICF, and an y written information provid ed to 
the participant must receive the Institutional Review Board/Independent Ethics Committee’s 
(IRB/IEC’s )approval/favorable opinion in advance of use. The participant should be 
informed in a timely  manner if new information becomes available that may be relevant to 
the participant’s willingness to continue participation in the study . The communication of 
this information will be provided and documented via a revised consent form or addendum to 
the original consent form that captures the participant’s dated signature.
Specifics about a stud y and the study population will be added to the consent form template 
at the protocol level.
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, 
and Sponsor requirements .
8.1.1.2 Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically  quali fied designee will explain the future biomedical r esearch 
consent to the participant, answer all of his/her questions, and obtain written informed 
consent before performin g any procedure related to the future biomedical research sub study . 
A cop y of the informed consent will be given to the participant.
Native American participants enrolled via the CAIH will not participate in future biomedical 
research.
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by the investigator ,who is a quali fied 
physician or medicall y qualified designee ,to ensure that the participant qualifies for the 
study .
If the participant meets any  of the Exclusion Criteria with an asterisk (*), Visit 1 (Screening ) 
may be rescheduled for a time when these criteria are n ot met.
8.1.3 Participant Identification Ca rd
All participants will be given a participant identification card identify ing them as participants 
in a research stud y. The card will contain study site contact information (including direct 
telephone numbers) to be u sed in the event of an emergency . The investigator or qualified 
designee will provide the participant with a participant identification card immediately after  
  050DGF 
  05KG3M
PRODUCT: V114 61
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
the participant provides written informed consent. At the time of intervention
allocation/randomi zation, site personnel will add the intervention/randomization number to 
the participant identification card.
The participant identification card also contains contact information for the emergency 
unblinding call center so that a healthcare provider can o btain information about study  
intervention in emergency situations where the investigator is not available.
8.1.4 Medical Histo ry
A medical history  will be obtained by  the investigator or qualified designee before 
vaccination at Visit 2(Day  1). The participant’s medical history  for the 5 y ears prior to 
Visit 2(Day  1) will be obtained to ensure that the participant satisfies the inclusion and 
exclusion criteria of the study . History  of tobacco use will also be collected for all 
particip ants.
8.1.5 Prior and Concomitant Medications Revi ew
8.1.5.1 Prior Medications
The investigator or qualified designee will review and record prior vaccinations and 
medication staken b y the participant within 30 days before the first dose of study  vaccin e at 
Visit 2 (Day 1).
8.1.5.2 Concomitant Medications
The investigator or qualified designee will record medication, if an y, taken by the participant 
during the stud y.
New and/or concomitant medications taken after Visit 2 (Day 1) and non -study  vaccines 
received since Visit 2 willbe recorded with the paper VRC/ eVRC as specified in 
Section 8.3.4.
8.1.6 Assignment of Screening Numb er
All consented participants will be given a unique screening number that will be used to 
identify  the participant for all procedures that occur prior to randomization. Each participant 
will be assigned onl y 1 screening number. Screening numbers must not be re -used for 
different participants.
Any participant who is screened multiple times will retain the original screening number 
assigned at the initial scr eening visit. Specific details on the screening/rescreening visit 
requirements are provided in Section 8.12.1. 
  050DGF 
  05KG3M
PRODUCT: V114 62
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
8.1.7 Assignment of Treatment/Randomization Numb er
All eligible participants will be randomly allocated and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment allocation/randomization. Once a 
treatment /randomization number is assigned to a participant, it can never be re -assigned to 
another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
8.1.8 Study Intervention Administrati on
V114 or Prevnar 13™ will be administered at Visit 2 (Day  1). PNEUMOVAX™23 will be 
administered at Visit 4 (Month 6).
Study vaccines should be removed from the refrigerator no more than 1 hour before 
vaccination. The time of removal and time of vaccination should be documented in the 
participant’s chart.
Unblinded study  personnel not otherwise involved in the conduct of th e study  will prepare 
and administer V114, Prevnar 13™, or PNEUMOVAX™23 at the stud y site. 
PNEUMOVAX™23 will be administered open label. Study  vaccines should be prepared and 
administered b y appropriately qualified members of the study personnel (eg, ph ysician, 
nurse, ph ysician’s assistant, nurse practitioner, pharmacist, or medical assistant) as allowed 
by local /state, country , and institutional guidance.
Prior to administration of V114, the unblinded pharmacist should shake the product 
vigorousl y to obtain a homogenous white suspension. If white -colored insoluble particle 
appears, the unblinded pharmacist should use rapid, horizontal hand shaking for 5 to 10 
seconds while holding the sy ringe in between the thumb and index finger until complete 
resuspension. This action should be repeated, as necessary . If appearance is otherwise, the 
vaccine should not be administered.  The vaccine should not be used if the vaccine cannot be 
resuspended. 
Study  personnel should follow the preparation and administration instr uctions for 
Prevnar 13™ and PNEUMOVAX™23 as specified in the product labels.
Study  vaccine will be administered as a single 0.5 -mL intramuscular injection in the deltoid 
region of the participant’s arm. Adequate treatment provision, including epinephrine and 
equipment for maintaining an airway, should be available for immediate use should an 
anaph ylactic or anaph ylactoid reaction occur [Centers for Disease Control and Prevention 
2015] .Vaccination information, such as Component I dentification Number and time of 
vaccination, must be recorded on the appropriate electronic case report form (eCRF) per the 
Data Entry  Guidelines.
All safet y and immunogenicity assessments will be conducted b y blinded personnel, and the
participant will be blinded to the intervention (ie, V114 or Prevnar 13™) received. 
  050DGF 
  05KG3M
PRODUCT: V114 63
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
8.1.8.1 Timing of Dose Administration
Vaccinations may  be administered at any  time of day , and without regard to timing of meals. 
Each participant's body  temperature must be take n before each vaccine administration.  
Individuals who present with fever (oral or t ympanic temperature ≥100.4°F [≥38.0°C]; 
axillary  or temporal temperature ≥99.4°F [≥37.4°C]; or rectal temperature ≥101.4°F 
[≥38.6°C]) will have the vaccination delayed unti l fever is resolved for at least 72 hours.
The collection of blood samples and administration of pregnancy tests (if applicable) must be 
done before each vaccine administration. 
All participants will be observed for 30 minutes after each vaccination for a ny immediate 
reactions. This observation must be performed b y blinded site personnel for all study  
vaccines (Section 1.3 and Section 6.3. 3).
8.1.9 Vaccination Report Card
Participants enrolled via the CAIH will use paper VRCs and all other subjects will use 
eVRC s. This choice is based on community  preference within the CAIH sites.
The eVRC was developed to be administered electronically via a hand -held device. The 
paper VRC s/eVRCs were structured as recommended in the final Food and Drug 
Administration Patient -Reported Outcome Guidance [U.S. Food and Drug Administration 
2009] .The investigator or delegate will
train the participant in the use of the paper VRC and 
eVRCs at Visit 2 (Day  1) and Visit 4 (Month 6). 
Temper atures, injection -site reactions, vaccine -specific complaints, other complaints or 
illnesses, and concomitant medications or vaccinations will be recorded on the paper 
VRC/eVRC as described in Section 1.3 and Section 8.3.4.
For the main stud y, site personn el will discuss information entered into the paper VRC/eVRC 
with participants during the telephone contacts conducted on Day 15 and Month 6.5. A full 
review of the completed paper VRC/eVRC will occur at Visit 3 (Day  30) and Visit 5 
(Month 7).
For Native Am ericans enrolled through the CAIH participating in the s ubstudy , site 
personnel will discuss information entered into the paper VRC with participants during 
Visit 2C and Visit 4C. The paper VRC can be collected at either Visit 2 Cor Visit 3, and at 
either Visit 4 Cor Visit 5 at the discretion of the study personnel. A full review of the 
completed paper VRC with the participant will occur at the time of collection by the site .
For the AEs outlined above, the investigator will use the information provided by the 
participant both on the paper VRC/ eVRC, and verbally  at the time of paper VRC/eVRC 
review, to appl y the appropriate assessment of intensity and toxicity as described in 
Appendix 3. 
  050DGF 
  05KG3M
PRODUCT: V114 64
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
8.1.10 6-month Safety Follow -up Questionnaire
Site personnel will review the information in the 6 -month Safety  Follow -up Questionnaire 
provided by the Sponsor with the participant. Data to be reported from this discussion will 
include SAEs and/or an y updates to previously  reported safet y information.
8.1.11 Discontinuation and Withdraw
al
Participants who discontinue study  intervention prior to completion of the protocol -specified 
vaccinations should be encouraged to continue to be followed for all remaining st udy visits.
When a participant withdraws from participation in the study, all applicable activities 
scheduled for the final study  visit should be performed (at the time of withdrawal). An y AEs
that are present at the time of withdrawal should be followed i n accordance with the safet y 
requirements outlined in Section 8.4 .
8.1.11.1 Withdrawal From Future Biomedical Resear ch
Participants may withdraw their consent for future biomedical r esearch. Participants may  
withdraw consent at an y time by  contacting the principal investigator for the main study . If 
medical records for the main study  are still available, the investigator will contact the 
Sponsor using the designated mailbox (clinical.specimen.management@merck.com). 
Subsequently ,the participant's consent for future biomedical research will be withdrawn. A 
letter will be sent from the Sponsor to the investigator confirming the withdrawal. It is the 
responsibility  of the investigator to inform the participant of completion of withdrawal. An y 
analyses in progress at the time of request for withdrawal or alread y performed prior to the 
request being received by the Sponsor will continue to be used as part of the overall research 
study  data and results. No new analys es would be generated after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study records) 
or the specimens have been completel y anon ymized, there will no longer be a link between 
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed .
Native American participants enrolled via the CAIH will not participate in future biomedical 
research.
8.1.12 Participant Blinding/Unblindi ng
STUDY INTERVENT ION IDENT IFICATION INFORMAT ION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency  situations where the investigator or medically  qualified designee (consistent 
with local requirements) needs to identify  the drug used by  a participant and /orthe dosage 
administered , he/she will contact the emergency  unblinding call center by t elephone and 
make a request for emergency  unblinding. As re quested by  the investigator or medicall y  
  050DGF 
  05KG3M
PRODUCT: V114 65
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
qualified designee the emergency  unblinding call center will provide the information to 
him/her promptly  and report unblinding to the Sponsor. Prior to contacting the emergency  
unblinding call center to request unbl inding of a participant’s treatment assignment, the 
investigator who is a qualified phy sician should make reasonable attempts to enter the 
intensity /toxicity  grade of the AEs observed, the relation to study  intervention, the reason 
thereof , etc., in the me dical chart. If it is not possible to record this assessment in the chart 
prior to the unblinding, the unblinding should not be delay ed.
In the event that unblinding has occurred, the circumstances around the unblinding (eg, date, 
reason, and person perfor ming the unblinding) must be documented promptly , and the 
Sponsor Clinical Director notified as soon as possible.
Once an emergency  unblinding has taken place, the principal investigator, site personnel, and 
Sponsor personnel may  be unblinded so that the a ppropriate follow -up medical care can be 
provided to the participant .
Participants whose treatment assignment has been unblinded by the investigator or medicall y 
qualified designee and/or nonstudy  treating ph ysician should continue to be monitored in the 
study.Participants may  receive PNEUMOVAX™23 at Visit 4 (Month 6) after a benefit/risk 
assessment and consultation between the investigator/delegate and Sponsor.
Additionally , the investigator or medically  qualified designee must go into the I RT sy stem 
and perform the unblind in the I RT sy stem to update drug disposition. In the event that the 
emergency  unblinding call center is not available for a given site in this study , the IRT 
system should be used for emergency  unblinding in the event that this is requi red for 
participant safety .
8.1.13 Calibration of Equipme nt
The investigator or qualified designee has the responsibility  to ensure that any  device or 
instrument used for a clinical evaluation/test during a clinica l study  that provides information 
about inclusion/exclusion criteria and/or safety or efficacy  parameters shall be suitably  
calibrated and /ormaintained to ensure that the data obtained is reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentati on at the 
study  site.
8.2 Immunogenicity Assessmen ts
Sera from participants will be used to measure vaccine -induced OPA and IgG for serot ypes 
included in V114 and Prevnar 13™. These endpoints will be tested for all blood draws. 
Blood collection, storage ,and s hipment instructions for serum samples will be provided in 
the operations/laboratory manual. 
The MOPA will be used for measuring OPA GMTs. Opsonization of pneumococci for 
phagocy tosis is an important mechanism by  which antibodies to poly saccharides protec t 
against disease in vivo. The OPA assay  is a useful tool for assessing the protective function 
of serot ype-specific antibodies and therefore ,the immunogenicit y of pneumococcal vaccine 
formulations. 
  050DGF 
  05KG3M
PRODUCT: V114 66
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Measurement of serot ype-specific IgG will be measured us ing the PnECL  v2.0 assay  to 
assess the concentration of binding antibodies to capsular pol ysaccharide of S. pneumoniae
for the serot ypes included in the study  vaccines .
8.2.1 Multiplex Opsonophagocytic Assay (MOPA)
The MOPA, developed and published by  Professor Moon Nahm (Director of the United 
States World Health Organization pneumococcal serology reference laboratory and National 
Institutes of Health pneumococcal reference laboratories), is a multiplexed OPA assay 
capable of measuring 4 serotypes at a time, against a total of 16 serot ypes of pneumococci 
[Burton, Robert L . and Nahm, Moon H. 2006] .The OPA is an antibod y-mediated killing 
assay  that measures the ability  of h uman serum to kill S. pneumoniae serot ypes with the help 
of complement and phagocytic effector cells. The ability  of the assay  to simultaneously  test 
4seroty pes/run reduces the amount of serum needed for testing. The assay  readout is the 
opsonization index, which is the reciprocal of the highest dilution that gives ≥50% bacterial 
killing, as determined b y comparison to assay  background controls. MSD has developed and
optimized the MOPA in a high throughput micro -colony  platform. The MOPA assay  for all 
15 V114 serot ypes has undergone validation. The validation study evaluated various 
performance parameters of the assay ,including precision, relative accuracy/dilutional
linearity , and specificity . The validation results were evaluated against prespecified 
acceptance criteria for each of the parameters.
8.2.2 Electrochemiluminescence (ECL)
MSD has developed and optimized a multiplex, ECL -based detection method for the 
quantitat ion of IgG serotype -specific antibodies to the 15 pneumococcal poly saccharide 
seroty pes contained in V114. The PnECL  v2.0 assay  is based on the Meso -Scale Discovery  
technology , which employ s disposable multi -spot microtiter plates. The benefits of the ECL 
multiplex technology  over the prior enzyme-linked immunosorbent assay methodology  
include speed, equivalent or better sensitivity , increased dy namic range, the ability  to 
multiplex, and reduction in required ser um sample and reagent volumes. The measuremen t of 
immune responses to the 15 seroty pes included in V114 is performed using an assay  format 
consisting of 2 groups of 7 and 8 serot ypes each. The PnECL  v2.0 assay  for all 15 seroty pes 
has undergone validation. The validation study evaluated various perfo rmance parameters of 
the assay ,including precision, ruggedness, relative accuracy, dilutional linearity, selectivity, 
and specificit y. The validation results were evaluated against prespecified acceptance criteria 
for each of the parameters.
8.3 Safety Assess ments
Details regarding specific safet y procedures/assessments to be performed in this study  are 
provided. The total amount of blood/tissue to be drawn/collected over the course of the stud y 
(from prestud y to poststudy visits), including approximate blood/ tissue volumes 
drawn/collected by visit and by sample type per particip ant, can be found in Section 8 .
Planned time points for all safety assessments are provided in the SoA. 
  050DGF 
  05KG3M
PRODUCT: V114 67
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
8.3.1 Physical Examinations
A complete ph ysical examination will be conducted by an inv estigator or medically qualified 
designee (consistent with local requirements) before vaccination at Visit 2 (Day  1).
A directed ph ysical exam ination will be conducted by an investigator or medically  qualified 
designee (consistent with local requirements) at Visit 1(Screening) to address disease -
specific inclusion/exclusion criteria, such as Child -Pugh Class for participants with chronic 
liver disease and NYHA Class for participants with chro nic heart disease. A directed ph ysical 
examination will also be conducted before vaccination at Visit 4 (Month 6) .
Investigators should pay  special attention to clinical signs related to previous illnesses.
8.3.2 Pregnancy Test
A pregnancy  test consistent with local requirements (sensitive to at least 25 IU beta human 
chorionic gonadotropin [β-hCG ]) must be performed before vaccination at Visit 2(Day 1) 
and Visit 4(Month 6) in WOCBP as described in Section 1.3. Pregnancy  tests can be 
repeated as needed based on local requirements. Urine or serum tests can be used, and re sults 
must be negative before vaccination can occur.
8.3.3 Body Temperature Measurement
Each participant's body  temperature should be taken before vacci nation as described in 
Section 1.3.
Oral bod y temperatures will also be documented by participants using their paper 
VRC/ eVRC during the VRC -specified postvaccina tion follow -up period (Section 8.3.4 ).
For this study , any  oral or ty mpanic temperature ≥100.4°F (≥38.0°C), axillary  or temporal 
temperature ≥99.4°F (≥37.4°C), or rectal temperature ≥101.4°F (≥38.6°C) wil l be considered 
an AE of fever. All fevers must be reported Day  1 through Day  14, unless the fever is a 
symptom of another reported AE.
8.3.4 Safety Assessment sand Use of the Paper VRC/eVRC
All participants will be observed for 30 minutes after each vaccination for any immediate 
reactions. If an y immediate AEs are observed during this period, the time at which the event 
occurred within this timeframe, as well as the event itself, any concomit ant medications that 
were administered, and resolution of the event, must be recorded on the appropriate eCRF.
Participants will use the paper VRC/eVRC (Section 8.1. 9) to document the following 
information:
•Oral bod y temperatures measured Day 1 (day of vac cination) through Day 5 
postvaccination; 
  050DGF 
  05KG3M
PRODUCT: V114 68
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
•Solicited injection -site AEs (redness/ery thema, swelling, tenderness/pain) Day  1 through 
Day 5 postvaccination;
•Solicited sy stemic AEs (muscle pain/my algia, joint pain/arthralgia, headache, 
tiredness/fatigue) Day  1 through Day  14 postvaccination;
•Any other injection -site or sy stemic AEs Day 1 through Day  14 postvaccination; and
•Concomitant medications and non -study  vaccinations Day  1 to Day  14 postvaccination.
8.3.5 Clinical Laboratory Assessments
•Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the 
SoA for the timing and frequency .
•All protocol -required laboratory  assessments, as defined in Appendix 2 , must be 
conducted in accordance with the laboratory  manual and the SoA .
•If laboratory  values from nonprotocol specified laboratory  assessments performed at the 
institution’s local laboratory  require a change in study  participant management or are 
considered clinically  significant by  the investigator (eg, SAE or AE or dose 
modification), the n the results must be recorded in the appropriate CRF (eg, SL AB).
•For an y laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 30 to 44 days after the last dose of stud y intervention , 
every  attempt should be made to perform repeat assessments until the values return to 
normal or baseline or if a new baseline is established as determined b y the investigator .
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs) ,and Other Reportable 
Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causalit y of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3.
Advers e events, SAEs, and other reportable safety  events will be reported by  the participant 
(or, when appropriate, b y a caregiver orsurrogate).
The investigator and an y designees are responsible for detecting, documenting, and reporting 
events that meet the de finition of an AE or SAE, as well as other reportable safet y events. 
Investigators remain responsible for following up AE, SAEs, and other reportable safety 
events for outcome according to Section 8. 4.3.
The investigator, who is a qualified ph ysician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safet y events with respect to seriousness, 
intensity /toxicity  and causality . 
  050DGF 
  05KG3M
PRODUCT: V114 69
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
8.4.1 Time Period and Frequency for Collecting AE, SAE ,and Other Reportable 
Safety Event Information
All AEs, SAEs, and other reportable safety events that occur after the consent form is signed 
but before allocation/randomization must be reported by  the investigator if they  cause the 
participant to be excluded from the study , or are the result of a prot ocol-specified 
intervention, including but not limited to washout or discontinuation of usual therap y, diet, 
placebo treatment, or a procedure.
All AEs, SAEs, and other reportable safety events must be reported b y the investigator from 
the day  of allocatio n/randomization to the first vaccination and from the day of each 
vaccination through 14 day s postvaccination.  SAEs must also be reported throughout the 
duration of the individual’s participation in the study, regardless of whether or not r elated to 
the S ponsor’s product.
Additionally , any SAE brought to the attention of an investigator at an y time outside of the 
time period specified in the previous paragraph also must be reported immediatel y to the 
Sponsor if the event is either:
1. A death that occurs prior to the p articipant completing the study .
OR
2. An SAE that is considered by  an investigator who is a qualified ph ysician to be 
vaccine related.
Investigators are not obligated to activel y seek AE or SAE or other reportable safet y events 
in former stud y participants. However, if the investigator learns of an y SAE, including a 
death, at an y time after a participant has been discharged from the study, and he/she 
considers the event to be reasonabl y related to the study intervention or study  participation, 
the investigator must promptly  notify  the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety  events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 4. 
  050DGF 
  05KG3M
PRODUCT: V114 70
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Table 4 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safet y Events
Type of Event Reporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation 
through Protocol -
Specified Follow -
up PeriodReporting Time Period:
After the Protocol 
Specified Follow -up 
PeriodTimefram e to 
Report Event 
and Follow -
up 
Information 
to 
SPONSOR:
Non-Serious Adverse 
Event (NSAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Not required Per data entry 
guidelines
Serious Adverse Event 
(SAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Report if:
-drug/vaccine related
-any death until 
participant completion of 
study
(Follow  ongoing to 
outcome)Within 
24hours of 
learning of 
event
Pregnancy/Lactation 
ExposureReport if:
-due to 
intervention
-causes exclusionReport all Previously reported –
Follow  to 
completion/termination; 
report outcomeWithin 
24hours of 
learning of 
event
Event of Clinical 
InterestThere are no Events of Clinical Interest for this study Not 
applicable
Cancer Report if:
-due to 
intervention
-causes exclusionReport all Not required Within 5 
calendar days 
of learning of 
event
Overdose Report if:
-receiving 
placebo run -in or 
other run -in 
medication Report all Not required Within 5 
calendar days 
of learning of 
event
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE and/or SAE and other reportable 
safet y events. Open -ended and nonleading verbal questioning of the participant is the 
preferred method to inquire about AE occurrence. 
  050DGF 
  05KG3M
PRODUCT: V114 71
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE re port, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All AE, SAE, and other reportable safet y events 
including pregnancy  and exposure during breastfeeding, cancer, and overdose will be 
followed until reso lution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3). In addition, the investigator will 
make every  attempt to follow all nonserious AEs that occur in randomized participants for
outcome. Further information on follow -up procedures is given in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by  the investigator to the Sponsor of SAE is essential 
so that legal obligations and ethical respo nsibilities towards the safet y of participants and the 
safety of a stud y intervention under clinical investigation are met.
The Sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. All 
AEs will be reported to regulatory  authorities, IRB/IECs, and investigators in accordance 
with all applicable global laws and regul ations (ie, per ICH Topic E6 (R2 ) Guidelines for 
Good Clinical Prac tice[GCP] ).
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (SUSAR s) according to local regulatory  requirements and Sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the IB and will notify  the IRB/IEC, if appropriate according to local requirements .
8.4.5 Pregnancy and Ex posure During Breastfeeding
Although pregnancy  and infant exposure during breastfeeding are not considered AEs, an y 
pregnancy  or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occur s during the stud y are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy . 
Pregnancy  outcomes of spontaneous abortion, missed abortion, benign h ydatidiform mole, 
blighted ovum, fetal death, i ntrauterine death, miscarriage, and stillbirth must be reported as 
serious events (Important Medical Events). If the pregnancy continues to term, the outcome 
(health of infant) must also be reported.
8.4.6 Disease -related Events and/or Disease -related Outcomes N ot Qualifying as 
AEs or SAEs
This is not applicable to this study . 
  050DGF 
  05KG3M
PRODUCT: V114 72
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
8.4.7 Events of Clinical Interest (ECI s)
There are no events of clinical interest for this study.
8.5 Treatment of Overdose
In this stud y, an overdose is the administration of more than 1 dose of an yindividual study  
vaccine in an y 24-hour period.
No specific information is availabl e on the treatment of overdose.
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the Sponsor Clinical Director based on the clinical evaluation of the 
participant.
All reports of overdose must be reported b y the investigator within 5 calendar day sto the 
Sponsor either by electronic media or paper. Electronic reporting procedures can be found in 
the electronic data collection (EDC )data entry  guidelines. Paper reporting procedures can be 
found in the Investigator Trial File Binder (or equivalent ).
8.6 Pharmacokinetics
PK parameters will not be evaluated in this study .
8.7 Pharmacodynamics
Pharmacod ynamic parameters will not be evaluated in this study .
8.8 Future Biomedical Research Sample Collection
If the participant signs the future biomedical r esearch consent, the following specime ns will 
be obtained as part of future biomedical r esearch:
•DNA for future research
•Leftover stud y serum after completion of immunogen icity testing stored for future
research
Native American participants enrolled via the CAIH will not participate in future biomedical 
research.
8.9 Planned Genetic Analysis Sample Collection
Planned genetic a nalysis samples will not be evaluated in this study .
8.10 Biomarkers
Biomarkers are not evaluated in this study . 
  050DGF 
  05KG3M
PRODUCT: V114 73
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
8.11 Medical Resource Utilization and Health Economics
Medical Resource Utilization and Health Economic s are not evaluated in this study .
8.12 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details are provided 
in Section 8.
8.12.1 Screening
Screening procedures will be conducted at Visit 1 as outlined in Section 1.3.
8.12.2 Treatment Period/Vaccination Visit
Requirements during the trea tment period are outlined in Section 1.3.
8.12.3 Discontinued Participants Continuing to be Monitored in the Study
In this trial, a participant may  discontinue from study  intervention (ie, vaccination) but 
continue to participate in subsequent protocol visits as outlined in Section 1.3, as long as the 
participant does not withdraw consent.  Protocol -specified activities, including blood draws 
for immunogenicity  assessments and AE monitoring, should occur at these visits.
9 STATISTICAL ANALYSIS PLAN
This section outl ines the statistical analysis strategy and procedures for the study.  Changes 
to analy ses made after the protocol has been finalized, but prior to unblinding, will be 
documented in a supplemental Statistical Analy sis Plan and referenced in the CSR for the 
study .  Post hoc exploratory anal yses will be clearly  identified in the CSR.
Other planned anal yses (ie , those specific to the substudy  or future biomedical research) are 
beyond the scope of this document or will be documented in separate anal ysis plans.
9.1 Statistical Analysis Plan Summary
Key elements of the Statistical Analysis Plan are summarized below; the comprehensive plan 
is provided in Sections 9.2 through 9.12.
Study Design Overview A Phase 3, Multicenter, Randomized, Double -Blind, Active Comparator -
Controlled Study to Evaluate the Safety, Tolerability, and 
Immunogenicity of V114 Follow ed by  Administration of 
PNEUMOVAX™23 Six Months Later in Immunocompetent Adults 
Betw een 18 and 49 Years of Age at Increased Risk for Pneumococcal 
Disease.
Intervention Assignment Participants will be randomly assigned in a 3:1 ratio to V114 or 
Prevnar 13™, respectively . Randomization will be stratified based on the 
categories defined in Section 6.3.2. 
  050DGF 
  05KG3M
PRODUCT: V114 74
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Analysis Populations Immunogenicity : Per -Protocol (PP)
Safety : All Participants as Treated (APaT)
Prim ary Endpoint(s) Immunogenicity :
Theserotype -specific OPA GMT sat 30 days postvaccination with 
V114 and Prevnar 13™ (Day 30)
Safety : 
Proportion of participants with solicited injection -site AEs 
(redness /erythema , swelling, tenderness /pain) from Day 1 through 
Day 5 following V114 orPrevnar 13™
Proportion of participants with solicited systemic AEs (muscle 
pain/myalgia , joint pain /arthralgia , headache, and tiredness /fatigue)
from Day 1 through Day 14 follow ing V114 or Prevnar 13™
Proportion of participants with vaccine -related SAEs in the 6 
months following V114 orPrevnar 13™ from Day 1 through Month 
6
Key Secondary Endpoints Immunogenicity :
Serotype -specific IgG GMC sat 30 days postvaccination with V114 
and Prevnar 13™ (Day 30)
Serotype -specific OPA GMT sand IgG GMC sat 30 days 
postvaccination with PNEUMOVAX™23 (Month 7)
Safety : 
Proportion of participants with solicited injection -site AEs 
(redness /erythema , swelling, tenderness /pain) from Day 1 through 
Day 5 following PNEUMOVAX ™23
Proportion of participants with solicited systemic AEs (muscle 
pain/myalgia , joint pain /arthralgia , headache, and tiredness /fatigue)
from Day 1 through Day 14 follow ing PNEUMOVAX ™23
Proportion of participants with vaccine -related SAEs in the 30 
days following PNEUMOVAX ™23from Month 6 through Month 
7
Statistical Methods for Key 
Immunogenicity AnalysesImmunogenicity analyses will be conducted for each of the 15 
pneumococcal serotypes separately. To address the primary 
immunogenicity objective, evaluation of the OPA GMTs at 30 days 
postvaccination with V114 or Prevnar 13™ (Day 30) will include 
descriptiv e summaries and within -group 95% CIs will be calculated for 
each vaccination group.
A similar statistical approach will be used to evaluate the IgG GMCs at 
30 days postvaccination with V114 or Prevnar 13™  (Day 30) and the 
OPA GMTs and IgG GMCs at 30 days postvaccination with 
PNEUMOVAX™23 (Month 7).
Statistical Methods for Key 
Safety AnalysesThe analysis strategy for safety parameters following each vaccination is 
described in Section 9.6.2. Safety parameters will be summarized via 
descriptive statistics. In addition, for select safety parameters, 95% 
within -group confidence intervals will be provided.  
  050DGF 
  05KG3M
PRODUCT: V114 75
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Interim Analyses To support the periodic review of safety and tolerability data across the
V114 Phase 3 program, an external unblinded statistician will provide 
unblinded interim safety summaries to an independent DMC for their 
review. There are no plans to conduct an interim analysis of unblinded 
immunogenicity data in this study. However, unb linded immunogenicity 
data w ill be made available to the DMC upon request to enable a benefit -
risk assessment.
Multiplicity No adjustment will be made for multiplicity.
Sample Size and Power Immunogenicity :
The planned sample size is 1500 participants. Participants are to be 
randomly assigned in a 3:1 ratio to V114 or Prevnar 13™, respectively
(resulting in approximately 1125 participants in the V114 group and
approximately 375 participants in the Prevnar 13™ group ). It is assumed 
that approximately 1013 participants in the V114 group and 337 in the 
Prevnar 13™ group will be evaluable for PP immunogenicity analyses at 
Day 30 (90% evaluability rate) .  There are no hypotheses to be evaluated , 
but Section 9.9.1 provides information about the expected variability of 
theOPA GMT sgiven the sample size.
Safety: 
Section 9.9.2 provides information about the ability of this study to 
estimate the incidence of AEs within the V114 group. 
9.2 Responsibility for Analyses/In -house Blinding
The statistical anal ysis of the data obtained from this study  will be the responsibility  of the 
Clinical Biostatistics department of the Sponsor.
This study  will be conducted as a double -blind study  under in -house blinding procedures. 
The official , final database will not be unblinded until medical/scientific review has been 
performed, protocol deviations have been identified, and data have been declared final and 
complete.
The Clinical Biostatistics department will generate the randomized allocati on schedule(s) for 
study  intervention assignment. Randomization will be implemented using an I RT.
Blinding issues related to the planned interim analyses are described in Section 9.7.
9.3 Hypotheses/Estimation
Objectives of the stud y are stated in Section 3. T his is an estimation study  and no formal 
hypothesis testing will be performed.
9.4 Analysis Endpoints
Immunogenicit y and safety analysis endpoints that will be summarized are listed below.
9.4.1 Immunogenicity Endpoints
A description of immunogenicity  assessments is contained in Section 8.2.  
  050DGF 
  05KG3M
PRODUCT: V114 76
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Immune responses will be measured for each of the following serot ypes contained in V114: 
1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23 F, and 33F .
The primary  immunogenicity  endpoint is the seroty pe-specific OPA GMT sat 30 days 
postvaccination with V114 and Prevnar 13™ (Day  30).
The secondary  immunogenicity  analysis endpoints include:
Seroty pe-specific IgG GMCs at 30 day s postvaccination with V114 and Prevnar 13™
(Day  30)
Seroty pe-specific OPA GMTs and IgG GMCs at 30 day s postvaccination with 
PNEUMOVAX™23 (Month 7)
Seroty pe-specific GMFR and proportion of participants with a ≥4-fold rise from 
prevaccination (Day 1) to 30 day s postvaccination with V114 or Prevnar 13™ (Day  
30)for both OPA and IgG responses
Seroty pe-specific GMFR and proportion of participants with a ≥4
-fold rise from 
prevaccination (Day  1) to 30 day s postvaccination with PNEUMOVAX™23 (Month 
7) for both OPA and IgG responses
Seroty pe-specific GMFR and proporti on of participants with a ≥4-fold rise from 
prevaccination with PNEUMOVAX™23 (Month 6) to 30 day s postvaccination with 
PNEUMOVAX™23 (Month 7) for both OPA and IgG responses
9.4.2 Safety Endpoints
A description of safet y measures is contained in Sections 8.3 and 8.4. The anal ysis of safety  
results is described in Section 9.6.2.
Safety  and tolerability  will be assessed b y clinical review of all relevant parameters including 
adverse events and postvaccination temperature measurements following V114 or Prevnar
13™ an d following PNEUMOVAX™23 (separately ).
The safet y analysis endpoints include :
Proportion of participants with solicited injection -site AEs (redness /erythema , 
swelling, tenderness /pain) from Day  1 through Day  5 postvaccination
Proportion of participants with solicited sy stemic AEs (muscle pain /myalgia, joint 
pain/arthralgia , headache, tiredness /fatigue ) from Day  1 through Day  14 
postvaccination
Proportions of participants with the broad AE categories consisting of an y AE, a 
vaccine -related AE, a SAE, an AE which is both vaccine -related and serious, and 
discontinuation due to an AE ,and the proportion of participants who died
Proportion of participants with maximum temperature measurements meeting the 
Brighton Collaboration cut points from Day  1 through Day 5 postvaccinatio n 
  050DGF 
  05KG3M
PRODUCT: V114 77
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
9.5 Analysis Populations
9.5.1 Immunogenicity Analysis Populations
The Per -Protocol (PP) population will serve as the primary  population for the anal ysis of 
immunogenicit y data in this study . The PP population consists of all randomized participants 
withoutdeviations from the protocol that may  substantially  affect the results of the 
immunogenicit y endpoints. Potential d eviations that may result in the exclusion of a 
participant from the PP population for all immunogenicity  analyses inclu de:
Failure to receive an y study  vaccine at Visit 2 (Day  1)
Failure to receive correct clinical material as per randomization schedule (ie, 
participants who were cross -treated)
Receipt of a prohibited medication or prohibited vaccine prior to study  vaccination
Additional potential deviations that may  result in the exclusion of a participant from the PP 
population for specific immunogenicit y analyses (depending on the time point) include:
Failure to receive PNEUMOVAX™23
Receipt of a prohibited medicat ion or prohibited vaccine prior to a blood sample 
collection
Collection of a blood sample outside of the prespecified window (as described in 
Section 1.3)
The final determination on protocol deviations , and thereb y the composition of the PP 
population, will be made prior to the final unblinding of the database. Participants will be 
included in the vaccination group to which they  are randomized for the analy sis of 
immunogenicit y data using the PP population.
A supportive anal ysis using the Full Anal ysis Set (FAS) population will also be performed 
for the primary  immunogenicity  endpoint. The FAS population consists of all randomized 
participants who received at least 1 study  vaccination and have at least 1serology result. 
Participants will be included in the vaccination group to which they are randomized for the 
analysis of immunogenicity  data using the FAS population.
9.5.2 Safety Analysis Populations
Safety  anal yses will be conducted in the All Participants as Treated (APaT) population, 
which consists of all rando mized participants who received at least 1 dose of study  
vaccination . Participants will be included in the group corresponding to the study  vaccination 
they actuall y received for the anal ysis of safety  data using the APaT population.  This will be 
the grou p to which they  are randomized except for p articipants who take incorrect study  
vaccination ; such participants will be included in the group corresponding to the study  
vaccination actually  received. 
  050DGF 
  05KG3M
PRODUCT: V114 78
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
At least 1temperature measurement obtained subsequent to study  intervention is required for 
inclusion in the analy sis of temperature . 
9.6 Statistical Methods
Statistical testing and inference for immunogenicity  and safet y anal yses are described in 
Section 9.6.1 and Sec tion 9.6.2, respectivel y. Section 9.6.3 describes how demographic and 
baseline characteristics will be summarized.
9.6.1 Statistical Methods for Immunogenicity Analyses
This section describes the statistical methods that address the primary and secondary 
immunog enicit y objectives.  Methods related to exploratory objectives will be described in 
the supplemental Statistical Anal ysis Plan .
Immunogenicit y anal yses will be conducted for each of the 15 pneumococcal serot ypes in 
V114 separatel y. To address the primary  immunogenicity  objective, evaluation of the OPA 
GMTs at 30 day s postvaccination with V114 or Prevnar 13™ (Day  30) will inclu de 
descriptive summaries ,and within -group 95% CI s will be calculated for each vaccination 
group. Point est imates for the OPA GMTs will be calculated b y exponentiating the estimates 
of the mean of the natural log values. The within -group CIs will be derived by  exponentiating 
the CI s of the mean of the natural log values based on the t -distribution.
A similar statistical approach will be used to evaluate the IgG GMCs at 30 day s 
postvaccination with V114 or Prevnar 13™ (Day  30) and OPA GMTs and IgG GMCs at
30days postvaccination with PNEUMOVAX™23 (Month 7).
Descriptive statistics with point estimates and within -group 95% CIs will be provided for all 
other immunogenicit y endpoints. For the continuous endpoints, a similar statistical approach 
will be used as described above for the primary  endpoint. Point estimates will be calculated 
by exponentiating the estimates of the mean of the natural log values ,and the within -group 
CIs will be derived b y exponentiating the CIs of the mean of the natural log values based on 
the t-distribution. For the dichotomous endpoints, the within -group CIs will be calculated 
based on the exact method proposed b y Clopper and Pearson [Clopper, C. J. and Pearson, E. 
S. 1934] .
To address the exploratory immunogenicit y objectives aiming to evaluate the OPA GMTs 
and the IgG GMCs 30 day s postvaccination with V114 or Prevnar 13™ (Day  30) and at 
30days postvaccination with PNEUMOVAX™23 (Month 7) for participants administered 
V114 compared to participants administered Prevnar 13™ , the seroty pe-specific OPA GMTs 
and IgG GMTs will be c ompared between vaccination groups through the estimation of 
seroty pe-specific OPA GMT ratios and IgG GMC ratios for each of the 15 serotypes in V114 
at each of these time points . Estimation of the OPA GMT ratios and computation of the 
corresponding 95% CI s will be calculated using a constrained longitudinal data anal ysis 
(cLDA) method proposed by  Liang and Zeger [Liang, K -Y and Zeger, S. L. 2000] .Details 
regarding the cLDA models will be included in the 
supplem ental Statistical Analy sis Plan . 
  050DGF 
  05KG3M
PRODUCT: V114 79
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Reverse Cumulative Distribution Curves for OPA titers and IgG concentrations will be 
graphicall y displayed b y seroty pe at each of the following time point s: Day 30and Month 7 . 
A detailed analy sis strategy  for immunogenicit y endpoints is listed in Table 5.
Table 5 Analy sis Strategy  for Immunogenicit y Variables
Endpoint/Variable
(Description, Time Point)Primary vs. 
Supportive 
Approach†Statistical 
MethodAnalysis 
Popula tionMissing Data 
Approach
Prim ary Endpoint
OPA GMTs atDay 30PDescriptive 
Statistics
(estimate, 95%
CI)PP Missing data 
will not be 
imputed S FAS
Secondary Endpoints
IgG GMCs atDay 30 PDescriptive 
Statistics 
(estimate, 95%
CI)PPMissing data 
will not be 
imputed
GMFR and % of participants who achieved a
≥4-fold rise from Day 1 to Day 30PDescriptive 
Statistics
(estimate, 95%
CI) PPMissing data 
will not be 
imputed
OPA GMTs and IgG GMCs atMonth 7 PDescriptive 
Statistics
(estimate, 95%
CI) PPMissing data 
will not be 
imputed
GMFR and % of participants who achieved a
≥4-fold rise from Day 1 to Month 7PDescriptive 
Statistics
(estimate, 95%
CI) PPMissing data 
will not be 
imputed
GMFR and % of participants who achieved a
≥4-fold risefrom Month 6 to Month 7PDescriptive 
Statistics
(estimate, 95%
CI) PPMissing data 
will not be 
imputed
†P = p rimary approach; S = supportive approach.
CI=confidence interval ; FAS = Full Analysis Set; GMC =Geom etric Mean Concentration; 
GMFR =Geometric Mean Fold Rise ; GMT =Geometric Mean Titer; IgG = immunoglobulin G; 
OPA = opsonophagocytic activity; PP =Per-Protocol
9.6.2 Statistical Methods for Safety Analyses
Safety  and tolerability  will be assessed b y clinical review of all relevant parameters,
including AEs and postvaccination temperature measurements.
The anal ysis strategy  for safet y parameters following each vaccination is summarized in 
Table 6. The proportion of participants with solicited injection -site AEs (redness/ery thema, 
swelling, tenderness/pain from Day  1 to Day  5 postvaccination) and solicited sy stemic AEs 
(muscle pain/my algia, joint pain/arthralgia, headache, tiredness /fatigue from Day  1 to Day  14  
  050DGF 
  05KG3M
PRODUCT: V114 80
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
postvaccination) will be provided ,along with the corresponding within -group 95% CIs 
(based on the exact binomial method proposed by Clopper and Pearson [Clopper, C. J. and 
Pearson, E. S. 1934] ).  In addition, the broad AE categories consisting of the proportion of 
participants with an y AE, a vaccine -related AE, a SAE, an AE that is both vaccine -related 
and serious, discontinuation due to an AE, and the proportion of participants who died will 
be summarized in the same manner.  The proportion of participants with maximum 
temperature measurements meeting the Brighton Collaboration cut points (from Day  1 
through Day  5) will also will be provided ,along with the corresponding within -group 95% 
CIs.Point estimates by  vaccination group will be provided for all other safety  parameters 
(specific AE terms and system organ class terms).
The anal ysis of safet y parameters will be evaluated at 2 separate time points: (1) following 
administration of V114 or Prevnar 13™ and (2) following administration of 
PNEUMOVAX™23.  Descriptive summaries of AEs following administration of V114 or 
Prevnar 13™ will include nonserious adverse events (NSAEs) within 14 day s of vaccination 
and SAEs occurring Day  1 through Month 6 (prior to vaccination with PNEUMOVAX™23). 
Descriptive summaries of AEs following administration of PNEUMOVAX™23 will include 
NSAEs with in 14 day s of vaccination and SAEs occurring Month 6 (Day  1 relative to 
vaccination with PNEUMOVAX™23) through Month 7 (Day  30 relative to vaccination with 
PNEUMOVAX™23). 
Safety  anal yses will be based on the observed data ( ie, with no imputation of missin g data). 
  050DGF 
  05KG3M
PRODUCT: V114 81
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Table 6 Analy sis Strategy for Safety  Parameters Following Each Vaccination
Safety Endpoint95% CI for Within -Group 
Com parisonDescriptive Statistics
Injection -site redness /erythema (Days 1 to 5)†X X
Injection -site swelling (Days 1 to 5)†X X
Injection -site tenderness /pain (Day s 1 to 5)†X X
Muscle pain /myalgia (Days 1 to 14)†X X
Joint pain /arthralgia (Days 1 to 14)†X X
Headache (Day s 1 to 14)†X X
Tiredness /fatigue (Day s 1 to 14)†X X
Any AE‡X X
Any vaccine -related AE‡X X
Any SAE‡X X
Any vaccine -related SAE‡X X
Discontinuation due to AE‡X X
Death‡X X
Maximum temperature measurements meeting the 
Brighton Collaboration cut points (Days 1 to 5)X X
Specific AEs by SOC and PT X
†Includes solicited events only.
‡   These endpoints are broad AE categories. For example, descriptive statistics for the safety endpoint of “Any 
AE” will provide the number and percentage of participants with at least 1AE.
AE=adverse event; CI = confidence interval; PT=preferred term; SAE =serious adverse event; 
SOC = system organ class; X =results will be provided.
9.6.3 Demographic and Baseline Characteristics
The comparability  of the vaccination groups for each relevant demographic and bas eline 
characteristic will be assessed by the use of summary tables. No statistical hypothesis tests 
will be performed on these characteristics. The number and percentage of participants 
screened and randomized and the primary  reasons for screening failure and discontinuation 
will be display ed. Demographic variables (eg, age, race, and gender), baseline characteristics, 
and prior and concomitant vaccinations and therapies will be summarized by  vaccination 
group either b y descriptive statistics or categorical tables.
9.7 Interim Analyses
A periodic review of safety  and tolerability  data across the adult V114 Phase 3 program will 
be conducted b y an independent, unblinded, external DMC. A description of the structure, 
function, and guidelines for decision -making by  the DMC, along with the timing and content 
of the safet y reviews ,will be outlined in the DMC charter. Information regarding the 
composition of the DMC is provided in Appendix 1. There are no plans to conduct an interim 
analysis of unblinded immunogenicit ydata in this study .However, unblinded 
immunogenicit y data will be made available to the DMC upon request to enable a benefit -
risk assessment. 
  050DGF 
  05KG3M
PRODUCT: V114 82
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Study  enrollment is likely  to be ongoing at the time of any  interim analy ses. Blinding to 
intervention assignment will be maintained at all investigational sites. The results of interim 
analyses will not be shared with the investigators prior to the completion of the study. 
Participant -level unblinding will be restricted to an external unblinded statisticia n performing 
the interim anal ysis.
The DMC will serve as the primary  reviewer of the results of the safet y interim anal yses and 
will make recommendations for discontinuation of the study or protocol modifications to an 
executive committee of the Sponsor (see Appendix 1 for details on the Committees Structure 
for this study ). If the DMC recommends modifications to the design of the protocol or 
discontinuation of the study , this executive committee (and potentiall y other limited Sponsor 
personnel) may  be u nblinded to results at the intervention level in order to act on these 
recommendations. The extent to which individuals are unblinded with respect to results of 
interim analy ses will be documented by  the external unblinded statistician. Additional 
logistic al details will be provided in the DMC Charter. 
Intervention -level results from the safety  interim analy sis will be provided by  the external 
unblinded statistician to the DMC.Prior to final study  unblinding, the external unblinded 
statistician will not b e involved in any discussions regarding modifications to the protocol, 
statistical methods, identification of protocol deviations, or data validation efforts after the 
interim analy ses.
9.8 Multiplicity
Noadjustment will be made for multiplicity .
9.9 Sample Size and Power Calculations
9.9.1 Sample Size and Power for Immunogenicity Analyses
This is a descriptive study. This study  will randomize approximately  1125 participants into 
the V114 group and 375 participants into the Prevnar 13™ group . It is assumed that 
approxim ately  1013 participants in the V114 group and 337 in the Prevnar 13™ group will 
be evaluable for PP immunogenicity  anal yses at Day  30 (based on a 90% evaluability  rate). 
The width of the within -group 95% CIs for the seroty pe-specific OPA GMT sdepend on th e 
sample size, variability  of the natural log concentrations, and the magnitude of the OPA 
GMT. InTable 7,95% CIs for various hy pothetical Day  30 OPA GMT sand various 
hypothetical standard deviation estimates for the natural log titers are display ed. 
  050DGF 
  05KG3M
PRODUCT: V114 83
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Table 7 Within -group 95% CIs for Vary ing Hypothetical OPA GMTs and Vary ing 
Standard Deviations
Standard 
Deviation 
of Natural 
Log 
Titers†Serotype -specific OPA GMT†
500 1000 5000
V114 Prevnar 13™ V114 Prevnar 13™ V114 Prevnar 13™
1.5 (456, 548) (426, 587) (912, 1097) (852, 1174) (4559, 5485) (4260, 5868)
2 (442, 566) (404, 619) (884, 1131) (808, 1238) (4421, 5655) (4039, 6190)
2.5 (429, 583) (383, 653) (857, 1166) (766, 1306) (4287, 5832) (3829, 6530)
Based on 1013 evaluable participants in the V114 group and 337 evaluable participants in the Prevnar 13™ 
group .
†The estimates of the standard deviation and OPA GMT sarerepresentative of those observed in V114 -006.
CI=confidence interval ; GM T= Geometric Mean Tier; OPA =opsonophagocytic activi ty.
9.9.2 Sample Size and Power for Safety Analyses
The sample size was selected to achieve a reasonably  sized safet y database in this population 
exposed to V114 . The probability  of observing at least 1SAE in this study  depends on the 
number of participants vaccinated and the underlying incidence of participants with a SAE in 
the study  population. Calculations below assume that 100% of the randomized participants 
will be evaluable for safety  analy ses. Th ere is an 80% chance of observing at least 1SAE 
among 1125 participants in the V114 group if the underly ing incidence of a SAE is 0. 14% 
(1of every  700participants receiving the vaccine). There is a 50% chance of observing at 
least 1SAE among 1125 parti cipants in the V114 group if the underl ying incidence of a SAE 
is 0.06% (1 of every  1623 participants receiving the vaccine). If no SAEs are observed 
among the 1125 participants in the V114 group, this study  will provide 97.5% confidence 
that the underl ying percentage of participants with a SAE is <0.34% ( 1in every  294 
participants) in the V114 group.
9.10 Subgroup Analyses
Seroty pe-specific OPA GMTs and IgG GMCs at Day  30 and at Month 7 and their 
corresponding within -group 95% CI s will be calculated among part icipants enrolled at 
CAIH.
In addition, these endpoints will be evaluated in additional subgroups depending on the 
distribution of participants across the risk factors. Details will be provided in the 
supplemental Statistical Analy sis Plan .
A similar appr oach will be used for subgroup analyses for safet y endpoints (including 
summary  of AEs and a summary  of solicited AEs).  
  050DGF 
  05KG3M
PRODUCT: V114 84
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
9.11 Compliance (Medication Adherence)
Given that participants will receive just a single dose of V114 or Prevnar 13™ and a single 
dose of P NEUMOVAX™23, compliance will not be calculated. However, the number and 
proportion of randomized participants receiving each vaccination will be summarized 
(Section 9.12).
9.12 Extent of Exposure
The extent of exposure will be summarized by  the number and propo rtion of randomized 
participants administered V114 or Prevnar 13™ and the number and proportion of 
randomized participants administered PNEUMOVAX™23. 
  050DGF 
  05KG3M
PRODUCT: V114 85
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversig ht Considerations
10.1.1 Code of Conduct for Clinical Trials
Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc. (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A.Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of parti cipant s inclinical trials is the 
overriding concern in the design of clinical trials . In all cases, M SD clinical trials will be conducted in compliance 
with local and/or national regulations (eg, International Council for Harmonisation Good Clinical Pract ice [ICH -
GCP]) and in accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B.Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
MSD irrespective of the party (parties) employed for their execution (eg, contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator -initiated trials , which are not under the 
full control of M SD.
II.Scientific Issues
A.Trial Conduct
1.Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis -driven to assess s afety, 
efficacy, and/or pharmacokinetic or pharmacodynamic indices of M SD or comparator products. 
Alternatively, M SDmay conduct outcomes research trials, trials to assess or validate various endpoint 
measures, or trials to determine patient preferences, e tc.
The design (ie, participant population, duration, statistical power) must be adequate to address the specific
purpose of the trial. P articipants must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
MSD selects investigative sites based on medical expertise, access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by M SD personnel to assess the ability to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Investigative t rial sites are monitored to assess compliance with the trial protocol and general principles of 
Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data 
are verified versus source documentation according to standard operating procedures. Per M SD policies and 
procedures, if fraud, scientific/research misc onduct, or serious GCP -noncomplia nce is suspected, the issues 
areinvestigated. When necessary, the clinical site will be closed, the responsible regulatory authorities and 
ethics review committees notified.
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the prespecified plans for data analysis. To the 
extent scientifically appropriate, M SDseeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pilot trials are intended to be hypothesis -generating rather  
  050DGF 
  05KG3M
PRODUCT: V114 86
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
than hypothesis testing , in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by statistical issues such as multiplicity.
MSD’s policy on authorship is consistent with the re commendations published by the International Committee of 
Medical Journal Editors (ICMJE). In summary, authorship s hould reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. M SD funding of a tri al will be acknowledged in 
publications.
III.Participant Protection
A. Ethics Committee Review (Institutiona Review Board [ IRB]/Independent Ethics Committee [ IEC])
All clinical trials will be reviewed and approved by an IRB/IEC before being initiated at each site. Significant 
changes or revisions to the protocol will be approved by the ethics committee prior to implementation, except 
changes required urgently to prot ect participant safety that may be enacted in anticipation of ethics committee 
approval. For each site, the ethics committee and M SDwill approve the par ticipant informed consent form.
B. Safety
The guiding principle in decision -making in clinical trials i s that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local stand ard of care.
All participation in M SD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Participants may withdraw from a n MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
law, only the investigator, Sponsor (or representative), ethics committee, and/or regulato ry authorities will have 
access to confidential medical records t hat might identify the participant by name.
D. Genomic Research
Genomic r esearch will only be conducted in accordance with a protocol and informed consent authorized by an 
ethics c ommittee.
IV. Financial Considerations
A. Paym ents to Investigators
Clinical trials are time -and labor -intensive. It is M SD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of M SD trials. M SD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. Howe ver, M SDmay compensate referring physicians for time spent 
on chart review to identify potentially eligible participants.
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by M SDand that the investigator or spo nsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, allpublications resulting from M SD trials will indicate M SD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by investigators and support staff (eg, to scientific meetings, investigator meetings, etc.) will be 
consistent wit h local guidelines and practices .
V. Investigator Commit ment
Investigators will be expected to review M SD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards. 
  050DGF 
  05KG3M
PRODUCT: V114 87
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
10.1.2 Financia l Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54). I t is the 
Sponsor's responsibility  to determine, based on these regulations, wh ether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.
The investigator/subinvestigator(s) agree, if requested by  the Sponsor in accordance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this informat ion on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by  
the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the United States for these purposes. This may  involve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.3 Data Protection
Participants will be assigned a unique identifier by the Sponsor. An y participant records or 
datasets that are transferred to th e Sponsor will contain the identifier only; participant names 
or an y information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by  the 
Sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other authori zed personne l appointed by  the S ponsor, by  
appropriate IRB/IEC members, and b y inspectors from regulatory authorities.
10.1.3.1 Confidentiality of Data
By signing this protocol, the investigator affirms to the Sponsor that information furnished to 
the investigator b y the Sponsor will be maintained in confidence, and such information will 
be divulged to the IRB, IEC,or similar or expert committee; affiliated institution and 
employ ees, only  under an appropriate understanding of confidentialit y with such board or 
committee, affiliated institution and employ ees. Data generated b y this study will be 
considered confidential by the investigator, except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
10.1.3.2 Confidentiality of P articipant Records
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory  authority  representatives may  consult and/or cop y study  documents to 
verify  worksheet/ CRF report form data. By  signing the consent form, the participant agrees 
to this process. If stud y documents will be photocopied during the process of verifying  
  050DGF 
  05KG3M
PRODUCT: V114 88
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
worksheet/ CRF information, the participant will be identified b y unique code only; full 
names/initials will be masked prior to transmission to the Sponsor.
By signing this protocol, the investigator agrees to treat all participant data used and 
disclosed in connection with this study  in accordance with all applicable privacy  laws, rules 
and regulations.
10.1.3.3 Confidentiality of IRB/IEC Information
The Sponsor is required to record the name and address of each IRB/IEC that reviews and 
approves this study . The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements b y requesting and maintaining rec ords of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies.
10.1.4 Committees Structure
10.1.4.1 External D ata Monitoring Committee
To supplement the routine study  monitoring outlined in this protocol, an external DMC will 
monitor the interim data from this study . The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be involved with the study in an y other 
way (eg, they  cannot be study investigators) and must have no competing interests that could 
affect their roles with respect to the study .
The DMC will make recommendations to the EOC regarding steps to ensure both participant 
safet y and the continued ethical integrity of the study. A lso, the DMC will review interim 
study  results, consider the overall risk and benefit to study  participants (Section 9.7) and 
recommend to the EOC whether the stud y should continue in accordance with the protocol.
Specific details regarding composition, re sponsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the study  governance structure; and requirements for and proper documentation 
of DMC reports, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by all the DMC members.
10.1.4.2 Executive Oversight Committee
The Executive Oversight Committee (EOC) is comprise d  of members of Sponsor Senior 
Management. The EOC will receive and decide upon any  recommendations made by  the
external DMC regarding the study .
10.1.4.3 Scientific Advisory Committee
This study  was developed in collaboration with a Scientific Advisory  Committee (SAC). The 
SAC is comprise d of both Sponsor and non -Sponsor scientific experts who provide input 
with respect to study  design, interpretation of study  results, and subsequent peer -reviewed 
scientific publications. 
  050DGF 
  05KG3M
PRODUCT: V114 89
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
10.1.5 Publication Policy
The results of this study  may  be published or presented at scientific meetings. The Sponsor 
will comply  with the requirements for publication of study  results. I n accordance with 
standard editorial and ethical practice, the Sponsor will generall y support publication of 
multicenter studies only  in their entiret y and not as individual site data. I n this case, a 
coordinating investigator will be designated b y mutual agreement.
If publication activity is not directed b y the Sponsor, the investigator agrees to submit all 
manuscripts or abstracts to the Sponsor before submission. This allows th e Sponsor to protect 
proprietary  information and to provide comments.  
Authorship will be determined by  mutual agreement and in line with I nternational Committee 
of Medical Journal Editors authorship requirements.
10.1.6 Compliance with Study Registration and Results Posting Requirements
Under the terms of the Food and Drug Administration Amendments Act (FDAAA) of 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the study  is solel y responsible for determining whether the stud yand its results are subject
to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study , will 
review this protocol and submit the information nece ssary  to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to identify  potentiall y appropriate studies for their 
disease conditions and pursue pa rticipation b y calling a central contact number for further 
information on appropriate study  locations and study  site contact information.
By signing this protocol, the investigator acknowledges that the statutory  obligations under 
FDAAA, the EMA clinical trials directive or other locally  mandated registries are that of the 
Sponsor and agrees not to submit any  information about this study or its results to those 
registries. 
10.1.7 Compliance with Law, Audit, and Debarmen t
By signing this protocol, the investigator agrees to conduct the study  in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of G CP
(eg, International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuti cals for Human Use G CP: Consolidated Guideline and other generally  
accepted standards of good clinical practice); and all applicable federal, state and local laws, 
rules and regulations relating to the conduct of the clinical study. The Code of Conduct, a 
collection of goals and considerations that govern the ethical and scientific conduct of 
clinical investigations sponsored b y MSD, is provided i n this appendix under the Code of 
Conduct for Clinical Studies. 
  050DGF 
  05KG3M
PRODUCT: V114 90
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
The investigator agrees not to seek reimbursemen t from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator b y the Sponsor.
The investigator will promptly  inform the Sponsor of an y regulatory authority inspection
conducted for this study .
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to an y citations resulting 
from regulatory  authority inspection and will provide the Sponsor with a copy  of the 
proposed response for consultation before submission to the regulatory  authority . 
Persons debarred from conducting or working on clinical studies by  any court or regulatory  
authority  will not be allowed to conduct or work on this Sponsor’s studies. The investigator 
will immediately  disclose in writing to the Sponsor if any  person who is involved in 
conducting the study  is debarred or if any  proceeding for debarment is pending or, to the best 
of the investigator’s know ledge, threatened.
10.1.8 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verify ing that data entries are accurate and correct by  
physicall y or electronically signing the CRF.
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
The investigator must maintain a ccurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents.
Study documentation will be promptly  and fully  disclosed to the Sponsor by the investigator 
upon request and also shall be made available at the study site upon request for inspection, 
copy ing, review, and audit at reasonable times b y representatives of the Spo nsor or an y 
regulatory  authorities. The investigator agrees to promptly  take an y reasonable steps that are 
requested b y the Sponsor or any regulatory  authorit ies as a result of an audit or inspection to 
cure deficiencies in the stud y documentation and work sheets/CRFs .
The Sponsor or designee is responsible for the data management of this study  including 
quality  checking of the data.
Study  monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF b y authorize d site personnel are accurate, complete, and verifiable from 
source documents; that the safet y and rights of participants are being protected; and that the  
  050DGF 
  05KG3M
PRODUCT: V114 91
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
study  is being conducted in accordance with the currentl y approved protocol and an y other 
study  agre ements, ICH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICF, pertaining to the conduct of this study  must 
be retained b y the investigator for 15 ye ars after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during 
the retention period without the written approval of the Sponsor. No records may be 
transferred to another location or part y without written notification to the Sponsor.
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical rec ords must be available.
10.1.10 Study and Site Closure
The Sponsor or its designee may  stop the study  or study  site participation in the study  for 
medical, safety , regulatory , administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurel y terminates a particular stud y site, the Sponsor will 
promptly  notify  that study  site’s IRB/IEC. 
  050DGF 
  05KG3M
PRODUCT: V114 92
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
10.2 Appendix 2: Clinical Laboratory Tests
The tests detailed in Table 8will be performed according to local requirements. 
Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol.
Additional tests may  be performed at an y time during the stud y as determined necessary 
by the investigator or required by  local regulations.
Table 8 Protocol -require d Safet yLaboratory  Assessments
Laboratory 
AssessmentsParameters
Other Screening 
TestsSerum or urine β-hCG pregnancy test (as needed for WOCBP)
Disease -specific laboratory assessments:
Diabetes mellitus : Hemoglobin A1c
Chronic liver disease : AST , ALT , total bilirubin, PT/INR, albumin, platelets
ALT = alanine aminotransferase; AST = aspartate aminotransferase; β-hCG =β human chorionic gonadotropin; 
INR = international normalized ratio; PT = prothrombin time; WOCBP = w oman/w omen of childbearing 
potential . 
  050DGF 
  05KG3M
PRODUCT: V114 93
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definiti on of AE
AE definition
•An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study  intervention, whether or not considered related to the 
study  intervention.
•NOTE: An AE can therefore be an y unfavor able and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study intervention.
•NOTE: For purposes of AE definition, study  intervention (also referred to as Sponsor’s
product) includes an y pharmaceutical product, biological product, vaccine, device, 
diagnostic agent, or protocol specified procedure whether investigational (including 
placebo or active comparator product) or marketed, manufactured b y, licensed by, 
provid ed by, or distributed by the Sponsor for human use in this study.
Events meeting the AE definition
•Any abnormal laboratory test results (hematology , clinical chemistry, or urinaly sis) or 
other safet y assessments (eg, ECG, radiological scans, vital signs me asurements), 
including those that worsen from baseline, or are considered clinicall y significant in the 
medical and scientific judgment of the investigator.
•Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
•New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
•Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
•Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication.
•For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical s ymptoms or abnormal test result. An overdose 
without any  associated clinical sy mptoms or abnormal laboratory  results is reported using 
the terminology  “accidental or intentional overdose without adverse effect.”
•Any new cancer or progression of e xisting cancer. 
  050DGF 
  05KG3M
PRODUCT: V114 94
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Events NOT meeting the AE d efinition
•Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
•Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study  that do not worsen.
•Surgery  planned prior to informed consent to treat a pre -existing conditi on that has not 
worsened.
•Refe r to Section 8.4.7 for protocol -specific exceptions.
10.3.2 Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met.
An SAE is defined as any untoward medical occur rence that, at any dose:
a.Results in death
b.Is life -threatening
•The term “ life-threatening ”in the definition of “serious ”refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which h ypothe tically  might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
•Hospitalization is defined as an inpatient admission, regardless of length of stay, even 
if the hospitalization is a pre cautionary  measure for continued observation. (Note: 
Hospitalization for an elective procedure to treat a pre -existing condition that has not 
worsened is not an SAE. A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history .
d.Results in persistent or significant disability/incapacity
•The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
•This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
every day life functions but do no t constitute a substantial disruption. 
  050DGF 
  05KG3M
PRODUCT: V114 95
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
e.Is a congenital anomaly/birth defect
•In offspring of participant taking the product regardless of time to diagnosis.
f.Other important medical events
•Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or hospitalization but may 
jeopardize the participant or may require medical or surgical intervention to prevent 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at home for allergic bronchospa sm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug dependency 
or drug abuse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
•Is a cancer
•Is associated with an overdose
10.3.4 Recording AE and SAE
AE and SAE r ecording
•When an AE/SAE occurs, it is the responsibility  of the investigator to review all
documentation (eg, hospital progress notes, laboratory , and diagnostics reports) related to 
the event.
•The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
•It is not acceptable for the investigator to send photocopies of the participant’s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
•There may  be instances when copies of medical records for certain cases are requested b y 
the Sponsor. I n this case, all participant identifie rs, with the exception of the participant 
number, will be blinded on the copies of the medical records before submission to the 
Sponsor. 
  050DGF 
  05KG3M
PRODUCT: V114 96
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical in formation. I n such cases, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity /Toxicity
•An event is defined as “serious ”when it meets at least 1 of the predefined outcomes as 
described in the definit ion of an SAE, not when it is rated as severe.
•The investigator will make an assessment of intensity  for each AE and SAE (and other 
reportable safet y event) reported during the stud y and assign it to 1 of the following 
categories:
-Mild: An event that is easily  tolerated b y the participant, causing minimal discomfort 
and not interfering with every day activities (for pediatric studies, awareness of 
symptoms, but easily  tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal
every day activities (for pediatric studies definitel y acting like something is wrong).
-Severe: An event that prevents normal everyday  activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category  utilized for rating
the intensity  of an event; and both AE and SAE can be assessed as severe (for 
pediatric studies, extremely distressed or unable to do usual activities).
•Injection -site redness /erythema or swelling from the day of vaccination through Day  5 
postvaccination will be evaluated b y maximum size.
•The investigator will make an assessment of toxicity for each AE and SAE (and other 
reportable event) reported during the stud y.  A toxicity  grade wil l be assigned to 
injection -site AEs, specific sy stemic AEs, other s ystemic AEs, and vital sign 
(temperature) AEs as shown in the following tables. The toxicity  grading scales used in 
this study  are adapted from the “FDA Guidance for Industry : Toxicity  Grad ing Scale for 
Health y Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, 
September 2007.” 
  050DGF 
  05KG3M
PRODUCT: V114 97
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Injection -Site AE Toxicity Grading Scale
Injection Site Reaction 
to Study 
Vaccine/PlaceboaGrade 1 Grade 2 Grade 3 Grade 4
Injection -site AEs occurring Days 1 through 5 following receipt of study vaccine/placebo
Pain/Tenderness Does not interfere 
with activityRepeated use of non -
narcotic pain reliever 
>24 hours or 
interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityERvisit or 
hospitalization
Erythema/Redness Size measured as
BSize measured as
C or DSize measured as
E→Necrosis or 
exfoliative dermatitis 
or results in ER visit 
or hospitalization
Induration/Swelling Size measured as 
BSize measured as
C or DSize measured as
E→Necrosis or ER visit 
or hospitalization
Other Does not interfere 
with activityRepeated use of non -
narcotic pain reliever 
>24 hours or 
interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospitalization
Any injection -site reaction that begins ≥ 6 days after receipt of study vaccine/placebo
Pain/tenderness
Erythema/Redness
Induration/Swelling
OtherDoes not interfere 
with activityRepeated use of non -
narcotic pain reliever 
>24 ho urs or 
interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospitalization
Abbreviations: AE = adverse event; ER = emergency room; eVRC = electronic Vaccine Report Card; SAE = serious 
adverse event
a Based upon information provided by the patient on the eVRC a nd verbally during VRC review. Erythema/Redness and 
Induration/Swelling are specific injection -site AEs with size designations of letters A through E →, based upon a graphic in 
the eVRC.  Size A is not assigned a toxicity grade; however, injection -site AEs that measure size A should be reported as 
adverse experiences.  If the participant has an ER visit or is hospitalized for any injection -site AE, that AE is to be assigned 
a toxicity grade of 4, regardl ess of the size measured.
Specific Systemic AE Toxicity Grading Scale
System ic (General)Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Headache No interference with 
activityRepeated use of non -
narcotic pain reliever 
>24hours or some 
interference with 
activitySignificant; any use of 
narcotic pain reliever 
or prevents daily 
activityER visit or 
hospitalization
Fatigue No interference with 
activitySome interference with 
activitySignificant; prevents 
daily activityER visit or 
hospitalization
Myalgia No interference with 
activitySome interference with 
activitySignificant; prevents 
daily activityER visit or 
hospitalization
Abbreviations: ER = emergency room 
  050DGF 
  05KG3M
PRODUCT: V114 98
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Other Systemic AE Toxicity Grading Scale
System ic IllnessaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)b
Illness or clinical AE 
(as defined according 
to applicable 
regulations)No interference with 
activitySome interference with 
activity not requi ring 
medical interventionPrevents daily activity 
and required medical 
interventionER visit or 
hospitalization
Abbreviations: ER = emergency room; eVRC = electronic Vaccine Report Card; SAE = serious adverse event
aBased upon information provided by the patient on the eVRC and verbally during the eVRC review during the primary 
safety follow -up period. For SAEs reported beyond the primary safety follow -up period, grading will be based upon the 
initial report and/or follow -up of the event.
bAEs resulting in death will be assessed as Grade 4
Vital Sign (Temperature) Toxicity Grading Scale
Vital SignsaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Fever (°C) b
(°F) b38.0 to 38.4
100.4 to 101.138.5 to 38.9
101.2 to 102.039.0 to 40.0
102.1 to 104.0>40.0
>104.0
aParticipant should be at rest for all vital sign requirements
b Oral temperature; no recent hot or cold beverages or smoking
Assessment of c ausality
•Did the Sponsor ’s product cause the AE?
•The determination of the likelihood that the Sponsor ’s product caused the AE will be 
provided b y an investigator who is a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causalit y noted on the AE 
form, ensures that a medically  qualified assessment of causalit y was done. This initia lled 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following components are to be used to assess the relationship between the 
Sponsor ’s product and the AE; thegreater the correlation with the components and 
their respective elements (in number and/or intensity ), the more likel y the Sponsor ’s 
product caused the AE:
-Exposure: Is there evidence that the participant was actuall y exposed to the 
Sponsor ’s product such as: reliable history , acceptable compliance assessment (diary , 
etc.), seroconversion or identification of vaccine virus in bodily  specimen?
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor ’s product? Is the time of onset of the AE compatible 
with a vaccine -induced effect? 
  050DGF 
  05KG3M
PRODUCT: V114 99
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
-Likely Cause: Is the AE not reasonabl y explained by  another etiology  such as 
underly ing disease, other drug(s)/vaccine(s), or other host or environmental factors ?
-Rechallenge: Was the participant re -exposed to the Sponsor ’s product in the study ?
-If yes, did the AE recur or worsen?
-If yes, this is a positive rechallenge.
-If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in dea th or permanent 
disability , or (2) the study  is a single -dose vaccine study ); or (3) Sponsor ’s product(s) is/are 
used only  1 time.)
NOTE: IF A RECHALLENGE IS PL ANNED FOR AN AE THAT WAS SERI OUS AND 
MAY HAVE BEEN CAUSED BY THE SPONSOR ’S PRODUCT, OR I F RE -EXP OSURE 
TO THE SPONSOR ’S PRODUCT POSES ADDITIONAL POTENTIAL SI GNIFICANT 
RISK TO THE PARTI CIPANT THEN THE RECHALLENGE MUST BE APPROVED I N 
ADVANCE BY THE SPONSOR CLINI CAL  DIRECTOR, AND IF REQUI RED, THE 
IRB/IEC .
-Consistency with study intervention profile: Is the clinical/pathological 
presentation of the AE consistent with previous knowledge regarding the Sponsor ’s 
product or drug class pharmacology  or toxicology?
-The assessment of relationship will be reported on the CRFs /worksheets by an 
investigator who is a qualified phy sician according to his/her best clinical judgment, 
including consideration of the above elements.
-Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor ’s product relationship).
-Yes, t here is a reasonable possibility  of Sponsor ’s product relationship:
-There is evidence of exposure to the Sponsor ’s product. The temporal sequence of the 
AE onset relative to the administration of the Sponsor ’s product is reasonable. The 
AE is more likely  explained by  the Sponsor ’s product than by  another cause.
-No, there is not a reasonable possibility  of Sponsor ’s product relationship:
-Participant did not receive the Sponsor ’s product OR temporal sequence of the AE 
onset relative to administration of the S ponsor ’s product is not reasonable OR the AE 
is more likely  explained by  another cause than the Sponsor’s product. (Also entered 
for a participant with overdose without an associated AE.)
•For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
•There may  be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causalit y for every event before the 
initial transmission of the SAE data to the Sponsor. 
  050DGF 
  05KG3M
PRODUCT: V114 100
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
•The investigator may change his/her opinion of causality  in light of follow -up 
information and send an SA E follow -up report with the updated causality  assessment.
•The causality  assessment is 1 of the criteria used when determining regulatory  reporting 
requirements.
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested b y Sponsor to 
elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
•New or updated information will be recorded in the CRF.
•The investigator will submit any  updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.5 Reporting of AE, SAE, and Other Reportable Safety Events to the Sponsor
AE, SAE, and other reportable safety event reporting to Sponsor via electronic data 
collection tool
•The primary  mechanism for reporting to the Sponsor will be the electronic data collection 
(EDC) tool .
•Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
•If the electronic s ystem is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
•Reference Section 8.4.1  for reporting time requirements.
•The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
•After the stud y is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry  of new data or changes to existing data.
•If asite receives a report of a new SAE from a study  participant or receives updated data 
on a previousl y reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by telephone (see next section) .
•Contacts for SAE reporting can be found in the Investigator Stud y File Binder (or 
equivalent). 
  050DGF 
  05KG3M
PRODUCT: V114 101
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
•In rare circumstances and in the absence of facsimile equipment, notification by  
telephone is acceptable with a cop y of the SAE data collection tool sent by overnight 
mail or courier service.
•Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
•Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the I nvestigator Study  File Binder (or equivalent). 
  050DGF 
  05KG3M
PRODUCT: V114 102
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
10.4 Appendix 4: Medical Device Incidents: Definition and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
Not ap plicable. 
  050DGF 
  05KG3M
PRODUCT: V114 103
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing
10.5.1 Definitions
Wome n of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile.
Women in the following categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the follow ing:
- Documented h ysterectomy
-Documented bilateral salpingectomy
-Documented bilateral oophorectom y
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history  interview.
•Postmen opausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause .
•A high follicle stimulating hormone (FSH) level in the postmenopausal range may be 
used to confirm a postmenopausal state in women not using h ormonal contraception or 
hormone replacement therap y (HRT). However, in the absence of 12 months of 
amenorrhea, confirmation with 2 FSH measurements in the postmenopausal range is 
required.
-Females on HRT and whose menopausal status is in doubt will be req uired to use 1 of 
the nonhormonal highl y effective contraception methods if they wish to continue their 
HRT during the stud y. Otherwise, they must discontinue HRT to allow confirmation 
of postmenopausal status before stud y enrollment. 
  050DGF 
  05KG3M
PRODUCT: V114 104
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
10.5.2 Contraception Requirements
Female Participants
Female participants of childbearing potential are eligible to participate if they agree to use 
1of the contraception methods described in Table 9consistently  and correctly  during the 
protocol -defined time frame in Section 5.1.
Table 9 Contraceptive Methods
Acceptable Contraceptive Methods
Failure rate of >1% per year when used consistently and correctly.
●Male or female condom with or without spermicide
●Cervical cap, diaphragm or sponge with spermicide
Highly Effective Contraceptive Methods That Are User Dependenta
Failure rate of <1% per year when used consistently and correctly.
●Com bined (estrogen -and progestogen -containing) hormonal contraceptionb
○Oral
○Intravaginal
○Transdermal
○Injectable
●Progestogen only hormonal contraceptionb,c
○Oral
○Injectable
Highly Effective Methods That Have Low User Dependency
Failure rate of <1% per year when used consistently and correctly.
●Progestogen -only contraceptive implantb
●Intrauterine hormone -releasing system (IUS)b
●Intrauterine device (IUD)
●Bilateral tubal occlusion
●Vasectomized partner
A vasectomized partner is a highly effective contraception method provided that the partner is the sole 
male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional 
highly effective method of contraception should be used.
●Sexual abstinence
Sexual abstinence i s considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of 
sexual abstinence needs to be evaluated in relation to the durati on of the study and the preferred and 
usual lifestyle of the participant.
Notes:
Use should be consistent with local regulations regarding the use of contraceptive methods for participants 
of clinical studies.
aTypical use failure rates are higher than per fect-use failure rates (ie, when used consistently and 
correctly).
bIf locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable 
hormonal contraceptives are limited to those which inhibit ovulation. 
  050DGF 
  05KG3M
PRODUCT: V114 105
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
10.5.3 Pregnancy Testing
WOCBP should only  be included after a negative highl y sensitive urine or serum pregnancy 
test.
Pregnancy  testing will be performed whenever an expected menstrual cy cle is missed or 
when pregnancy  is otherwise suspected.
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research (Does not apply to CAIH participants)
1.Definitions
Biomarker: A biological molecule found in blood, other bod y fluids, or tissues that is
a sign of a normal or abnormal process or of a condition or dise ase. A biomarker may
be used to see how well the body responds to a treatment for a disease or condition . 
Pharmacogenomics: The investigation of variations of DNA and RNA characteristics 
as related to drug/vaccine response.2
Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence 
of variations in DNA sequence on drug/vaccine response.2
DNA: Deox yribonucleic acid.
RNA: Ribonucleic acid.
2.Scope of Future Biomedical Research
The specimens consented and/or collected in this study  as outlined in Section 8. 8will be 
used in various experiments to understand:
•The biology  of how drugs/vaccines work
•Biomarkers responsible for how a drug/vaccine enters and is removed b y the body
•Other pathway s drugs/vaccines may  interact with
•The biology  ofdisease
The specimen(s) may  be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately  
improve public health through development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by the Sponsor or those working for or 
with the Sponsor. 
  050DGF 
  05KG3M
PRODUCT: V114 106
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
3.Summary of Procedures for Future Biomedical Research .
Participants for Enrollment
All participants enrolled in the clinical study study  who are not Native American 
participants enrolled via the CAIH will be considered for enrollment in the future 
biomedical research substudy
Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all participants or legal guardians, at a 
study  visit by the investigator or his or her d esignate. Informed consent for future 
biomedical r esearch should be presented to the participants on the visit designated in 
the SoA. If delay ed, present consent at next possible Participant Visit. Consent forms 
signed b y the participant will be kept at the clinical study  site under secure storage for 
regulatory  reasons.
A template of each stud y site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository .
eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical research will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified 
will be destroy ed.
Future Biomedical Research Specimen(s)
Collect ion of specimens for future biomedical r esearch will be performed as outlined 
in the SoA. I n general, if additional blood specimens are being collected for future 
biomedical r esearch, these will usually  be obtained at a time when the participant is 
having blood drawn for other study  purposes.
4.Confidential Participant Information for Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
specimens, it is critical to link participant' clinical information with future test results. I n 
fact little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like gender, age , medical history  and treatment outcomes are 
critical to understanding clinical context of anal ytical results.
To maintain privacy  of information collect ed from specimens obtained for future 
biomedical r esearch, the Sponsor has developed secure policies an d procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below. 
  050DGF 
  05KG3M
PRODUCT: V114 107
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
At the clinical study  site, unique codes will be placed on the future biomedical r esearch 
specimens. This code is a random number which does not contain an y persona lly 
identify ing information embedded within it. The link (or key ) between participant 
identifiers and this unique code will be held at the study  site. No personal identifiers will 
appear on the specimen tube.
5.Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for anal yses using good scientific 
practices. Anal yses utilizing the future biomedical r esearch specimens may  be performed 
by the Sponsor, or an additional third party  (eg, a university  investigator) designated by 
the Sponsor. The investigator conducting the anal ysis will follow the Sponsor’s privacy 
and confidentialit y requirements. An y contracted third part y anal yses will conform to the 
specific scope o f anal ysis outlined in this substudy . Future biomedical r esearch 
specimens remaining with the third part y after specific anal ysis is performed will be 
reported to the Sponsor.
6.Withdrawal From Future Biomedical Research
Participants may withdraw their consent for future biomedical research and ask that thei r 
biospecimens not be u sed for future biomedical r esearch. Participants may withdraw 
consent at an y time b y contacting the principal investigator for the main study. If medical 
records for the main study are still available, the investigator will contact the Sponsor 
using the de signated mailbox (clinical.specimen.management@merck.com). 
Subsequently , the participant's specimens will be flagged in the biorepository  and 
restricted to main stud y use only . If specimens were collected from study participants 
specificall y for future bio medical r esearch, these specimens will be removed from the 
biorepository  and destroyed. Documentation will be sent to the investigator confirming 
withdrawal and/or destruction, if applicable. It is the responsibility  of the investigator to 
inform the parti cipant of completion of the withdrawal and/or destruction, if applicable. 
Any anal yses in progress at the time of request for withdrawal/destruction or alread y 
performed prior to the request being received b y the Sponsor will continue to be used as 
part of the overall research study  data and results. No new analy ses would be generated 
after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory au thorities to retain the main study  
records) or the specimens have been completel y anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situation, 
the request for withdrawal of consent and/or destruction cannot be processed.
7.Retention of Specimens
Future biomedical r esearch specimens will be stored in the biorepository  for potential 
analysis for up to 20 y ears from the end of the main study . Specimens may  be stored for 
longer if a regulatory  or governmental authorit y has active questions that are being 
answered. In this special circumstance, specimens will be stored until these questions 
have been adequatel y addressed. 
  050DGF 
  05KG3M
PRODUCT: V114 108
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Specimens from the study  site will be shipped to a central laboratory  and th en shipped to 
the Sponsor -designated biorepository . If a central laboratory  is not utilized in a particular 
study , the stud y site will ship directly to the Sponsor -designated biorepository . The 
specimens will be stored under strict supervision in a limited access facility which 
operates to assure the integrity of the specimens. Specimens will be destroy ed according 
to Sponsor policies and procedures and this destruction will be documented in the 
biorepository  database.
8.Data Security
Databases containing specimen information and test results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highl y secure, and is 
accomplished using networ k securit y policies and practices based on international 
standards to protect against unauthorized access.
9.Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory  laboratory  studies will be reported to the 
participant, famil y, or physicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability , and concerns regarding misinterpretation.
If important research fin dings are discovered, the Sponsor may  publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapidly  report this information to doctors and participants. Participants will not be 
identified by  nam e in an y published reports about this study  or in any  other scientific 
publication or presentation.
10. Future Biomedical Research Study Population
Every  effort will be made to recruit all participants diagnosed and treated o n Sponsor 
clinical studies who are not Native American participants enrolled via the CAIH for 
future biomedical r esearch.
11.Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been minimized and are 
described in the Future Biomedical Research informed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy  concerns. Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality . In this highl y unlikely  situation, there is risk that the 
information, like all medical information, may  be misused.
12.Questions
Any questions related to the future biomedical research should be e mailed directly  to 
clinical.specimen.management@merck.com. 
  050DGF 
  05KG3M
PRODUCT: V114 109
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
13.References
1.National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=45618
2.International Conference on Harmonization [Internet] : E15 : Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharm acogenetics, Genomic Data and Sample 
Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy /efficacy -single/article/definitions -
for-genomic -biomarkers -pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html 
3.Industry  Pharmacogenomics Working Group [Internet]: Understanding the I ntent, 
Scope and Public Health Benefits of Exploratory  Biomarker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Available at http://i -pwg.org/ 
4.Industry  Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for I RBs/IECs and Investigational Site Staff. Available at 
http://i -pwg.org/ 
  050DGF 
  05KG3M
PRODUCT: V114 110
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
10.7 Appendix 7: Country -specific Requirements
Not applicable. 
  050DGF 
  05KG3M
PRODUCT: V114 111
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
10.8 Appendix 8: Abbreviations
Abbreviation Expanded Term
ACIP Advisory Committee on Immunization Practices
AE adverse event
ALT alanine transaminase
APaT All Participants as Treated
APRI AST: platelet ratio index
AST aspartate transaminase
β-hCG beta-human chorionic gonadotropin
BNP brain natriuretic peptide
CAIH Center for American Indian Health
CAPiTA Community -Acquired Pneumonia Immunization Trial in Adults
CI confidence interval
cLDA constrained longitudinal data analysis
CSR Clinical Study Report
DMC Data Monitoring Committee
DNA deoxyribonucleic acid
ECI event of clinical interest
ECL electrochemiluminescence
eCRF electronic case report form
EDC electronic data collection
EF ejection fraction
EMA European Medicines Agency
EOC Executive Oversight Committee
eVRC electronic Vaccination Report Card
FAS Full Analysis Set
FDAAA Food and Drug Administration Amendments Act
FEV 1 forced expiratory volume in 1 second
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GMC Geom etric Mean Concentration
GMFR Geom etric Mean Fold Rise
GMT Geom etric Mean Titer
HIV Human Immunodeficiency Virus
HRT hormonal replacement therapy 
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council for Harmonisation Good Clinical Practice
IEC Independent Ethics Committee
IgG Immunoglobulin G
IMP investigational medicinal product
IRB Institutional Review Board
IPD Invasive Pneumococcal Disease
IRT interactive response technology
IUD intrauterine device
MOPA Multiplexed Opsonophagocytic Assay
MSD Merck Sharp & Dohme Corp.
NIMP non-investigational medicinal product
NP nasopharyngeal
NSAE nonserious adverse event
NYHA New  York Heart Association 
  050DGF 
  05KG3M
PRODUCT: V114 112
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
Abbreviation Expanded Term
OP oropharyngeal
OPA opsonophagocytic activity
PCV pneumococcal conjugate vaccine
PCV13 Prevnar 13™
PE physical examination
PnECL pneumococcal electrochemiluminescence
PP Per-Protocol
RNA ribonucleic acid
SAE serious adverse event
SLAB supplemental laboratory test
SoA schedule of activities
S.pneumoniae Streptococcus pneumoniae
TEE transesophageal echocardiography
TTE transthoracic echocardiography
UAD urine antigen detection assay
ULN upper limit of normal
US United States
VRC Vaccination Report Card
WHO World Health Organization
WOCBP woman/womenof childbearing potential 
  050DGF 
  05KG3M
PRODUCT: V114 113
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
11 REFERENCES
[Anttila, M., et al 1999] Anttila M, Voutilainen M, Jäntti V, Eskola J, 
Käyhty H. Contribution of serot ype-specific IgG 
concentration, IgG subclasses and relative 
antibody  avidit y to opsonophagocytic activity 
against Streptococcus pneumoniae. Clin Exp 
Immunol 1999;118(3):402 -7.03QY70
[Australian Government 
Department of Health 
2017]Australian Government Department of Health. 
The Australian immunisation handbook: 4.13 
pneumococcal disease [Internet]. 10th edition. 
Australia: Australian Government Department of 
Health; 2017 Aug. 21 p. Available from: 
http://immunise.health.gov.au/internet/immunise
/publishing.nsf/Content/9234F08B6DE9BB34C
A257D4D00234E27/$File/4%2013_Pneumococ
cal.pdf.04VSW6
[Bhatty , M., et al 2011] Bhatt y M, Pruett SB, Swiatlo E, Nanduri B. 
Alcohol abuse and Streptococcus pneumoniae 
infections: consideration of virulence factors and 
impaired immune responses. Alcohol. 
2011;45:523 -39.04WB7Q
[Bonten, M. J., et al 
2015]Bonte n MJ, Huijts SM, Bolkenbaas M, Webber 
C, Patterson S, Gault S, et al. Poly saccharide 
conjugate vaccine against pneumococcal 
pneumonia in adults. N Engl J Med. 2015 Mar 
19;372(12):1114 -25.04NFHD
[Burton, Robert L . and 
Nahm, Moon H. 2006]Burton RL, Nahm M H. Development and 
validation of a fourfold multiplexed opsonization 
assay  (MOPA4) for pneumococcal antibodies. 
Clin Vaccine Immunol 2006;13(9):1004 -9.03QT2R
[Castiglia P. 2014] Castiglia P. Recommendations for 
pneumococcal immunization outside routine 
childhood immunization programs in Western 
Europe. Adv Ther. 2014Oct;31(10):1011 -44.04P7L W
[Castiglia, P. 2014] Castiglia P. Recommendations for 
pneumococcal immunization outside routine 
childhood immunization programs in Western 
Europe. Adv Ther. 2014 Oct 10;31:1011 -44.04VSVW 
  050DGF 
  05KG3M
PRODUCT: V114 114
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
[Center for Disease 
Control 1978]CDC. Recommendation of the Public Health 
Service Advisory  Committee on I mmunization 
Practices: Pneumococcal poly saccharide 
vaccine. MMWR Morb Mortal Wkly  Rep. 1978 
Jan 27;27(4):25 -32.04VSJL
[Center for Disease 
Control and Prevention 
2012]Center for Disease Control and Prevention. 
Geographic differences in HIV infection among 
hispanics or latinos -46 states and Puerto Rico, 
2010. MMWR 2012;61(40):805 -24.03RS5J
[Centers for Disease 
Control and Prevention 
(CDC) 2010]Centers for Disease Control and Prevention 
(CDC). Multiple -seroty pe Salmonella 
gastroenteritis outbreak after a reception ---
Connecticut, 2009. MMWR Morb Mortal Wkly  
Rep. 2010 Sep 3;59(34):1093 -7.04NJRK
[Centers for Disease 
Control and Prevention 
1997]CDC. Prevention of pneumococcal disease: 
recommendations of the Advisory Committee on 
Immunization Practices (ACI P). MMWR Morb 
Mortal Wkly  Rep. 1997;46(RR -8):1-24.04VSTK
[Centers for Disease 
Control and Prevention 
2008]Centers for Disease Control and Prevention 
(CDC). Invasive pneumococcal disease in 
children 5 years after conjugate vaccine 
introduction -eight states,1998 -2005. MMWR 
Morb Mortal Wkly  Rep. 2008 Feb 15;57(6):144 -
8.04KW8S
[Centers for Disease 
Control and Prevention
2010]Centers for Disease Control and Prevention. 
Updated recommendations for prevention of 
invasive pneumococcal disease among adults 
using the 23- valent pneumococcal 
polysaccharide vaccine (PPSV23). MMWR 
2010;59(34):1102 -6.03RCFX
[Centers for Disease 
Control and Prevention 
2010]Centers for Disease Control and Prevention. 
Prevention of Pneumococcal Disease Among 
Infants and Children -Use of 13 -Valent 
Pneumococcal Conjugate Vaccine and 23 -Valent 
Pneumococcal Pol ysaccharide Vaccine; 
Recommendations of t he Advisory  Committee 
on Immunization Practices (ACI P). MMWR 
2010;59(RR -11):1 -19.03RSB6 
  050DGF 
  05KG3M
PRODUCT: V114 115
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
[Centers for Disease 
Control and Prevention 
2015]Centers for Disease Control and Prevention. 
Epidemiology  and prevention of vaccine -
preventable diseases. 13th ed. Ha mborsky  J, 
Kroger A, Wolfe S, editors. Washington (DC): 
Department of Health and Human Services 
(HHS); c2015. Chapter 6, Vaccine 
administration; p. 79 -106.0508PV
[Clopper, C. J. and 
Pearson, E. S. 1934]Clopper CJ, Pearson ES. The use of confidence 
or fiducial limits illustrated in the case of the 
binomial. Biometrika 1934;26(4):404 -13.03Q0L W
[Curcio, D., et al 2015] Curcio D, Cane A, Isturiz R. Redefining risk 
categories for pneumococcal disease in adults: 
critical anal ysis of the evidence. Int J Infect Dis. 
2015;37:30 -5.04VSHL
[Esposito, S., et al 2004] Esposito S, Bosis S, Colombo R, Carlucci P, 
Faelli N, Fossali E, et al. Evaluation of rapid 
assay  for detection of Streptococcus pneumoniae 
urinary  antigen among infants and y oung 
children with p ossible invasive pneumococcal 
disease. Pediatr Infect Dis J. 2004 
Apr;23(4):365 -7.04VSTS
[European Centre for 
Disease Prevention and 
Control 2016]European Centre for Disease Prevention and 
Control. Annual Epidemiological Report 2016 –
Invasive pneumococ cal disease. [I nternet]. 
Stockholm: ECDC; 2016. Available from: 
http://ecdc.europa.eu/en/healthtopics/pneumococ
cal_infection/Pages/Annual -epidemiological -
report -2016.aspx.04LP3M
[Falkenhorst, G., et al 
2017]Falkenhorst G, Remschmidt C, Harder T, 
Hummers -Pradier E, Wichmann O, Bogdan C. 
Effectiveness of the 23 -valent pneumococcal 
polysaccharide vaccine (PPV23) against 
pneumococcal disease in the elderl y: systematic 
review and meta -analysis. PL oS One. 2017 Jan 
6;12(1):e0169368.04VSWH 
  050DGF 
  05KG3M
PRODUCT: V114 116
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
[Farrell, D. J, et a l 2007] Farrell DJ, Klugman KP, Pichichero M. 
Increased antimicrobial resistance among 
nonvaccine serot ypes of Streptococcus 
pneumoniae in the pediatric population after the 
introduction of 7 -valent pneumococcal vaccine 
in the United States. Pediatr Infect Dis J. 2007 
Feb;26(2):123 -8.04KWD9
[French High Council for 
Public Health 2017]French High Council for Public Health. 
Recommendations for vaccination against 
invasive pneumococcal disease in adults. 2017.04VYX3
[Gillis, H. D., et al 2017] Gillis HD, Lang ALS, ElSherif M, Martin I, 
Hatchette TF, McNeil SA, et al. Assessing the 
diagnostic accuracy  of PCR -based detection of 
Streptococcus pneumoniae from nasophary ngeal 
swabs collected for viral studies in Canadian 
adults hospitalised with community -acquir ed 
pneumonia: a Serious Outcomes Surveillance 
(SOS) Network of the Canadian Immunization 
Research (CIRN) stud y. BMJ Open. 
2017;7:e015008.04VSWN
[Grijalva, C. G., et al 
2015]Grijalva CG, Wunderink RG, Zhu Y, Williams 
DJ, Balk R, Fakhran S, et al. I n-hosp ital 
pneumococcal poly saccharide vaccination is 
associated with detection of pneumococcal 
vaccine serot ypes in adults hospitalized for 
community -acquired pneumonia. Open Forum 
Infect Dis. 2015:2(4):ofv135.04VT53
[Guevara, M., et al 2016] Guevara M, Barri carte A, Torroba L, Herranz M, 
Gil-Setas A, Gil F, et al. Direct, indirect and 
total effects of 13 -valent pneumococcal 
conjugate vaccination on invasive pneumococcal 
disease in children in Navarra, Spain, 2001 to 
2014: cohort and case -control study . Euro 
Surveill. 2016;21(14).04KSQ3
[Huijts, S. M., et al 2017] Huijts SM, van Werkhoven CH, Bolkenbaas M, 
Grobbee DE, Bonten MJM. Post -hoc anal ysis of 
a randomized controlled trial: diabetes mellitus 
modifies the efficacy  of the 13 -valent 
pneumococcal conjugate vaccine in elderl y. 
Vaccine. 2017;35:4444 -9.04VSYC 
  050DGF 
  05KG3M
PRODUCT: V114 117
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
[Jackson, L . A., et al 
2013]Jackson L A, Gurtman A, van Cleeff M, Jansen 
KU, Jay awardene D, Devlin C, et al. 
Immunogenicit y and safety of a 13 -valent 
pneumococcal conjugate vaccine compared to a 
23-valent pneumococcal poly saccharide vaccine 
in pneumococcal vaccine -naive adults. Vaccine. 
2013;31:3577 -84.04VT2S
[Jokinen, J., et al 2015] Jokinen J, Rinta -Kokko H, Siira L , Palmu AA, 
Virtanen MJ, Nohy nek H, et al. I mpact of ten -
valent pneumococcal co njugate vaccination on 
invasive pneumococcal disease in Finnish 
children a population -based study . PLoS One. 
2015 Mar 17;10(3):e0120290.04KW7F
[Knoll, M. D., et al 2016] Knoll MD, Pride MW, Sebastian S, Hilton B, 
Isturiz R, Jansen KU. Pilot evaluation of a 
quantitative serot ype-specific urine antigen 
detection (SS -UAD) assay  to identify  
pneumococcal pneumonia in children <5 y ears 
[abstract]. Presented at: International 
Symposium on Pneumococci and Pneumococcal 
Diseases Conference; 2016 Jun 26 -30; Glasgow,
Scotland. Abstract No. 499.04VT6W
[Kobay ashi, M., et al 
2015]Kobay ashi M, Bennett NM, Gierke R, 
Almendares O, Moore MR, Whitney  CG, et al. 
Intervals Between PCV13 and PPSV23 
Vaccines: Recommendations of the Advisory  
Committee on I mmunization Practices (ACIP). 
MMWR Morb Mortal Wkly  Rep. 2015 Sep 
4;64(34):944 -7.04P7L H
[Lepoutre, A., et al 2015] Lepoutre A, Varon E, Georges S, Dorleans F, 
Janoir C, Gutmann L , et al. I mpact of the 
pneumococcal conjugate vaccines on invasive 
pneumococcal disease in France, 2001 -2012. 
Vaccine. 2015 Jan 3;33(2):359 -66.04KW88
[Lexau, C. A., et al 2005] Lexau CA, Ly nfield R, Danila R, Pilishvili T, 
Facklam R, Farley  MM, et al. Changing 
epidemiology  of invasive pneumococcal disease 
among older adults in the era of pediatric 
pneumococcal conjugate vaccine. JAMA 
2005;294(16):2043 -51.03RBPW 
  050DGF 
  05KG3M
PRODUCT: V114 118
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
[Liang, K -Y and Zeger, 
S. L. 2000]Liang K -Y, Zeger SL. Longitudinal data anal ysis 
of continuous and discrete responses for pre -post 
designs. Sank yha: The Indian Journal of 
Statistics 2000; 62(Series B, Part 1):134- 48.00V5V6
[Martinelli, D., et al 
2014]Martinelli D, Pedalino B, Cappelli MG, Caputi 
G, Sallustio A, Fortunato F, et al Towards the 
13-valent pneumococcal conjugate universal 
vaccination: effectiveness in the transition era 
betwe en PCV7 and PCV13 in I taly, 2010 -2013. 
Hum Vaccin Immunother. 2014;10(1):33 -9.04KW8B
[McMahon, B. J., et al 
1993]McMahon BJ, Parkinson AJ, Bulkow L , 
Davidson M, Wainwright K, Wolfe P, et al. 
Immunogenicit y of the 23 -valent pneumococcal 
polysaccharide va ccine in Alaska Native chronic 
alcoholics compared with nonalcoholic Native 
and non -Native controls. Am J Med. 1993 
Dec;95:589 -94.04WB7S
[Metlay , J. P., et al 2006] Metlay  JP, Fishman NO, Joffe M, Edelstein PH. 
Impact of pediatric vaccination with 
pneumo coccal conjugate vaccine on the risk of 
bacteremic pneumococcal pneumonia in adults. 
Vaccine 2006;24:468 -75.03RC46
[Moore, M. R., et al 
2015]Moore MR, L ink-Gelles R, Schaffner W, 
Lynfield R, Lexau C, Bennett NM, et al. Effect 
of use of 13 -valent pneumococcal conjugate 
vaccine in children on invasive pneumococcal 
disease in children and adults in the USA: 
analysis of multisite, population -based 
surveillance. Lancet Infect Dis. 2015 Feb 3. 
[Epub ahead of print].043MRP
[Morton, J. B., et al 2017] Morton JB, Morrill HJ, LaPlante KL, Caffrey  
AR. Risk stacking of pneumococcal vaccination 
indications increases mortality  in unvaccinated 
adults with Streptococcus pneumoniae 
infections. Vaccine. 2017;35:1692 -7.04VSTC 
  050DGF 
  05KG3M
PRODUCT: V114 119
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
[Palmu, A. A., et al 2015] Palmu AA, Kilpi TM, Rinta -Kokko H, Noh ynek 
H, Toropainen M, Nuorti JP, et al. 
Pneumococcal conjugate vaccine and clinicall y 
suspected invasive pneumococcal disease. 
Pediatrics. 2015 Jul;136(1):e22 -7.04KVRL
[Pilishvili, T., et al 2014] Pilishvili T, Ahmed s, Xing W , Farley  M, 
Schaffner W, Thomas A, et al. Impact of 13 -
valent pneumococcal conjugate vaccine 
(PCV13) in the U.S. on invasive pneumococcal 
disease (IPD) among adults with chronic 
conditions [abstract].  National center for 
Immunization and Respiratory  Disea se, Division 
of Bacterial Diseases, Department of Health and 
Human Services USA. Report No. ISPPD -0638.04VT67
[Pilishvili, Tamara, et al 
2010]Pilishvili T, Lexau C, Farley MM, Hadler J, 
Harrison LH, Bennett NM, et al. Sustained 
reductions in invasive pn eumococcal disease in 
the era of conjugate vaccine. J I nfect Dis 
2010;201(1):32 -41.03R5S4
[Priner, M., et al 2008] Priner M, Cornillon C, Forestier D, Valero S, 
Paccalin M. Might Streptococcus pneumoniae 
urinary  antigen test be positive because of 
pneumococcal vaccine? J Am Geriatr Soc. 2008 
Jan;56(1):170 -1.04VSP8
[Romero -Steiner, S., et al 
1997]Romero -Steiner S, L ibutti D, Pais LB, Dy kes J, 
Anderson P, Whitin JC, et al. Standardization of 
an opsonophagocy tic assay  for the measurement 
of function al antibod y activity  against 
streptococcus pneumoniae using differentiated 
HL-60 cells. Clin Diagn Lab Immunol 
1997;4(4):415 -22.03NWQ5
[Ruckinger, S., et al 
2009]Ruckinger S, van der Linden M, Reinert RR, von 
Kries R, Burckhardt F, Siedler A. Reduction in 
the incidence of invasive pneumococcal disease 
after general vaccination with 7 -valent 
pneumococcal conjugate vaccine in German y. 
Vaccine 2009;27:4136 -41.03QYQQ 
  050DGF 
  05KG3M
PRODUCT: V114 120
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
[Shea, K. M., et al 2014] Shea KM, Edelsberg J, Wey cker D, Farkouh 
RA, Strutton DR, Pelton SI. Rates of 
pneumococcal disease in adults with chronic 
medical conditions. Open Forum Infect Dis. 
2014 May  27;1(1):ofu024.04NK7X
[Tomczy k, S., et al 2014] Tomczy k S, Bennett NM, Stoecker C, Gierke R, 
Moore MR, Whitney  CG, et al. Use of 13 -valent 
pneum ococcal conjugate vaccine and 23 -valent 
pneumococcal poly saccharide vaccine among 
adults aged is greater than or equal to 65 y ears: 
recommendations of the Advisory Committee on 
Immunization Practices (ACI P). MMWR Morb 
Mortal Wkly  Rep. 2014 Sep 19;63(37):82 2-5.040XNF
[Torres, A., et al 2015] Torres A, Blasi F, Dartois N, Akova M. Which 
individuals are at increased risk of 
pneumococcal disease and why ? Impact of 
COPD, asthma, smoking, diabetes, and/or 
chronic heart disease on community -acquired 
pneumonia and invasive pneumococcal disease. 
Thorax. 2015:70:984 -9.04VSHQ
[Turner, P., et al 2011] Turner P, Turner C, Kaewcharernnet N, Mon 
NY, Goldblatt D, Nosten F. A prospective stud y 
of urinary  pneumococcal antigen detection in 
healthy  Karen mothers with high rates of 
pneumococcal nasopharyngeal carriage. BMC 
Infect Dis. 2011;11:108.04VSPG
[U.S. Food and Drug 
Administration 2009]U.S. Food and Drug Administration (CDER, 
CBER, CDRH). Guidance for industry  patient -
reported outcome measures: use in medical 
product development to support labeling claims 
[Internet]. Washington: U.S. Department of 
Health and Human Services; 2009. Available 
from: 
https://www.fda.gov/downloads/drugs/guidances
/ucm193282.pdf04MG9J 
  050DGF 
  05KG3M
PRODUCT: V114 121
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
[Wagenvoort, G. H., et al 
2016]Wagenvoort GH, Knol M J, de Melker HE, 
Vlaminckx BJ, van der Ende A, Rozenbaum  
MH, et al.  Risk and outcomes of invasive 
pneumococcal disease in adults with underly ing 
conditions in the post -PCV7 era, The 
Netherlands. Vaccine. 2016 Jan 12;34(3):334 -
40.04KTDB
[Waight, P. A., et al 
2015]Waight PA, Andrews NJ, L adhani SN, Sheppard 
CL, Slack MP, Miller E. Effect of the 13 -valent 
pneumococcal conjugate vaccine on invasive 
pneumococcal disease in England and Wales 4 
years after its introduction: an observational 
cohort study . Lanc et Infect Dis. 2015 
May;15(5):535 -43.04KTF2
[Watt, J. P., et al 2007] Watt JP, O'Brien KL, Benin AL , McCoy  SI, 
Donaldson CM, Reid R, et al. Risk factors for 
invasive pneumococcal disease among Navajo 
adults. Am J Epidemiol. 2007;166(9):1080 -7.04VSPB
[Weatherholtz, R., et al 
2010]Weatherholtz R, Millar EV, Moulton L H, Reid 
R, Rudolph K, Santosham M, et al. I nvasive 
pneumococcal disease a decade after 
pneumococcal conjugate vaccine use in an 
American Indian population at high risk for 
disease. Clin I nfect Dis. 2010 May  1;50(9):1238 -
46.04VSP6
[Weiss, S., et al 2015] Weiss S, Falkenhorst G, van der Linden M, 
Imohl M, von Kries R. Impact of 10 -  and 13-
valent pneumococcal conjugate vaccines on 
incidence of invasive pneumococcal disease in 
children aged u nder 16 years in Germany , 2009 
to 2012. Euro Surveill. 2015 Mar 
12;20(10):21057.04KTFC
[Wey cker, D., et al 2016] Wey cker D, Farkouh RA, Strutton DR, 
Edelsberg J, Shea KM, Pelton SL . Rates and 
costs of invasive pneumococcal disease and 
pneumonia in person s with underly ing medical 
conditions. BMC Health Serv Res. 2016;16:182.04VSTX 
  050DGF 
  05KG3M
PRODUCT: V114 122
PROTOCOL/AMENDMENT N O.: 017 -02 
V114 -017-02FINAL PROTOCOL 31-AUG -2018
[Whitney , Cynthia G., et 
al 2003]Whitney  CG, Farley  MM, Hadler J, Harrison 
LH, Bennett NM, Ly nfield R, et al. Decline in 
invasive pneumococcal disease after the 
introduction o f protein- polysaccharide conjugate 
vaccine. N Engl J Med 2003;348(18):1737 -46.03QT0D 
  050DGF 
  05KG3M